

การตรวจหาแบคทีเรียที่มีประโยชน์ในน้ำนมมารดาและทดสอบ  
ความสามารถในการยับยั้งแบคทีเรียก่อโรค

นางสาวยุพาวดี ชาวดง

วิทยานิพนธ์นี้เป็นส่วนหนึ่งของการศึกษาตามหลักสูตรปริญญาวิทยาศาสตรมหาบัณฑิต

สาขาวิชาจุลชีววิทยาทางการแพทย์ (สหสาขาวิชา)

บัณฑิตวิทยาลัย จุฬาลงกรณ์มหาวิทยาลัย

ปีการศึกษา 2554

ลิขสิทธิ์ของจุฬาลงกรณ์มหาวิทยาลัย

บทคัดย่อและแฟ้มข้อมูลฉบับเต็มของวิทยานิพนธ์ตั้งแต่ปีการศึกษา 2554 ที่ให้บริการในคลังปัญญาจุฬาฯ (CUIR)

เป็นแฟ้มข้อมูลของนิสิตเจ้าของวิทยานิพนธ์ที่ส่งผ่านทางบัณฑิตวิทยาลัย

The abstract and full text of theses from the academic year 2011 in Chulalongkorn University Intellectual Repository (CUIR)

are the thesis authors' files submitted through the Graduate School.

DETECTION OF BENEFICIAL BACTERIA IN BREAST MILK AND  
ASSESSMENT OF THEIR ANTAGONISTIC ACTIVITY  
AGAINST BACTERIAL PATHOGENS

Miss Yupawadee Chaodong

A Thesis Submitted in Partial Fulfillment of the Requirements  
for the Degree of Master of Science Program in Medical Microbiology  
(Interdisciplinary Program)  
Graduate School  
Chulalongkorn University  
Academic Year 2011  
Copyright of Chulalongkorn University

Thesis Title	DETECTION OF BENEFICIAL BACTERIA IN BREAST MILK AND ASSESSMENT OF THEIR ANTAGONISTIC ACTIVITY AGAINST BACTERIAL PATHOGENS
By	Miss Yupawadee Chaodong
Field of Study	Medical Microbiology
Thesis Advisor	Associate Professor Somying Tumwasorn, Ph.D.

---

Accepted by the Graduate School, Chulalongkorn University in Partial Fulfillment of the Requirements for the Master's Degree

..... Dean of the Graduate School  
(Associate Professor Pornpote Piumsomboon, Ph.D.)

#### THESIS COMMITTEE

..... Chairman  
(Associate Professor Ariya Chindamporn, Ph.D.)

..... Thesis Advisor  
(Associate Professor Somying Tumwasorn, Ph.D.)

..... Examiner  
(Tanittha Chatsuwan, Ph.D.)

..... External Examiner  
(Associate Professor Amornrut Leelaporn, Ph.D.)

ยุพาดิ ชาวดง : การตรวจหาแบคทีเรียที่มีประโยชน์ในน้ำนมมารดาและทดสอบความสามารถในการยับยั้งแบคทีเรียก่อโรค (DETECTION OF BENEFICIAL BACTERIA IN BREAST MILK AND ASSESSMENT OF THEIR ANTAGONISTIC ACTIVITY AGAINST BACTERIAL PATHOGENS) อ. ที่ปรึกษาวิทยานิพนธ์หลัก: รศ.ดร. สมหญิง ชัมวาสร, 129 หน้า.

น้ำนมมารดาเป็นแหล่งอาหารที่สำคัญต่อทารกและมีบทบาทในการเริ่มต้นพัฒนาจุลินทรีย์ในลำไส้ของทารก ในการวิจัยครั้งนี้มีวัตถุประสงค์เพื่อตรวจแยกและพิสูจน์เอกลักษณ์ของเชื้อแบคทีเรียที่มีประโยชน์ในน้ำนมมารดา ได้แก่ lactobacilli, bifidobacteria และ streptococci และทดสอบคุณสมบัติของเชื้อเหล่านี้ในการยับยั้งเชื้อแบคทีเรียก่อโรค ได้แก่ enterotoxigenic *E. coli* (ETEC), enteroinvasive *E. coli* (EIEC), enteropathogenic *E. coli* (EPEC), enterohemorrhagic *E. coli* (EHEC), *Salmonella* Typhimurium, *Shigella flexneri*, *Vibrio cholerae*, *Helicobacter pylori* and methicillin-resistant *Staphylococcus aureus* (MRSA) ทำการเก็บตัวอย่างน้ำนมจากมารดาชาวไทยที่มีสุขภาพดี มีระยะเวลาให้นมบุตรในช่วง 15-60 วัน (จำนวน 102 คน) พิสูจน์เอกลักษณ์ของ lactobacilli, bifidobacteria และ streptococci โดยการวิเคราะห์ลำดับนิวคลีโอไทด์บางส่วนของ 16S rRNA gene และทดสอบคุณสมบัติในการยับยั้งเชื้อแบคทีเรียก่อโรค โดยใช้ spot method ผลการตรวจแยกเชื้อพบ *Lactobacillus* ใน 37 ตัวอย่าง (36.27%) จำนวน 40 สายพันธุ์ ได้แก่ *L. gasseri*, *L. salivarius*, *L. fermentum*, *L. mucosae*, *L. rhamnosus*, *L. casei*, *L. plantarum* และ *L. oris* พบ *Bifidobacterium* ใน 31 ตัวอย่าง (30.39%) จำนวน 33 สายพันธุ์ ได้แก่ *B. longum*, *B. breve*, *B. pseudocatenulatum*, *B. dentium* and *B. bifidum* และพบ *Streptococcus* ใน 17 ตัวอย่าง (16.67%) จำนวน 26 สายพันธุ์ ได้แก่ *S. salivarius*, *S. lactarius*, *Streptococcus* sp., *Streptococcus mitis* และ *Streptococcus parasangius* ผลการตรวจหาดีเอ็นเอในตัวอย่างน้ำนม โดยวิธี พีซีอาร์ ตรวจพบดีเอ็นเอของ lactobacilli 94 ตัวอย่าง (92.16%) bifidobacteria 60 ตัวอย่าง (58.82%) และ streptococci 56 ตัวอย่าง (54.90%) ตามลำดับ การทดสอบการยับยั้งเชื้อ ETEC, EIEC, EPEC, EHEC and *S. Typhimurium* พบว่า *Lactobacillus* ทั้งหมดสามารถยับยั้งได้เล็กน้อย *Bifidobacterium* สามารถยับยั้งได้ไม่ชัดเจน และ *Streptococcus* ไม่มีความสามารถในการยับยั้ง ส่วนผลในการยับยั้งเชื้อ *V. cholerae* และ *S. flexneri* พบว่า *Lactobacillus* 13 สายพันธุ์ (Lac43, Lac44, Lac45, NL1, NL3, NL5, NL6, NL7, NL8, NL10, NL18, NL26 และ NL50) และ *Bifidobacterium* 11 สายพันธุ์ (Bif29, NB4, NB11, NB13, NB14, NB15, NB16, NB17, NB28, NB31 และ NB40) สามารถยับยั้งได้ชัดเจน นอกจากนี้ *Lactobacillus* 6 สายพันธุ์ (Lac 40, Lac41, NL26 NL50, NL52 และ NL53) และ *Streptococcus* 5 สายพันธุ์ (St10, St11, NL4, NL9 และ St27) สามารถยับยั้งเชื้อ MRSA ได้เล็กน้อย และ พบว่า *Bifidobacterium* 5 สายพันธุ์ (NB6, NB8, NB14, NB28 และ NB31) สามารถยับยั้งเชื้อ *Helicobacter pylori* ได้อย่างชัดเจน *Lactobacillus*, *Bifidobacterium* และ *Streptococcus* มีความสามารถในการยับยั้งเชื้อแบคทีเรียก่อโรคเหล่านี้มีคุณสมบัติที่จะนำไปใช้เป็นโพรไบโอติกส์ในการยับยั้งเชื้อแบคทีเรียก่อโรค

สาขาวิชา จุลชีววิทยาทางการแพทย์ ลายมือชื่อนิสิต .....

ปีการศึกษา 2554..... ลายมือชื่อ อ.ที่ปรึกษาวิทยานิพนธ์หลัก.....

## 5287245420 : MAJOR MEDICAL MICROBIOLOGY

KEYWORDS : BENEFICIAL BACTERIA/ BREAST MILK/ LACTOBACILLI/  
BIFIDOBACTERIA/ STREPTOCOCCI

YUPAWADEE CHAODONG: DETECTION OF BENEFICIAL  
BACTERIA IN BREAST MILK AND ASSESSMENT OF THEIR  
ANTAGONISTIC ACTIVITY AGAINST BACTERIAL PATHOGENS.  
ADVISOR: ASSOC. PROF. SOMYING TUMWASORN, Ph.D., 129 pp.

Breast milk is an important nutrient for neonates and plays role in the initiation of the neonatal gut microbiota. This study aimed to isolate beneficial bacteria including lactobacilli, bifidobacteria and streptococci from breast milk and assess their antagonistic activity against bacterial pathogens including enterotoxigenic *E. coli* (ETEC), enteroinvasive *E. coli* (EIEC), enteropathogenic *E. coli* (EPEC), enterohemorrhagic *E. coli* (EHEC), *Salmonella* Typhimurium, *Shigella flexneri*, *Vibrio cholerae*, *Helicobacter pylori* and methicillin-resistant *Staphylococcus aureus* (MRSA). Breast milk samples were collected from Thai healthy mothers (n=102) lactating at range 15-60 days. *Lactobacillus*, *Bifidobacterium* and *Streptococcus* species were identified by 16S rRNA gene sequencing and tested for their antagonistic activity against bacterial pathogens by agar spot method. Forty isolates of *Lactobacillus* which were *L. gasseri*, *L. salivarius*, *L. fermentum*, *L. mucosae*, *L. rhamnosus*, *L. casei*, *L. plantarum* and *L. oris* were recovered from 37 (36.27%) milk samples. Thirty-three isolates of *Bifidobacterium* including *B. longum*, *B. breve*, *B. pseudocatenulatum*, *B. dentium* and *B. bifidum* were recovered from 31 (30.39%) milk samples. Twenty-six isolates of *Streptococcus* including *S. salivarius*, *S. lactarius*, *Streptococcus* sp., *Streptococcus mitis* and *Streptococcus parasangius* were presented from 17 (16.67%) milk samples. PCR assay demonstrated that DNAs of lactobacilli, bifidobacteria and streptococci were detected in 94 (92.16%), 60 (58.82%) and 56 (54.90%) of 102 breast milk samples, respectively. Antagonistic activity assay demonstrated that all *Lactobacillus*, *Bifidobacterium* and *Streptococcus* isolates had weak, partial as microcolony and no inhibition against ETEC, EIEC, EPEC, EHEC and *S. Typhimurium*, respectively. Thirteen *Lactobacillus* isolates (Lac43, Lac44, Lac45, NL1, NL3, NL5, NL6, NL7, NL8, NL10, NL18, NL26 and NL50) and 11 *Bifidobacterium* isolates (Bif29, NB4, NB11, NB13, NB14, NB15, NB16, NB17, NB28, NB31 and NB40) had strong inhibitory activities against *V. cholerae* and *S. flexneri*. Furthermore, six *Lactobacillus* isolates (Lac 40, Lac41, NL26 NL50, NL52 and NL53) and 5 *Streptococcus* isolates (St10, St11, NL4, NL9 and St27) weakly inhibited the growth of MRSA. In addition, 5 *Bifidobacterium* isolates (NB6, NB8, NB14, NB28 and NB31) had strong inhibitory activities against *H. pylori*. These *Lactobacillus*, *Bifidobacterium* and *Streptococcus* with antagonistic activity had potential for use as probiotics against bacterial pathogens.

Field of Study : Medical Microbiology

Student's Signature .....

Academic Year : 2011 .....

Advisor's Signature .....

## ACKNOWLEDGEMENTS

I wish to express my deep gratitude to my thesis advisor, Associate Professor Somying Tumwasorn Ph.D., Department of Microbiology, Faculty of Medicine, Chulalongkorn University, my principal advisor for her valuable advice, encouraging guidance and indispensable help throughout the period of this study.

I am also grateful to my thesis committee, Associate Professor Ariya Chindamporn Ph.D., Department of Microbiology, Faculty of Medicine, Chulalongkorn University, the Chairperson and Associate Professor Sunee Korbsrisate, Ph.D., Department of Immunology, Faculty of Medicine, Mahidol University for their valuable comments and constructive criticisms.

Special thanks are given to Associate Professor Boosba Vivatvakin M.D., Faculty of Medicine, Chulalongkorn University and the staffs of well baby clinic, King Chulalongkorn Memorial Hospital for her kindness and help in specimen collection.

I would also like to thank all friends, and all staff members of Bacteriology Division, Department of Microbiology, Faculty of Medicine, Chulalongkorn University for their friendship, kindness and help in the laboratory during my study.

Finally, I would like to express my deepest gratitude to my parents for their love, encouragement, understanding and support during my study.

## CONTENTS

	<b>Page</b>
ABSTRACT (THAI).....	iv
ABSTRACT (ENGLISH).....	v
ACKNOWLEDGEMENTS.....	vi
CONTENTS.....	vii
LIST OF TABLES.....	ix
LIST OF FIGURES.....	x
LIST OF ABBREVIATIONS.....	xi
<b>CHAPTER</b>	
I INTRODUCTION.....	1
OBJECTIVE.....	3
CONCEPTUAL FRAMEWORK.....	4
II LITERATURE REVIEWS.....	5
BREAST MILK.....	5
THE GENUS <i>LACTOBACILLUS</i> .....	7
BACKGROUND OF LACTOBACILLI.....	7
BIOLOGY OF LACTOBACILLI.....	9
BENEFICIAL EFFECT OF LACTOBACILLI.....	10
THE GENUS <i>BIFIDOBACTERIUM</i> .....	12
BACKGROUND OF BIFIDOBACTERIA.....	12
BIOLOGY OF BIFIDOBACTERIA.....	14
BENEFICIAL EFFECT OF BIFIDOBACTERIA.....	15
THE GENUS <i>STREPTOCOCCUS</i> .....	21
BACKGROUND OF STREPTOCOCCI.....	21
BIOLOGY OF STREPTOCOCCI.....	22
BENEFICIAL EFFECT OF STREPTOCOCCI.....	22
ANTIMICROBIAL COMPOUND OF <i>LACTOBACILLUS</i> , <i>BIFIDOBACTERIUM</i> AND <i>STREPTOCOCCUS</i> .....	23
METHODS FOR EVALUATION OF ANTIMICROBIAL	

ACTIVITY.....	25
III MATERIAL AND METHODS.....	27
HUMAN SUBJECTS AND SAMPLE COLLECTION.....	27
BACTERIAL CULTIVATION.....	27
SELECTION OF <i>LACTOBACILLUS</i> , <i>BIFIDOBACTERIUM</i> AND <i>STREPTOCOCCUS</i> ISOLATES.....	28
GENOTYPIC IDENTIFICATION OF <i>LACTOBACILLUS</i> , <i>BIFIDIBACTERIUM</i> , AND <i>STREPTOCOCCUS</i> ISOLATES.....	28
DETECTION DNA OF LACTOBACILLI, BIFIDOBACTERIA AND STREPTOCOCCI BY PCR METHOD.....	30
ANTAGONISTIC ACTIVITY ASSAY.....	31
IV RESULTS.....	33
CULTIVATION AND PRESUMPTIVE IDENTIFICATION OF <i>LACTOBACILLUS</i> , <i>BIFIDOBACTERIUM</i> AND <i>STREPTOCOCOCUS</i> FROM BREAST MILK.....	33
GENOTYPIC IDENTIFICATION OF LACTOBACILLI, BIFIDOBACTERIA AND STREPTOCOCCI.....	36
PCR ANALYSES OF LACTOBACILLI, BIFIDOBACTERIA AND STREPTOCOCCI FROM BREAST MILK SAMPLES.....	59
ANTAGONISTIC ACTIVITY OF <i>LACTOBACILLUS</i> , <i>BIFIDOBACTERIUM</i> AND <i>STREPTOCOCCUS</i> ISOLATES AGAINST BACTERIAL PATHOGENS.....	61
V DISCUSSION.....	75
VI CONCLUSION.....	81
REFERENCES.....	82
APPENDICES.....	97
APPENDIX A.....	98
APPENDIX B.....	101
APPENDIX C.....	105
APPENDIX D.....	109
BIOGRAPHY.....	129



## LIST OF TABLES

		Page
Table 1	<i>Lactobacillus</i> species of research interest as probiotics.....	7
Table 2	The summary of beneficial effect of lactobacilli.....	10
Table 3	Currently assigned species of the genus <i>Bifidobacterium</i> species.....	12
Table 4	Summary of potential health benefits of bifidobacteria.....	16
Table 5	The species groups in genus <i>Streptococcus</i> .....	22
Table 6	Genotypic identification of <i>Lactobacillus</i> spp. based on 16S rRNA gene sequencing.....	44
Table 7	Genotypic identification of <i>Bifidobacterium</i> spp. based on 16S rRNA gene sequencing.....	49
Table 8	Genotypic identification of <i>Streptococcus</i> spp. based on 16S rRNA gene sequencing.....	54
Table 9	Bacterial isolates cultivated from breast milk samples and genotypically identified.....	57
Table 10	<i>Lactobacillus</i> , <i>Bifidobacterium</i> and <i>Streptococcus</i> species in breast milk identified by 16S rRNA gene sequencing.....	58
Table 11	Other bacterial species found in breast milk.....	59
Table 12	<i>Lactobacillus</i> antagonistic activity against bacterial pathogens.....	63
Table 13	<i>Bifidobacterium</i> antagonistic activity against bacterial pathogens.....	66
Table 14	<i>Streptococcus</i> antagonistic activity against bacterial pathogens.....	69
Table 15	The summary antagonistic activity of <i>Lactobacillus</i> spp. against bacterial pathogens.....	73
Table 16	The summary antagonistic activity of <i>Bifidobacterium</i> spp. against bacterial pathogens.....	73

## LIST OF FIGURES

		<b>Page</b>
Figure 1	The hypothetical model to explain how some bacterial strains could be presented in breast milk.....	6
Figure 2	Colony growth from breast milk on different media.....	34
Figure 3	Colony growth from skin swabs on different media.....	35
Figure 4	Cell morphology of bacteria isolated from breast milk.....	35
Figure 5	The alignment of genus-specific primers L159F and L677R with 16S rRNA gene sequence of <i>Lactobacillus</i> spp.....	37
Figure 6	The alignment of genus-specific primers Bif164F and Bif601R with 16S rRNA gene sequence of <i>Bifidobacterium</i> spp.....	38
Figure 7	The alignment of genus-specific primers Tuf-Strep-1 and Tuf-Strep-R with 16S rRNA gene sequence of <i>Streptococcus</i> spp.....	39
Figure 8	The alignment of universal primers 16S-8F and 16S-1541R with 16S rRNA gene sequence of <i>Lactobacillus</i> spp.....	40
Figure 9	The alignment of universal primers Im 26 and Im3 with 16S rRNA gene sequence of <i>Bifidobacterium</i> spp.....	42
Figure 10	The alignment of universal primers F and U926 with 16S rRNA gene sequence of <i>Streptococcus</i> spp.....	43
Figure 11	Genus-specific amplification by PCR.....	60
Figure 12	Percentage of bacterial DNA detected by PCR.....	60
Figure 13	Antagonistic activity of <i>Lactobacillus</i> against <i>Vibrio cholerae</i> .....	71
Figure 14	Antagonistic activity of <i>Lactobacillus</i> against methicillin-resistant <i>Staphylococcus aureus</i> (MRSA).....	71
Figure 15	Antagonistic activity of <i>Bifidobacterium</i> against <i>Vibrio cholerae</i> .....	72

**LIST OF ABBREVIATIONS**

ATCC	American type culture collection
bp	base pair
BHI	brain heart infusion
CFU	colony forming unit
CO <sub>2</sub>	carbon dioxide
°C	degree celsius
DNA	deoxyribonucleic acid
DMST	Department of Medical Science, Thailand
DW	distilled water
EDTA	ethylenediamine tetraaceticacid
EHEC	enterohemorrhagic <i>Escherichia coli</i>
EIEC	enteroinvasive <i>Escherichia coli</i>
EPEC	enteropathogenic <i>Escherichia coli</i>
ETEC	enterotoxigenic <i>Escherichia coli</i>
<i>et al.</i>	et alii
g	gram
g/l	gram per liter
h	hour
HCl	hydrochloric acid
i.e.	id est
kb	kilobase
l	liter
M	molar
mg	milligram
mg/l	milligram per liter
min	minute(s)
ml	milliliter
mm	millimeter
MC	modified Columbia medium

MRS	deMan Rogosa Sharp
PCR	polymerase chain reaction
pmol	picomol
rpm	round per minute
16SrRNA	16S ribosomal ribonucleic acid
sec	second
TBE	tris-boric acid-EDTA
Tris	tris-(hydroxymethyl)-aminoethane
$\mu\text{g}$	microgram
$\mu\text{l}$	microliter
$\mu\text{M}$	micromolar
WHO	World Health Organization

# CHAPTER I

## INTRODUCTION

Breast milk is an important source of nutritional requirements for the growing infant because of the composition of protective factors such as immunoglobulin A (IgA), immunocompetent cells, fatty acids, oligosaccharides, lysozyme and lactoferrin that improve and protect breast-fed infants against infectious diseases [1, 2]. In addition, breast milk is an important factor in the initiation and development of the infant gut microbiota because it is a source of microorganisms to the infant gut during breast-feeding after birth. An infant fed breast milk about 800 ml/d will ingest microorganisms about  $1 \times 10^5$ - $1 \times 10^7$  commensal bacteria [2] depending on hygiene and antibiotic use. In addition, it has been reported that the bacterial composition of the breast-fed infant flora reflected the bacterial composition of breast milk [3]. Heikkilä and Saris isolated commensal bacteria from breast milk, of which include four bacterial groups of staphylococci (64%), streptococci (30%), lactobacilli (10%), and enterococci (4%) [3]. Recently, it has been reported that bifidobacteria were also isolated from breast milk [4]. It was suggested that breast milk bacteria may be originated not only from external sources but also from the maternal gut microorganism. It was suspected that dendritic cells that penetrated the gut epithelium take up bacteria directly from gut lumen. In addition, M cells on Peyer's patch can phagocytose the gut microorganism. Once inside the cells, bacteria may be able to move from the intestinal mucosa to colonize distant mucosal surfaces, such as those of respiratory and genitourinary tracts, salivary and lacrimal glands and most significantly that of lactating mammary gland [5].

Specific strains of commensal bacteria in breast milk are beneficial bacteria, which include *Lactobacillus*, *Bifidobacterium*, and *Streptococcus*. *Lactobacillus* belongs to the lactic acid bacteria (LAB). They are Gram-positive rods or coccobacilli, catalase-negative, non-pathogenic and desirable members of the intestinal tract. They produce lactic acid as main end-product of the fermentation of carbohydrates [6]. *Lactobacillus* strains isolated from breast milk such as *L. gasseri*, *L. rhamnosus*, *L. plantarum* and *L. fermentum*, have beneficial effect of probiotic [7].

*Bifidobacterium* are Gram-positive polymorphic branched rods that occur singly, in chain or clumps. They are non-spore-forming, non motile, catalase-negative and produce acid but no gas from a variety of carbohydrates. They occur in animal and human habitats, in particular they have been isolated from feces, rumen of cattle, sewage, human vagina, dental caries and honey bee intestine [6]. Martin *et al.* recently reported the first isolation of bifidobacteria, i.e., *B. breve*, *B. adolescentis* and *B. bifidum* from breast milk [4]. Genus *Streptococcus* contains 60 species and its members are known for their pathogenicity, except *S. thermophilus*. It is Gram-positive, catalase-negative, non-motile, non-spore-forming, and used as starter for yoghurt production. The properties of this product attributed beneficial such as alleviation of symptoms of lactose intolerance and other gastrointestinal disorder [6]. Streptococci were the second most abundant bacteria in breast milk. Most common streptococci found in breast milk are *S. agalactiae*, *S. mitis*, *S. oralis*, *S. parasagis*, *S. peroris* and *S. salivarius*. It has been shown that *S. salivarius* could inhibit the growth of *Staphylococcus aureus* [3].

Commensal bacteria such as genera of *Lactobacillus*, *Bifidobacterium*, and *Streptococcus* are considered to be among the potential probiotic bacteria. Probiotics are “live microorganisms, which, when consumed in adequate amounts, confer a health benefit on the host” (FAO/WHO) [8]. The mechanisms of probiotics include remodeling of microbial communities, immunomodulation by up-regulation of anti-inflammatory factors, immunomodulation by suppression of pro-inflammatory factors, enhancement of immunity, effects on epithelial cell differentiation, proliferation, promotion of intestinal barrier function and suppression of pathogens [8]. Probiotic bacteria were able to suppress pathogens by producing acid, hydrogen peroxide or bacteriocin and small organic molecules [9]. It has been known for several decades that specific probiotic lactobacilli and bifidobacteria inhibit the growth of pathogen microorganisms such as *Escherichia coli*, *Salmonella enterica*, *Shigella sonnei*, *Helicobacter pylori*, *Staphylococcus aureus*, *Salmonella typhimurium*, *Yersinia enterocolitica* and *Clostridium perfringens* [7, 10]. *Lactobacillus* such as *L.reuteri* strains produces antimicrobial compound as reuterin that ability to inhibit the growth of enteric pathogens [11]. *Bifidobacterium* sp. produce bacteriocin that is able to inhibit the growth of food-borne pathogens such as

*C. perfringens*, *E. coli*, *Salmonella* and other human health-threatening pathogens such as the *H. pylori* [12]. *Streptococcus thermophilus* can produce bacteriocin as thermophilins that inhibits *Clostridium tyrobutyricum* [13].

Identification of *Lactobacillus*, *Bifidobacterium* and *Streptococcus* employs conventional culture and molecular techniques. Culture technique is limited in the identification and quantification of these fastidious bacteria. Therefore culture-independent molecular method based on 16S rRNA genes, plays role in the identification of these bacteria. This study aims to isolate and identify beneficial bacteria such as *Lactobacillus*, *Bifidobacterium*, and *Streptococcus* in breast milk and investigate their antagonistic activity against bacterial pathogens of these bacteria.


### **Hypothesis**

*Lactobacillus*, *Bifidobacterium*, and *Streptococcus* isolated from breast milk confer antagonistic activity against bacterial pathogens.


### **Objective**

- Isolate and identify *Lactobacillus*, *Bifidobacterium*, and *Streptococcus* from breast milk.
- Detect DNA of *Lactobacillus*, *Bifidobacterium*, and *Streptococcus* in breast milk using PCR method.
- Test the antagonistic activity of *Lactobacillus*, *Bifidobacterium*, and *Streptococcus* isolates from breast milk to bacterial pathogens.

### Conceptual framework



### Workflow





## CHAPTER II


### LITERATURE REVIEWS

#### 1. Breast milk

Breast milk is a unique, species-specific, complex nutritive fluid with immunologic and growth-promoting properties as follows. Immunoglobulin A (IgA) is an important protective factor against infection especially when the infant has limited defense against ingested pathogens. Lactoferrin in breast milk is an iron-binding protein which binds to iron, thus making it unavailable to pathogenic bacteria. Lysozyme which enhance sIgA bactericidal activity against gram-negative organisms. Oligosaccharides which intercept bacteria and form harmless compounds that the baby excretes. Lipids are known to be potent antimicrobial/microbicidal agents *in vitro* and to kill enveloped viruses, Gram-positive and Gram-negative bacteria and fungi on contact. Mucins which are present on milk-fat globule membrane. Mucins adhere to bacteria and viruses and help eliminate them from the body. In addition, breast milk also contains growth modulators such as epidermal growth factor (EGF), nerve growth factor (NGF), insulinlike growth factors (IGFs), interleukins, Transforming growth factor (TGF)-alpha and TGF-beta [14, 15]. The composition of breast milk that improve and protect breast-fed infants against infectious diseases [3, 5]. Breast milk consists of commensal bacteria such as genus *Staphylococcus* sp., i.e. *S. epidermidis*, *S. hominis*, *S. capitis* and *S. aureus* that bacterial flora of the maternal skin. *Streptococcus* sp., i.e. *S. salivarius*, *S. mitis*, *S. parasanguis* and *S. peroris*, genus *Lactobacillus* sp., i.e. *L. gasseri*, *L. rhamnosus*, *L. acidophilus*, *L. plantarum* and *L. fermentum*, genus *Enterococcus* sp., i.e. *E. faecium* and *E. faecalis* [5] and genus *Bifidobacterium* sp., i.e. *B. adolescentis*, *B. longum*, *B. breve* and *B. bifidum* [4].

It was suggested that breast milk bacteria may be originated not only from external sources but also from the maternal gut microorganism. It was suspected that dendritic cell that penetrated the gut epithelium take up bacteria directly from gut

lumen [16]. In addition, M cells on Peyer's patch can phagocytose the gut microorganism. Once inside the cells, bacteria may be able to move from the intestinal mucosa to colonize distant mucosal surfaces, such as those of respiratory and genitourinary tracts, salivary and lachrymal glands and most significantly that of lactating mammary gland shown in Figure 1 [5, 17].



**Figure 1.** The hypothetical model to explain how some bacterial strains could be presented in breast milk. (A) dendritic cell that penetrated the gut epithelium take up bacteria directly from gut lumen. (B) M cells on Peyer's patch can phagocytose the gut microorganism. Abbreviations: GUM, genitourinary tract mucosa; LMGM, mucosa of the lactating mammary gland; MLN, mesenteric lymph node; PP, Peyer patches and associated lymphoid tissue; RM, respiratory tract mucosa; SLGM, mucosa of the salivary and lacrimal glands.

The commensal bacteria exhibited in breast milk was suggested to be a major factor in the initiation and development of the infant gut microbiota [5]. In addition, it has been reported that the bacterial composition of the breast-fed infant flora reflected the bacterial composition of breast milk [3]. Beneficial bacteria were presented in breast milk such as *Lactobacillus*, *Bifidobacterium* and *Streptococcus*.

## 1. The genus *Lactobacillus*

### 1.1 Background of lactobacilli

The genus *Lactobacillus* belongs to the phylum *Firmicutes*, class *Bacilli*, order, *Lactobacillales*, family *Lactobacillaceae*. The first species of genus *Lactobacillus* was isolated from milk as *Lactobacillus delbruceckii* by Leichman (1896). After the few years, Moro (1900) recovered was *Lactobacillus acidophilus* by culture from the breast-fed infant feces. *Lactobacillus casei* is the name of lactobacilli isolated from cheese, milk and dairy product by Orla-jensen (1904). Lauer and Kandler (1980) isolated *Lactobacillus gasseri* from human mouth, vagina and intestinal tract of man. In 1953 Rogosa *et al.* isolated *Lactobacillus salivarius* from mouth and intestinal tracts which similar *Lactobacillus murinus* isolated by Heijenoort *et al* [18]. Currently, genus *Lactobacillus* consists of more than 175 species of which 19 species are of research interest as probiotics as shown in Table 1.

**Table 1.** *Lactobacillus* species of research interest as probiotics [19].

Species	Original isolated	Mol% G+C
<i>L. acidophilus</i>	Breast-fed infant feces, intestinal tract of human and animal	32-37
<i>L. agilis</i>	Sewage , human intestinal tract	34-36
<i>L. aviarius</i>	Human and chicken intestinal tract	34-36
<i>L. amylovorus</i>	Cattle waste-corn fermentation	40-41

**Table 1.** *Lactobacillus* species of research interest as probiotics [19] (Continued)

<b>Species</b>	<b>Original isolated</b>	<b>Mol% G+C</b>
<i>L. brevis</i>	Milk, cheese, feces, mouth, gastrointestinal tract of human	44-47
<i>L. casei</i>	Milk, cheese, dairy product, human intestinal tract, mouth, vagina	45-47
<i>L. crispatus</i>	Human feces, vagina	35-38
<i>L. delbrueckii</i> subsp. <i>bulgaricus</i>	Yoghurt and cheese	49-51
<i>L. galinarum</i>	Human intestinal tract, vagina	36-37
<i>L. gasseri</i>	Human mouth and vagina	33-35
<i>L. johnsonii</i>	Human vaginal discharge and blood clot	35-37
<i>L. murinus</i>	Intestinal tract of mice and rat	43-44
<i>L. hamsteri</i>	Feces of hamster	33-35
<i>L. intestinalis</i>	Intestine of human and animal	33-35
<i>L. plantarum</i>	Dairy products and environment	44-46
<i>L. reuteri</i>	Feces of human and animal, meat products	40-42
<i>L. ruminis</i>	Rumen of cow and sewage, human feces	44-47
<i>L. salivarius</i>	Mouth and intestinal tract of human and hamster	34-36
<i>L. rhamnosus</i>	Intestine, mouth and vagina of human, dairy environment	45-47

## 1.2 Biology of lactobacilli

Lactobacilli are Gram-positive rod or coccobacilli shape, non-spore-forming, non-motile microorganisms. They are fermentative, microaerophilic and chemo-organotrophic, requiring rich media to grow. They are catalase negative, even if pseudocatalase activity can sometime be present in some strains. Members of the genus *Lactobacillus* can be selected on solid culture media that have an acidic pH (e.g. Rososa SL agar). While many *Lactobacillus* strains used in the dairy industry can be culture under microaerophilic, or aerobic conditions, intestinal isolates proliferate best under anaerobic conditions [18].

The genus *Lactobacillus* includes more than 175 validly described species. They are found in environments where carbohydrates are available such as food (dairy products, fermented meat, sour doughs, vegetables, fruits, beverages), respiratory, GI and genital tracts from human and animals and in sewage and plant material [20]. They are growth at temperature range 2-53 °C and optimum generally at 30-40°C. Optimum pH for growth at 5.5-6.2 and growth generally occur pH 5.0 or less. The G+C content of DNA 32-53 mol%. They are complex nutritional requirement for growth found as amino acid, vitamin, peptide, salt, nucleic acid, fatty acid or fatty acid esters and fermentable carbohydrates [18]. The main of fermentation pathways are obligately homofermentative; lactobacilli are able degrade hexoses to lactic acid by the Embden-Meyerhof pathway (EMP), facultatively heterofermentative; lactobacilli degrade hexoses to lactic acid by the EMP and are also able degrade pentose or glucose to aldolase and phosphoketolase, finally, obligately heterofermentative; lactobacilli are degrade hexoses to lactate, ethanol or acetic and CO<sub>2</sub> by the phosphogluconate pathway [21]. Genus *Lactobacillus* are identify base on metabolic characteristics, phylogenetic grouping, genome GC. In addition, the fastest way to identify lactobacilli used molecular method such as comparison of 16S rDNA gene sequences, the method shows that the V1, V2 and V3 regions contain the species-specific information, 16S, 23S and 5S rRNA genes are arranged within an operon on the bacterial chromosome [22, 23].

## 1.3 Beneficial effect of lactobacilli

Lactobacilli are lactic acid bacteria (LAB) and are normally consumed in the form of yoghurt, fermented milk or fermented food. They are colonized in the human

large intestine and suggested a beneficial role for the host. In addition, some strains of *Lactobacillus* are plays role of probiotics. These effects are likely to involve both microbe-microbe and microbe-host interaction such as anti-microbial effects, immunomodulatory properties and gastrointestinal benefits. The beneficial effect of lactobacilli summarized shown in Table 2.

**Table 2.** The summary of beneficial effect of lactobacilli

Beneficial effect	Study summary	Reference
Prevention of gastrointestinal disease	Lactobacillus GG compared with a placebo product has been shown to significantly reduce the risk of in particular rotavirus gastroenteritis (2.2% compared with 17%, $P = 0.02$ ) in hospitalized children	[24]
	Lactobacillus GG and <i>L. acidophilus</i> were evaluated and compared with placebo for the prevention of side-effects in the treatment of <i>H. pylori</i>	[25]
	<i>L. rhamnosus</i> 19070-2 and <i>L. reuteri</i> DSM 12246, ameliorated acute diarrhea in hospitalized children and reduced the period of rotavirus excretion.	[26]
	<i>L. paracasei</i> could act as a potential barrier to prevent <i>S. aureus</i> - associated injury	[27]

**Table 2.** The summary of beneficial effect of lactobacilli (Continued)

Beneficial effect	Study summary	Reference
Cancer prevention	Specific strain <i>L. casei</i> showing significantly ( $P= 0.03$ ) postponed tumor recurrence in 48 patients after removal of one or more bladder tumors.	[28]
Cholesterol reduction	The tablets contains <i>L. bulgaricus</i> ATCC 33409 and <i>L. acidophilus</i> ATCC 4962 showing serum cholesterol reduced from 5.7 to 5.3 mmol/L after 7 wk ( $P < 0.05$ ) in the 23 pilots.	[29]
Anti- microbial effects	Specific strain of <i>L. acidophilus</i> contains with buffalo fermented milk showing serum cholesterol reduced to 12-20% after 1 month	[30]
Anti- microbial effects	<i>L. salivarius</i> UCC118 produce bacteriocin for against <i>Listeria monocytogenes</i> the invasive food-borne pathogen	[31]
Anti- microbial effects	<i>L.gasseri</i> CECT5714 isolated from breast milk produce anti-microbial compound to inhibit <i>E.coli</i> , <i>Salmonella</i> spp. and <i>Listeria monocytogenes</i>	[32]

## 2. The genus *Bifidobacterium*

### 2.1 Background of bifidobacteria

The genus *Bifidobacterium* belongs to the phylum *Actinobacteria*, class *Actinobacteria*, subclass *Actinobacteridae*, order *Bifidobacteriales*, family *Bifidobacteriaceae*. Bifidobacteria were first isolated from the breast-fed infant feces in 1899, by Henri Tissier, and were designated *Bacillus bididus* [33]. Even though Orla-Jensen proposed the genus *Bifidobacterium* in 1924[34], bifidobacteria were classified into other taxonomic group, such as *Bcillus bifidus* (1900), *Bacteroides bifidus* (1923 to 1934, in the 1st to 4<sup>th</sup> editions of Bergey's Manual of Systematic Bacteriology Bergey's Manual) and *Lactobacillus bifidus* (1939 to 1957, in the 5<sup>th</sup> to 7<sup>th</sup> editions of Bergey's Manual), for several decades. In 1973, Poupard *et al.*[35], and subsequently the 8th edition of Bergey's Manual [36], reclassified them as a separate taxon and designated the genus *Bifidobacterium*. Currently, genus *Bifidobacterium* contains 31 species that have been isolates from intestine of humans, animal and insects, and also from human dental caries and raw milk shown in Table 3.

**Table 3.** Currently defined species of the genus *Bifidobacterium* [37]

Species	Subspecies	Original isolated	%G+C <sup>a</sup>	Reference
<i>B. adolescentis</i>		Intestine of adult	59.6 _ 0.8	[38]
<i>B. angulatum</i>		Human feces	59.0 _ 0.1	[39]
<i>B. animalis</i>	<i>B. animalis</i> subsp. <i>Animalis</i>	Animal feces	60.1 _ 0.3	[40]
	<i>B. animalis</i> subsp. <i>lactis</i>	Yogurt	61.9	[41]
<i>B. asteroides</i>		Intestine of honeybee	59.0	[42]
<i>B. bifidum</i>		Infant feces	62.3	[43]
<i>B. bombi</i>		Intestine of bumblebee	47.2	[44]
<i>B. boum</i>		Rumen of cattle	60 _ 0.2	[45]
<i>B. breve</i>		Intestine of infant	58.8 _ 0.4	[46]

a; Mean \_ SD. , ND, not determine



**Table 3.** Currently defined species of the genus *Bifidobacterium* (Continued)[37]

Species	Subspecies	Original isolated	%G+C <sup>a</sup>	Reference
<i>B. catenulatum</i>		Intestine of adult	54.0 _ 0.2	[39]
<i>B. choerinum</i>		Porcine feces	66.3 _ 0.2	[45]
<i>B. coryneforme</i>		Intestine of honeybee	ND	[47]
<i>B. crudilactis</i>		Raw milk	56.4	[48]
<i>B. cuniculi</i>		Feces of rabbit	64.1 _ 0.4	[45]
<i>B. dentium</i>		Human dental caries	61.2 _ 0.4	[39]
<i>B. gallicum</i>		Human feces	ND	[49]
<i>B. gallinarum</i>		Chicken cecum	65.7 _ 1.5	[50]
<i>B. indicum</i>		Intestine of honeybee	60.0	[42]
	<i>B. longum</i> subsp. <i>Infantis</i>	Intestine of infant	60.5 _ 0.3	[46]
<i>B. longum</i>	<i>B. longum</i> subsp. <i>Longum</i>	Intestine of adult	60.8 _ 0.8	[46]
	<i>B. longum</i> subsp. <i>Suis</i>	Porcine feces	62.0	[51]
<i>B. magnum</i>		Rabbit feces	60.0 _ 0.6	[52]
<i>B. merycicum</i>		Bovine rumen	ND	[53]
<i>B. minimum</i>		Sewage	61.5	[47]
<i>B. pseudocatenulatum</i>		Infant feces	57.5 _ 0.3	[45]
	<i>B. pseudolongum</i> subsp. <i>Globosum</i>	Bovine rumen	63.8 _ 0.4	[47]
<i>B. pseudolongum</i>	<i>B. pseudolongum</i> subsp. <i>Pseudolongum</i>	Porcine feces	59.5 _ 0.4	[54]

<sup>a</sup>; Mean \_ SD. , ND, not determine

**Table 3.** Currently defined species of the genus *Bifidobacterium* (Continued)[37]

Species	Subspecies	Original isolated	%G+C <sup>a</sup>	Reference
<i>B. psychraerophilum</i>		Porcine feces	59.2	[55]
<i>B. pullorum</i>		Chicken feces	67.5 _ 0.4	[56]
<i>B. ruminantium</i>		Bovine rumen	ND	[53]
<i>B. saeculare</i>		Rabbit feces	ND	[57]
<i>B. scardovii</i>		Human blood	ND	[58]
<i>B. subtile</i>		Sewage	61.5	[59]
<i>B. thermophilum</i>		Porcine feces	60.0	[40]
	<i>B. thermacidophilum</i> subsp. <i>porcinum</i>			
<i>B. thermacidophilum</i>	<i>B. thermacidophilum</i> subsp. <i>Thermacidophilum</i>	Sewage	ND	[60]

<sup>a</sup>; Mean \_ SD. , ND, not determine

## 2.2 Biology of bifidobacteria

Bifidobacteria are anaerobic bacteria. They are Gram-positive, polymorphic branched rods that occur singly, in chains or clumps. *N*-acetyl-amino-sugar, Ca<sup>2+</sup> ions, or amino acid (alanine, aspartic acid, glutamic acid, and serine) has revealed of bifidobacteria morphology, that the absence or low concentrations of in growth media exclusively induce the bifid shape of bifidobacteria [61]. They are non-motile, non-spore-forming and non-filamentous. Bifidobacteria produce acid but not gas from a variety of carbohydrates. They are catalase negative, with some exception, *Bifidobacterium incidum* and *Bifidobacterium asteroides* when grown in presence of air [6]. Optimum growth temperature 37-41 °C, the strains isolated from human intestine growth at 37-38 °C and isolated from animal intestine growth at 41 °C. The high growth temperature 46 °C and low growth temperature 25-28 °C. Optimum pH

for growth 6.5-7.5 and could not growth at lower than pH 4.5-5.0 or higher than pH 8.0-8.5 [62]. Bifidobacteria has with a high G+C content 55 to 57 mol % [6, 63, 64]. They present in many habitats such as feces of human and animal, rumen of cattle, sewage, human vagina, dental caries and honey bee intestine [6, 37]. Recently, has isolated bifidobacteria from breast milk [4]. Bifidobacteria degrade hexose through fructose-6-phosphate pathway by using fructose-6-phosphate phosphoketolase, adolase and glucose-6-phosphate dehydrogenase enzyme and the end product is lactic acid and acetic acid [61]. The taxonomic character for identify on genus level was considered with the enzyme [65]. Detection and identification of bifidobacteria were approached for three principal such as culturing method using a selective media for selection and identification, culture absence molecular methods for detection and molecular method for identification and differentiation. Selective media developed for bifidobacteria contain with antibiotic, it was inhibitory to some bifidobacteria [66, 67]. Beerens (1990) improved *Bifidobacterium*-selective medium, columbia medium by addition of 5 g/l glucose, 5 g/l cysteine hydrochloride, 5 g/l agar, 5 ml propionic acid and adjusted to pH 5.0 was both elective and selective for all species of *Bifidobacterium* [68]. Molecular method has highly enhanced approaches for detection, differentiation and identification of bifidobacteria. The molecular tools for use and development of these bifidobacteria such as AP-PCR (arbitrarily primed PCR) use of a single indiscriminate primer to gain of banding patterns for strain-specific; the subject can be to reproducibility problems [69], ARDRA (amplified rRNA gene restriction analysis) i.e., RFLP analysis of the *ldh* gene [70] or RFLP analysis of the 16S rRNA gene [71], PFGE (pulsed-field gel electrophoresis) use of a band profile analysis of complete genome by use of scarce-cutting enzymes [72] and 16S rRNA gene sequence analysis [73, 74].

### 2.3 Beneficial effect of bifidobacteria

Bifidobacteria are bacteria in the human large intestine and suggested a helpful for the host. There shown significantly event higher in the un-weaned infant gut more than in adults, they may a more important role in gut microbiota development than in other gut function. The properties of bifidobacteria in the large intestine of human including interactions with other gut microbes, production of

vitamins including group of B vitamins, modulation of convinced bacterial groups that may be baneful to the host, production antimicrobial compounds found as organic acid [62] , iron-scavenging compounds [75] and bacteriocin [76, 77]. The function of bifidobacteria in the intestine may be in protection against some immune-based disorders, as previous studies have shown them to stimulate a host innate immune response [78, 79]. Numerous studies have suggested that the human health benefits is associated possession of bifidobacteria in the human large intestine such as prevention of diarrhea, establishment of a healthy microflora in premature infants, colon regularity, lactose intolerance, cholesterol reduction and immunostimulatory effects. These potential health benefits were summaries in Table 4.

**Table 4.** Summary of potential health benefits of bifidobacteria

Health benefit	Study summary	Reference
	<i>B. bifidum</i> and <i>B. longum</i> subsp. <i>infantis</i> showing a protective effect against rotaviral diarrhea, a statistically significant ( $P$ _ 0.001)	[80]
	<i>B. breve</i> showing a protective effect against rotaviral diarrhea but non-statistically significant	[81]
Prevention of diarrhea	<i>B. bifidum</i> showing a protective effect reduced shedding of rotavirus ( $P$ _ 0.01)	[82]
	<i>B. animalis</i> subsp. <i>lactis</i> showing protective effect against all forms of diarrhea and a higher titer of antirotaviral antibodies in the feces, statistically significant ( $P$ _ 0.01)	[83]

**Table 4.** Summary of potential health benefits of bifidobacteria (Continued)

Health benefit	Study summary	Reference
Prevention of diarrhea	<i>B. bifidum</i> and <i>Streptococcus thermophilus</i> showing protective effect reduced shedding of rotavirus , statistically significant ( $P_{0.035}$ )	[84]
	<i>B. animalis</i> subsp. <i>lactis</i> showing protective effect but a non-statistically significant	[85]
	<i>B. breve</i> and <i>S. thermophilus</i> showing a reduced severity of diarrhea episodes over a 5-month period ( $P_{0.01}$ )	[86]
	<i>B. animalis</i> and 4 species of <i>Lactobacillus</i> showing reduced the incidence of necrotizing enterocolitis ( $P_{0.05}$ )	[87]
Establishment of a healthy microflora in premature infants	<i>B. breve</i> showing resulted in establishment of a bifidobacterial flora in the majority of infants during the first week of life, whereas it took the control group several weeks, with only 3 of 9 infants showing bifidobacteria by week 7	[88]
	<i>B. breve</i> showing reduced fecal butyric acid levels, but only in the subgroup of infants that weighed 2,500 g ( $P_{0.05}$ )	[89]

**Table 4.** Summary of potential health benefits of bifidobacteria (Continued)

Health benefit	Study summary	Reference
Colon regularity	<i>B. animalis</i> subsp. <i>lactis</i> and yogurt cultures showing some reduce in colonic transit times ( $P < 0.05$ )	[90]
	<i>B. animalis</i> subsp. <i>lactis</i> and yogurt cultures showing no statistically significant reduce in colonic transit times	[91]
	Supplementation with <i>B. animalis</i> subsp. <i>lactis</i> showing some reduce in colonic transit times ( $P < 0.05$ )	[92]
	<i>B. animalis</i> subsp. <i>lactis</i> showing a reduce in colonic transit after 2 weeks ( $P < 0.001$ )	[93]
Lactose intolerance	<i>B. longum</i> showing some reduce in breath hydrogen ( $P < 0.05$ )	[94]
	<i>B. animalis</i> subsp. <i>lactis</i> and yogurt cultures showing some reduce in symptom scores ( $P < 0.05$ )	[95]
Cholesterol reduction	<i>B. animalis</i> subsp. <i>lactis</i> and <i>L. acidophilus</i> showing some reduce in serum cholesterol levels ( $P < 0.05$ )	[96]

**Table 4.** Summary of potential health benefits of bifidobacteria (Continued)

Health benefit	Study summary	Reference
Cholesterol reduction	Yoghurt containing with <i>L. acidophilus</i> 145, <i>B. longum</i> 913 and 1% oligofructose (synbiotic). showing no reduction in total cholesterol but an increase in high-density lipoprotein (HDL) levels ( $P \_ 0.001$ )	[97]
	<i>B. longum</i> and <i>L. acidophilus</i> showing did not affect cholesterol levels	[98]
Immunostimulatory effects	<i>B. bifidum</i> showing reduce in CD4_ T cells in the spleen and colon ( $P \_ 0.05$ )	[99]
	<i>B. longum</i> subsp. <i>infantis</i> showing some reduce in the proinflammatory cytokines IFN-, TNF-, and IL-12	[100]
	<i>B. longum</i> showing some increase in mucosal IgA ( $P \_ 0.05$ )	[101]
	<i>B. animalis</i> subsp. <i>lactis</i> and <i>Lactobacillus paracasei</i> showing no statistically significant changes in cytokine levels	[102]
	<i>B. animalis</i> subsp. <i>lactis</i> showing some increase in the anti-inflammatory cytokine IFN- and in phagocytic activity ( $P \_ 0.05$ )	[78]

**Table 4.** Summary of potential health benefits of bifidobacteria (Continued)

Health benefit	Study summary	Reference
Immunostimulatory effects	<i>B. longum</i> , inulin, and fructooligosaccharides showing some decrease in expression of genes encoding human proinflammatory cytokines ( $P \leq 0.05$ )	[103]
	<i>B. longum</i> subsp. <i>infantis</i> showing reductions in symptom scores and in the ratio of IL-10 to IL-12 (anti-inflammatory to proinflammatory cytokines), normalized to that of healthy individuals	[104]
Cancer prevention	Heat-killed <i>B. infantis</i> showing some reduce in the incidence of tumors ( $P \leq 0.01$ ) in mice	[105]
	<i>B. longum</i> showing some decrease in carcinogenesis reduced aberrant crypt foci ( $P \leq 0.05$ ) and a significant decrease following co-supplementation with <i>B. longum</i> and inulin ( $P \leq 0.001$ ) in mice	[106]
	<i>B. animalis</i> subsp. <i>lactis</i> showing a significant reduce in carcinogen-induced colonic neoplasms ( $P \leq 0.001$ ) in mice	[107]
	<i>B. animalis</i> subsp. <i>lactis</i> , <i>L. rhamnosus</i> , and inulin showing some improve in epithelial barrier function and cell toxicity only in polypectomized patients ( $P \leq 0.05$ ) in cancer or polypectomized patients	[108]



### 3. The genus *Streptococcus*

#### 3.1 Background of streptococci

The genus *Streptococcus* belongs to the phylum *Firmicutes*, class *Bacilli*, order *Lactobacillales* family *Streptococcaceae*. This species originally isolated from suppurative lesions in human. Since 1874, Billroth he observe to chain-forming cocci in wounds and applied the term “streptococcus” as organisms to designate their morphological arrangement. A few years later, Rosenbach (1884) first used the word *Streptococcus* in the generic sense and describe the species *Streptococcus pyogenes* which is now the type species of the genus. The species group recognized to genus *Streptococcus* in currently such as pyogenic, mitis, salivarius, anginosus, mutans and bovis (Table 5). Genus *Streptococcus* including about 60 species and a number of them is known for their pathogenicity. The beneficial streptococci found as salivarius group. *Streptococcus thermophilus* species is contain in the group of lactic acid bacteria (LAB). It is one the microorganisms using in dairy product and most commercially important of all LAB. It is association with *L. delbrueckii* subsp. *Bulgaricus*. Since 1984 Farrow and Collins reclassify *S. thermophilus* as *S. salivarius* subsp. *thermophilus* but the definition of its status of separate species have definitively been established by Schleifer *et al.* (1991) with the name of *Streptococcus thermophilus*

**Table 5.** The species groups in genus *Streptococcus* [109, 110]

Group	Species
Pyogenic	<i>S. pyogenes</i> , <i>S. agalactiae</i> , <i>S. canis</i> , <i>S. dysgalactiae</i> , <i>S. equi</i> , <i>S. parauberis</i> , <i>S. iniae</i> , <i>S. parauberis</i> , <i>S. porcinus</i> , <i>S. uberis</i>
Mitis	<i>S. gordonii</i> , <i>S. mitis</i> , <i>S. oralis</i> , <i>S. parasanguis</i> , <i>S. pneumoniae</i> , <i>S. sanguis</i>
Salivarius	<i>S. salivarius</i> , <i>S. thermophilus</i> , <i>S. vestibularis</i>
Anginosus	<i>S. anginosus</i> , <i>S. constellatus</i> , <i>S. intermedius</i>
Mutans	<i>S. mutans</i> , <i>S. cricetus</i> , <i>S. downei</i> , <i>S. macacae</i> , <i>S.</i> <i>rattus</i> , <i>S. sobrinus</i>
Bovis	<i>S. vobis</i> , <i>S. alactolyticus</i> , <i>S. equinus</i>

### 3.2 Biology of streptococci

Streptococci are Gram-positive cocci, which may be spherical or ovoid in shape and are usually arranged in chain or pairs. They are non motile and do not form endospores. These streptococci are growth in facultative anaerobe, but some strains require CO<sub>2</sub>. They are catalase-negative and homofermentative. The growth temperature at 10-45 °C and low of G+C DNA content 35-43 mol%. The streptococci are found on the mucous membranes of the mouth, upper respiratory tract, alimentary tract and human and animal skin [111]. In addition, lactic acid streptococci were recovered in fermented milk such as yoghurt and cheese [112, 113]. *Streptococcus thermophilus* detected by specific amplified of *lacZ* gene, rapid and reliable PCR-based technique [114].

### 3.3 Beneficial effect of streptococci

Genus *Streptococcus* is considered to be lactic acid bacteria (LAB). *Streptococcus thermophilus* is an important LAB used for the food industry such as used for the manufacture of dairy product, used for as starter culture combination with *Lactobacillus delbrueckii* subsp. *bulgaricus* for production of yoghurts [113] and usage in cheese production i.e., Swiss cheese, Brick cheese, Parmesan, Provolone, Mozzarella and Asiago [112]. *Streptococcus thermophilus* is ability to survive in

gastrointestinal tract and moderately adhere to intestinal epithelial cells [115]. The beneficial effect of *Streptococcus thermophilus* has been shown as positive effects on diarrheas in young children, enterocolitis in premature neonates and inflammatory gut disease [116]. Furthermore, it has shown produce antioxidants [117], stimulate the gut immune system [116], alleviate the risk of certain cancer and improve lactose digestion in lactose intolerant individuals [118]. In addition, it has shown inhibits *Clostridium tyrobutyricum* by production of bacteriocin [13].

#### **4. Antimicrobial compound of *Lactobacillus*, *Bifidobacterium* and *Streptococcus***

Antimicrobial compound is produced by lactic acid bacteria (LAB) such as *Lactobacillus*, *Bifidobacterium* and *Streptococcus*. The antimicrobial compound is classified as low-molecular-mass (LMM) compounds such as organic acid, hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>), carbon dioxide (CO<sub>2</sub>), diacetyl (2,3-butanedione) and high-molecular-mass (HMM) compounds like bacteriocins [119].

##### 4.1 Organic acid

The organic acid is product by LAB fermentation and the character of organic acid associate with accumulation of organic acids and the accompanying reduction in pH. The type of organic acid found as lactic acid, acetic acid and propionic acid. Lactic acid is the main metabolite of LAB fermentation and the boundary of the dissociation depends on pH. It is toxicity to many bacteria, fungi and yeasts. At pH 5.0 lactic acid was inhibit to spore-forming of bacteria but was no effective against yeasts and moulds [120]. Acetic acid and propinonic are more effective of antimicrobial than lactic acid because their have higher pKa values (lactic acid 3.08, acetic acid 4.75, and propionic acid 4.87), and their have higher percent of undissociated acids than lactic acid at a given pH [121]. Acetic acid was more inhibition growth of *Listeria monocytogenes* [122] and *Bacillus cereus* [123] more than acetic acid.

##### 4.2 Hydrogen peroxide

The antimicrobial effect of H<sub>2</sub>O<sub>2</sub> may result from the oxidation of sulfhydryl groups causing denaturing of a number of enzymes, and from the peroxidation of

membrane lipids thus the increased membrane permeability. It has been reported that H<sub>2</sub>O<sub>2</sub> produce by *Lactobacillus* and *Lactococcus* strains could be inhibit *Staphylococcus aureus*, *Pseudomonas* sp.[124].

#### 4.3 Carbon dioxide

Carbon dioxide CO<sub>2</sub> may properties in creating an anaerobic environment which inhibits enzymatic decarboxylations and the accumulation of CO<sub>2</sub> in the membrane lipid bilayer may cause a dysfunction in permeability. CO<sub>2</sub> can inhibit the growth of many food spoilage microorganisms, especially Gram-negative psychrotrophic bacteria [125].

#### 4.4 Diacetyl (2,3-butanedione)

Diacetyl is produced by strains within all genera of LAB by citrate fermentation. It inhibits the growth of Gram-negative bacteria more than Gram-positive bacteria by reaction of the arginine-binding protein, thus affecting the arginine utilization [126].

#### 4.5 Reuterin

Reuterin is a product by heterofermentative of *Lactobacillus reuteri*, species a member of microbiota of human and animal gastrointestinal tract. Reuterin presented a broad spectrum of antimicrobial activity against pathogens such as Gram-positive and Gram-negative bacteria, yeast, fungi and protozoa. The organisms have sensitive to reuterin such as *Salmonella*, *Shigella*, *Clostridium*, *Staphylococcus*, *Listeria*, *Candida*, and *Trypanosoma* [127].

#### 4.6 Bacteriocins

Bacteriocins are proteinaceous compounds produced by bacteria strains in order to inhibit the growth of other bacteria. Bacteriocins groups are classified base on molecular weight differences. Class I- bacteriocins are small peptides (<5 kDa), Class II- small hydrophobic bacteriocins are heat-stable peptides (<13 kDa), Class III- large bacteriocins are heat-labile proteins (>30 kDa) and Class IV- complex bacteriocins are proteins with lipid and/or carbohydrate moieties [128]. The activity spectrum of

bacteriocins can be narrow and confined to inhibition of closely related species, or it can be relatively broad and include many different bacterial species.

## **5. Methods for evaluation of antimicrobial activity**

### 5.1 The agar diffusion method

The agar diffusion method was first used by Fleming in 1924. The method used for detection of antimicrobial activity and has long been widely used for evaluation of antimicrobial activity, especially for biologically derived compounds. It including agar well diffusion assay and disc assay. In this test, an antimicrobial compound is applied to an agar plate on a paper disc or in a well. The compound diffuses into agar resulting in a concentration gradient that is inversely proportional to the distance from the disc or well. The size of the inhibition zone able measured of degree around the disc or well. The results of the test are generally qualitative [129]. The method requires that the indicator organisms must grow rapidly, uniformly, and aerobically. Since highly hydrophobic antimicrobial compounds cannot diffuse in agar, they are not suitable for tests by this method [130]. The method with modified for used testing antimicrobial activity based on the agar diffusion method such as agar spot method [131] and spot-on-lawn method [132].

### 5.2 The agar and broth dilution methods

Agar and broth dilution methods are quantitative methods for suit microorganisms with variable growth rate and for anaerobic, microaerophilic microorganisms. The results are exhibited as MIC, which is the lowest concentration of an antimicrobial that prevents growth of a microorganism after a specific incubation period. In this test, serial dilution of antimicrobial and add a single concentration to culture tube (nonselective broth) or plate (melted agar medium), which is then inoculated with test organisms and incubated. The MIC is defined as the lowest concentration at which no growth occurs (absence of turbidity) in a medium following incubation [129]. The broth dilution assay has been used for the determination of the antimicrobial activity of reuterin produced by *Lb. reuteri*, and the

activity of reuterin was exhibited as MIC values or as the maximum dilutions of the reuterin fraction[127].

### 5.3 The automated turbidometric assay

A turbidometric assay used for determines the effect of a compound on the growth or death kinetics of a microorganism. The assay is based on automated systems. It result shown information concerning the effect of an antimicrobial that may cause a delayed lag phase or reduced growth rate at concentrations below the MIC. Since the bacterial growth is monitored by measuring the turbidity of the broth medium, the method demands that the instrument be highly sensitive [133].

## CHAPTER III

### MATERIAL AND METHODS

#### 1. Human subjects and sample collection

Breast milk were collected from healthy lactating Thai women who brought infants to receive vaccination at well baby clinic, 9<sup>th</sup> floor Por-Por-Ror building, King Chulalongkorn Memorial Hospital. Participated volunteers were enrolled according to following criteria (i) healthy women without present or past underlying condition (ii) aged 18-40 years (iii) lactating at range 15 days to 60 days and (iv) never received antibiotics during pregnancy and at least 1 month before sample collection. The sample calculated from the formula  $n = z_{\alpha}^2 P (1-P) / e^2$  where  $z_{\alpha} = 1.96$ ,  $P = 0.07$ ,  $e = 0.05$ ) was found to be 99.99. In this study, a total of 102 milk samples were then collected from volunteers, All volunteers were gave written informed consent to the protocol, which were approved by Ethical Committee of Faculty of Medicine, Chulalongkorn University. The participants provide samples of breast milk and, breast skin swabs. Nipple and mammary were first cleaned with sterile water and skin sampling was performed using sterile cotton swabs to rub around area of the outer quarter of breast and placed into a sterile tubes containing 0.15% peptone water. The milk samples were collected in sterile tube by manual expression using sterile gloves. The milk samples and skin swabs were kept in an icebox and transported to the laboratory within 3 h and immediately cultured on appropriate media.

#### 2. Bacterial cultivation

Three culture media were used: (a) MRS medium (de Man, Rogosa and Sharpe) for isolation of lactobacilli. (b) MC medium (Modified Columbia, with 0.03 g/l bromocresol purple) as described by Beerens [68] for isolation of bifidobacteria. (c) M17 medium for isolation of streptococci. Breast milk samples of 1 ml were diluted in 9 ml buffered peptone water and ten-fold serial diluted to  $10^{-2}$ - $10^{-3}$  Diluted

sample of 100 µl were spreaded onto MRS, MC, and M17 medium. Plates of MRS and MC media were incubated under anaerobic condition for 48-72 h. at 37 °C in an anaerobic chamber. Plates of M17 medium were incubated under aerobic condition for 24-48 h. at 37 °C. The remaining samples were kept at -80 °C for experimental use. Skin swabs were plated on the above media and incubated with plates of milk samples.

### **3. Selection of *Lactobacillus*, *Bifidobacterium*, and *Streptococcus* isolates**

After incubation, colonies developed on MRS, MC, and M17 media were selected according to different morphologies. Colonies of each morphotype were tested for catalase activity and catalase-negative colonies were Gram-stained and microscopically examined. Subcultured were performed to obtain isolated colonies on appropriate media. Catalase-negative, Gram-positive rods or coccobacilli were tentatively considered *Lactobacillus*-like bacteria. Catalase-negative, Gram-positive bifid-shaped rods were tentatively considered *Bifidobacterium*-like bacteria and catalase- negative, Gram-positive cocci in chain were tentatively considered *Streptococcus*-like bacteria. Isolates of suspected lactobacilli, bifidobacteria, and streptococci were kept in MRS, brain heart infusion broth (BHB), and M17 with 20% glycerol respectively, and stored in frozen cultures at -80 °C for experimental use.

### **4. Genotypic identification of *Lactobacillus*, *Bifidibacterium*, and *Streptococcus* isolates**

Bacterial colonies were first tested with genus-specific primers. Bacterial DNAs were extracted from 2-3 colonies as follow: colonies were picked and put in to an eppendorf tube. After 200 µl sterile water was added, the suspension was mixed and spun down to remove water and resuspended with 180 µl sterile water. Solution of 20 µl 10X digestion buffer (5% tween 20 and 10 mg/ml proteinase K in 0.2 M Tris pH 8.3) was added and incubated at 60 °C for 1 h. After inactivation of proteinase K at 100 °C for 15 min, the suspension was centrifuged at 13,000 rpm for 5 min.



Supernatant was collected for amplification and identification of *Lactobacillus*, *Bifidobacterium*, and *Streptococcus* using 16S rRNA genes sequencing.

*Lactobacillus* genus-specific primers L159F (5'-GGA AAC AG(A/G) TGC TAA TAC CG-3') and L677R (5'-CAC CGC TAC ACA TGG AG-3'),[134] were used. The 25- $\mu$ l reaction mixture contains 12.5  $\mu$ l of Hot start master mix (GE Healthcare illustra, UK), 10 pmol of each primer, 5  $\mu$ l DNA template and 2.5  $\mu$ l H<sub>2</sub>O. Amplification was performed: 95°C for 5 min; 35 cycles of 95 °C for 30 s, 57 °C for 1 min, and 72 °C for 1 min and a final extension of 72 °C for 5 min.

*Bifidobacterium* genus-specific primers Bif164F (5'-GGG TGG TAA TGC CGG ATG-3') and Bif601R (5'-TAA GCG ATG GAC TTT CAC ACC-3'),[135] were used. The 25- $\mu$ l reaction mixture contains 12.5  $\mu$ l of Hot start master mix (GE Healthcare illustra, UK), 10 pmol of each primer, 5  $\mu$ l DNA template and 2.5  $\mu$ l H<sub>2</sub>O. Amplification was performed: 95 °C for 5 min; 35 cycles of 95 °C for 1 min, 59 °C for 1 min, and 72 °C for 1 min and a final extension of 72 °C for 10 min.

*Streptococcus* genus-specific primer Tuf-Strp-1 (5'- GAA GAA TTG CTT GAA TTG GTT GAA-3') and Tuf-Strep-R (5'- GGA CGG TAG TTG TTG AAG AAT GG-3') [136] were used. The 25- $\mu$ l reaction mixture contains 12.5  $\mu$ l of Hot start master mix (GE Healthcare illustra, UK), 10 pmol of each primer, 5  $\mu$ l DNA template and 2.5  $\mu$ l H<sub>2</sub>O. Amplification was performed: 95 °C for 5 min; 35 cycles of 95 °C for 1 min, 56° C for 1 min, and 72 °C for 1 min and a final extension of 72 °C for 10 min.

Bacterial isolate which gave positive result with genus-specific primers, was subjected to DNA sequencing. The 16S rRNA gene sequences was amplified by PCR using the universal primer 16S-8F (5'-AGA GTT TGA TCY TGG YTY AG-3') and 16S-1541R (5'-AAG GAG GTG WTC CAR CC-3') [137] for genus *Lactobacillus*. The 50- $\mu$ l reaction mixture contains 25  $\mu$ l of Hot start master mix (GE Healthcare illustra, UK), 10 pmol primer, 5  $\mu$ l DNA template and 15  $\mu$ l H<sub>2</sub>O. Amplification was performed: 95 °C for 5 min; 35 cycles of 95 °C for 30 s, 57 °C for 1 min, and 72 °C for 1 min and a final extension of 72 °C for 10 min. Genus *Bifidobacterium* was amplified using the universal primers Im26 (5'-GAT TCT GGC TCA GGA TGA ACG-3') and Im3 (5'-CGG GTG CTI CCC ACT TTC ATG-3') [138]. The 50- $\mu$ l reaction mixture contains 25  $\mu$ l of Hot start master mix (GE), 10 pmol of each primer, 5  $\mu$ l DNA template and 15  $\mu$ l H<sub>2</sub>O. Amplification was performed: 95 °C for 5 min; 35

cycles of 94 °C for 1 min, 57 °C for 3 min, and 72 °C for 4 min and a final extension of 72 °C for 10 min. Genus *Streptococcus* was amplified using universal primers forward primer (5'-AGA GTT TGA TCC TGG CTC AG-3') and U926 (5'-CCG TCA ATT CCT TTR AGT TT-3') [139]. The 50- $\mu$ l reaction mixture contains 25  $\mu$ l of Hot start master mix (GE Healthcare illustra, UK), 10 pmol of each primer, 5  $\mu$ l DNA template and 15  $\mu$ l H<sub>2</sub>O. Amplification was performed: 95 °C for 5 min; 35 cycles of 95 °C for 1 min, 56° C for 1 min, and 72 °C for 1 min and a final extension of 72 °C for 10 min.

PCR product was individually purified by using QIAquick PCR purification kit (Qiagen Inc., USA). Sequencing will be performed by using 10 ng purified PCR product with the same primer as in PCR amplification by the dideoxynucleotide chain termination method at the 1 st BASE Sequencing, Shan Alan, Malasia (<http://www.base-asia.com>). The nucleotide sequence will be analysed using the sequence match program of Ribosomal Database Project II (RDP-II; <http://rdp.cme.msu.edu>) and GenBank DNA database search ([www.ncbi.nlm.nih.gov/BLAST](http://www.ncbi.nlm.nih.gov/BLAST)). The closest relative of the partial 16S rRNA gene sequences was evaluated. The identities of the isolates were determined on the basis of the highest score.

## **5. Detection DNA of lactobacilli, bifidobacteria and streptococci by PCR method**

DNA was isolated from 100 samples of breast milk stored at -80 °C by using QIAamp DNA stool minikit (Qiagen, Hilden, Germany). One milliliter of breast milk samples were centrifuged for 20 min at 6,000 rpm. After the supernatant was removed, used pellets and added a bead-beading with 0.3 g of 0.1 mm zirconium beads and 1.4 ml of ASL buffer (Qiagen) and mixed by vortex. The suspension was incubated at 95°C for 5 min and centrifuged, then supernatant was transferred to clean vial and an InhibitEX Tablet (Qiagen) was added. After centrifugation the supernatant was transferred to QIAamp spin columns (Qiagen) and made following the manufacturer's instruction. DNA eluted in 200  $\mu$ l of buffer AE (provided in the kit), and the extracted-purified DNA were stored at -20 °C. DNA targets were amplified by PCR using genus-specific primers L159F (5'-GGA AAC AG(A/G) TGC TAA

TAC CG-3') and L677R (5'-CAC CGC TAC ACA TGG AG-3') [134] for *Lactobacillus*. Bif164F (5'-GGG TGG TAA TGC CGG ATG-3') and Bif601R (5'-TAA GCG ATG GAC TTT CAC ACC-3') [135] for *Bifidobacterium* and Tuf-Strep-1 (5'- GAA GAA TTG CTT GAA TTG GTT GAA-3') and Tuf-Strep-R (5'- GGA CGG TAG TTG TTG AAG AAT GG-3') [136] for *Streptococcus*. The PCR amplicons were detected with agarose gel electrophoresis and stained with ethidium bromide.

## 6. Antagonistic activity assay

Antagonistic activities of *Lactobacillus*, *Bifidobacterium*, and *Streptococcus* against various bacterial pathogens were performed by agar spot method as previously described by Spinler *et al*[11]. Enterotoxigenic *E. coli* (ETEC) DMST 20970, enteroinvasive *E. coli* (EIEC) DMST 20971, enteropathogenic *E. coli* (EPEC) DMST 20972, enterohemorrhagic *E. coli* (EHEC) DMST 20973, *Salmonella* Typhimurium ATCC 13311, *Shigella flexneri* DMST 4423, *Vibrio cholerae* non O1 DMST 2873, *Helicobacter pylori* ATCC 43504 and Methicillin-resistant *Staphylococcus aureus* (MRSA) ATCC 43300 were selected bacterial pathogen to be tested. All target bacteria were grown on appropriate media and condition for experimental use.

*Lactobacillus* and *Bifidobacterium* were precultivated on MRS and MC, respectively for 48-72 h. in an anaerobic condition (the AnaeroPack system, Mitsubishi Gas Chemical, H<sub>2</sub>: 5%, CO<sub>2</sub>: 10%, N<sub>2</sub>: 85%). *Streptococcus* was precultivated on M17 agar in an aerobic condition for 24-48 h. They were subcultured on MRS, BHI and M17 broth (media for lactobacilli, bifidobacteria and streptococci, respectively) twice in a 96-well plate. Forty-eight hour culture of *Lactobacillus*, *Bifidobacterium*, and 24 h. of *Streptococcus* were spotted by frogger (Dan-Kar Corp, MA, USA) onto the surface of BHI agar in a 140-mm plate and incubated in anaerobic condition at 37 °C for 48 h., except plates of *Streptococcus* incubated in aerobic condition at 37 °C for 24 h. Twenty milliliters of tryptic soft agar (agar 7.5 g/l) containing target bacterial pathogens at concentration about 1 x 10<sup>7</sup>CFU/ml (1 x 10<sup>9</sup>CFU/ml of *Helicobacter pylori*) were overlain on plate of *Lactobacillus*, *Bifidobacterium*, and *Streptococcus* developed spots. Each plate was incubated under appropriate condition depending on each target pathogen. Inhibition zones were

measured and a clear zone of 1-2 mm was scored as weak inhibitory activity, 3-4 mm as strong inhibitory activity and an opaque zone of inhibition <1 mm as microcolonies (M).

## CHAPTER IV


### RESULTS

#### **1. Cultivation and presumptive identification of *Lactobacillus*, *Bifidobacterium* and *Streptococcus* from breast milk**


One hundred and two milk samples and skin swabs were collected from Thai healthy mothers. These samples were cultured in MRS, MC and M17 agar for the isolation of *Lactobacillus*, *Bifidobacterium* and *Streptococcus*, respectively. The colonies of bacterial isolates from breast milk on MRS agar were small to medium, circular and convex, white or yellow turbid or transparent, whereas those on MC agar were small to medium, circular and convex or flat, white or yellow and transparent. On M17 agar, the colonies were medium to large, circular and convex or flat and white turbid. Colony morphologies of these bacteria on MRS, MC and M17 agar were shown in Figure 2. The colonies of bacterial isolates from skin swabs grown on MRS were small to medium, circular and convex or flat, white or yellow turbid or transparent (Figure 3 A). On MC agar, the colonies were small to medium, circular and convex or flat, white or yellow or green and turbid or transparent (Figure 3 B) and on M17 agar the colonies were medium to large, circular and convex or flat, white or grey and turbid or transparent (Figure 3 C).

Bacterial colonies grown on each medium with different appearance were picked and tested for catalase enzyme. The catalase-negative ones were Gram- stained and examined microscopically. Isolates visualized as Gram-positive short or long rods or coccobacilli on MRS agar were suspected of *Lactobacillus* (Figure 4 A). Isolates with Gram- positive, bifid or polymorphic branched or irregular rods on MC or MRS agar were suspected of *Bifidobacterium* (Figure 4 B) and isolates on M17 agar or MRS suspected to be *Streptococcus* were Gram-positive, cocci in chain or single (Figure 4 C). Suspected colonies were re-streaked for single colony isolation on new media. A single pure colony was re-tested for catalase enzyme, Gram- stained and examined microscopically.


A total of 176 bacterial isolates were selected for further identification. They were 74, 62 and 40 suspected *Lactobacillus*, *Bifidobacterium* and *Streptococcus*, respectively. All bacterial isolates from skin swabs were catalase-positive. They were either Gram-positive cocci in cluster or single Gram-negative cocci or Gram-negative cocci in small cluster.



**Figure 2.** Colony growth from breast milk on different media, (A) MRS agar, (B) MC agar and (C) M17 agar.



**Figure 3.** Colony growth from skin swabs on different media, (A) MRS agar, (B) MC agar and (C) M17 agar.



A

B

C

**Figure 4.** Cell morphology of bacteria isolated from breast milk, (A) Gram-positive short rods suspected to be *Lactobacillus* (B) Gram-positive bifid or irregular rods suspected to be *Bifidobacterium* (C) Gram-positive cocci in chain suspected to be *Streptococcus*.

## 2. Genotypic identification of lactobacilli, bifidobacteria and streptococci


DNAs of all 176 isolates were amplified using genus-specific primers. These genus-specific primers were aligned with the 16S rRNA gene sequence of *Lactobacillus* spp., *Bifidobacterium* spp., and *Streptococcus* spp. with Multalin program and the result was shown in Figures 5-7. Out of 74 suspected *Lactobacillus* isolates, 53 (71.62 %) were positive for *Lactobacillus*. Out of 62 suspected *Bifidobacterium* isolates, 45 (72.58%) were positive for *Bifidobacterium*. Out of 40 suspected *Streptococcus* isolates, 26 (65%) were positive for *Streptococcus*. Isolates with positive results from genus-specific amplification were then amplified using universal primers. These universal primers were aligned with the 16S rRNA gene sequence of *Lactobacillus* spp., *Bifidobacterium* spp., and *Streptococcus* spp. with Multalin program and the result was shown in Figures 8-10.

The amplification products were sequenced and analysed with NCBI and RDP II database. Forty out of 53 isolates (75.47%) were identified as *Lactobacillus* spp. such as *L. gasseri* (6 isolates), *L. salivarius* (16 isolates), *L. fermentum* (5 isolates), *L. mucosae* (5 isolates), *L. rhamnosus* (3 isolates), *L. casei* (3 isolates), *L. plantarum* (1 isolate) and *L. oris* (1 isolate) as shown in Table 6. These *Lactobacillus* isolates were recovered from 37 (36.27%) milk samples. Thirty-three out of 45 isolates (73.33%) were identified as *Bifidobacterium* spp. such as *B. longum* (8 isolates), *B. breve* (7 isolates), *B. pseudocatenulatum* (5 isolates), *B. dentium* (8 isolates) and *B. bifidum* (5 isolates) as shown in Table 7. These *Bifidobacterium* isolates were recovered from 31 (30.39%) milk samples. All 26 isolates which were positive by *Streptococcus*-specific PCR were identified as *Streptococcus* spp. such as *S. salivarius* (13 isolates), *S. lactarius* (4 isolates), *Streptococcus* sp. (4 isolates), *Streptococcus mitis* (3 isolates) and *Streptococcus parasanguis* (2 isolates) as shown in Table 8. These *Streptococcus* isolates were recovered from 17 (16.67%) milk samples. The summary of bacterial isolates recovered from breast milk was shown in Tables 9-10.


Thirteen isolates positive with *Lactobacillus*-specific amplification were identified to be *Staphylococcus aureus* (5 isolates), *Staphylococcus epidermidis* (4 isolates) and uncultured bacteria (4 isolates). Twelve isolates positive with *Bifidobacterium*-specific amplification were identified to be *Actinomyces radidentis*




(1 isolate) and uncultured bacteria (11 isolates). The summary of other bacterial species found in breast milk was shown in Table 11.



**Figure 5.** The alignment of genus-specific primer L159F and L677R with 16S rRNA gene sequence of *Lactobacillus* spp.



**Figure 6.** The alignment of genus-specific primer Bif164F and Bif601R with 16S rRNA gene sequence of *Bifidobacterium* spp.



**Figure 7.** The alignment of genus-specific primer Tuf-Strep-1 and Tuf-Strep-R with 16S rRNA gene sequence of *Streptococcus* spp.

1 10 20 30 40 50 60 70 80 90 100 110 120 130  
L.gasseri ARAATGAGAGTTGATCTGGCTCAGGACGACGCTGGCCGCGTCCATACATGCAAGTCGAGCGAGCTTGCCTAGATGAT--TTGGTCTTGCACC--AGATGAACTAGAT--ACAGGCGAGCGG  
L.casei AGAGTTGATCTGGCTCAGGATGACGCTGGCCGCGTCCATACATGCAAGTCGAGCGAGCTTGCCTAGATGAT--TTGGTCTTGCACC--AGATGAACTAGAT--ACAGGCGAGCGG  
L.plantarum ATTAATTTGAGAGTTGATCTGGCTCAGGACGACGCTGGCCGCGTCCATACATGCAAGTCGAGCGAGCTTGCCTAGATGAT--TTGGTCTTGCACC--AGATGAACTAGAT--ACAGGCGAGCGG  
L.fermentum ARAAGAGTT--GAACCTGGCTCAGGATGACGCTGGCC--TGTGC--TATACATGCAAGTCGAGCGAGCTTGCCTAGATGAT--TTGGTCTTGCACC--AGATGAACTAGAT--ACAGGCGAGCGG  
L.acidophilus ARAACGAGAGTTGATCTGGCTCAGGACGACGCTGGCCGCGTCCATACATGCAAGTCGAGCGAGCTTGCCTAGATGAT--TTGGTCTTGCACC--AGATGAACTAGAT--ACAGGCGAGCGG  
L.bervis ARAAGAGTTGATCTGGCTCAGGACGACGCTGGCCGCGTCCATACATGCAAGTCGAGCGAGCTTGCCTAGATGAT--TTGGTCTTGCACC--AGATGAACTAGAT--ACAGGCGAGCGG  
L.salivarius  
16S-8F AGAGTTGATCTGGCTCAGGACGACGCTGGCCGCGTCCATACATGCAAGTCGAGCGAGCTTGCCTAGATGAT--TTGGTCTTGCACC--AGATGAACTAGAT--ACAGGCGAGCGG  
16S-1541R TACACCGAATGCT-----TGCRTTCATCTAGAGAGTT-----GAGTGG  
Consensus .....agagttgatctggctcag.....

131 140 150 160 170 180 190 200 210 220 230 240 250 260  
L.gasseri CGACCGGTTAGTARACGCTGGGTARCTGCCAGAGACGGGATARACCTGGAAACAGATGCTATACCGGATACACACAGACAGATGCTTGGTGGAGATGGGTAA--GCTATCAGCTT  
L.casei CGACCGGTTAGTARACGCTGGGTARCTGCCAGAGACGGGATARACCTGGAAACAGATGCTATACCGGATACACACAGACAGATGCTTGGTGGAGATGGGTAA--GCTATCAGCTT  
L.plantarum CGACCGGTTAGTARACGCTGGGTARCTGCCAGAGACGGGATARACCTGGAAACAGATGCTATACCGGATACACACAGACAGATGCTTGGTGGAGATGGGTAA--GCTATCAGCTT  
L.fermentum CGACCGGTTAGTARACGCTGGGTARCTGCCAGAGACGGGATARACCTGGAAACAGATGCTATACCGGATACACACAGACAGATGCTTGGTGGAGATGGGTAA--GCTATCAGCTT  
L.acidophilus CGATGGGTTAGTARACGCTGGGTARCTGCCAGAGACGGGATARACCTGGAAACAGATGCTATACCGGATACACACAGACAGATGCTTGGTGGAGATGGGTAA--GCTATCAGCTT  
L.bervis CGACCGGTTAGTARACGCTGGGTARCTGCCAGAGACGGGATARACCTGGAAACAGATGCTATACCGGATACACACAGACAGATGCTTGGTGGAGATGGGTAA--GCTATCAGCTT  
L.salivarius CGACCGGTTAGTARACGCTGGGTARCTGCCAGAGACGGGATARACCTGGAAACAGATGCTATACCGGATACACACAGACAGATGCTTGGTGGAGATGGGTAA--GCTATCAGCTT  
16S-8F  
16S-1541R  
Consensus .....

261 270 280 290 300 310 320 330 340 350 360 370 380 390  
L.gasseri TGATGGACCTGCGGTCATAGCTAGTTGGTARAGTACGGCTTACCAGGCGATGATGCTAGCCGAGTTGAGAGACTGATGGCCACATTTGGACTGAGACACGCGCCAAACCTTACGGGAGGCG  
L.casei TGATGGACCTGCGGTCATAGCTAGTTGGTARAGTACGGCTTACCAGGCGATGATGCTAGCCGAGTTGAGAGACTGATGGCCACATTTGGACTGAGACACGCGCCAAACCTTACGGGAGGCG  
L.plantarum TGATGGACCTGCGGTCATAGCTAGTTGGTARAGTACGGCTTACCAGGCGATGATGCTAGCCGAGTTGAGAGACTGATGGCCACATTTGGACTGAGACACGCGCCAAACCTTACGGGAGGCG  
L.fermentum TGATGGACCTGCGGTCATAGCTAGTTGGTARAGTACGGCTTACCAGGCGATGATGCTAGCCGAGTTGAGAGACTGATGGCCACATTTGGACTGAGACACGCGCCAAACCTTACGGGAGGCG  
L.acidophilus CGATGGGTTAGTARACGCTGGGTARCTGCCAGAGACGGGATARACCTGGAAACAGATGCTATACCGGATACACACAGACAGATGCTTGGTGGAGATGGGTAA--GCTATCAGCTT  
L.bervis CGATGGGTTAGTARACGCTGGGTARCTGCCAGAGACGGGATARACCTGGAAACAGATGCTATACCGGATACACACAGACAGATGCTTGGTGGAGATGGGTAA--GCTATCAGCTT  
L.salivarius CGATGGGTTAGTARACGCTGGGTARCTGCCAGAGACGGGATARACCTGGAAACAGATGCTATACCGGATACACACAGACAGATGCTTGGTGGAGATGGGTAA--GCTATCAGCTT  
16S-8F  
16S-1541R  
Consensus .....


391 400 410 420 430 440 450 460 470 480 490 500 510 520  
L.gasseri CAGTAGGGATCTCCACAAATGGACGAGGCTGATGGAGCAGCGCGCTGAGTGAAGAGGGTTTCGGCTCGTAAAGCTCTGTTGGTAGTGAAGAGAGATAGAGTAGTARCTGGCCTTATTGGAC  
L.casei CAGTAGGGATCTCCACAAATGGACGAGGCTGATGGAGCAGCGCGCTGAGTGAAGAGGGTTTCGGCTCGTAAAGCTCTGTTGGTAGTGAAGAGAGATAGAGTAGTARCTGGCCTTATTGGAC  
L.plantarum CAGTAGGGATCTCCACAAATGGACGAGGCTGATGGAGCAGCGCGCTGAGTGAAGAGGGTTTCGGCTCGTAAAGCTCTGTTGGTAGTGAAGAGAGATAGAGTAGTARCTGGCCTTATTGGAC  
L.fermentum CAGTAGGGATCTCCACAAATGGACGAGGCTGATGGAGCAGCGCGCTGAGTGAAGAGGGTTTCGGCTCGTAAAGCTCTGTTGGTAGTGAAGAGAGATAGAGTAGTARCTGGCCTTATTGGAC  
L.acidophilus CAGTAGGGATCTCCACAAATGGACGAGGCTGATGGAGCAGCGCGCTGAGTGAAGAGGGTTTCGGCTCGTAAAGCTCTGTTGGTAGTGAAGAGAGATAGAGTAGTARCTGGCCTTATTGGAC  
L.bervis CAGTAGGGATCTCCACAAATGGACGAGGCTGATGGAGCAGCGCGCTGAGTGAAGAGGGTTTCGGCTCGTAAAGCTCTGTTGGTAGTGAAGAGAGATAGAGTAGTARCTGGCCTTATTGGAC  
L.salivarius CAGTAGGGATCTCCACAAATGGACGAGGCTGATGGAGCAGCGCGCTGAGTGAAGAGGGTTTCGGCTCGTAAAGCTCTGTTGGTAGTGAAGAGAGATAGAGTAGTARCTGGCCTTATTGGAC  
16S-8F  
16S-1541R  
Consensus .....

521 530 540 550 560 570 580 590 600 610 620 630 640 650  
L.gasseri GTRATTAATGAAAGTCAAGCTTACCTGACGACCGCCGGATACCTAGTGGTGGCAGGCTTGTCCGGATTTATGGGCTAAGACGAGTGCAGGCGGTTCAATAGTCTGATGAAAGCCTT  
L.casei GTRATTAATGAAAGTCAAGCTTACCTGACGACCGCCGGATACCTAGTGGTGGCAGGCTTGTCCGGATTTATGGGCTAAGACGAGTGCAGGCGGTTCAATAGTCTGATGAAAGCCTT  
L.plantarum GTRATTAATGAAAGTCAAGCTTACCTGACGACCGCCGGATACCTAGTGGTGGCAGGCTTGTCCGGATTTATGGGCTAAGACGAGTGCAGGCGGTTCAATAGTCTGATGAAAGCCTT  
L.fermentum GTRATTAATGAAAGTCAAGCTTACCTGACGACCGCCGGATACCTAGTGGTGGCAGGCTTGTCCGGATTTATGGGCTAAGACGAGTGCAGGCGGTTCAATAGTCTGATGAAAGCCTT  
L.acidophilus GTRATTAATGAAAGTCAAGCTTACCTGACGACCGCCGGATACCTAGTGGTGGCAGGCTTGTCCGGATTTATGGGCTAAGACGAGTGCAGGCGGTTCAATAGTCTGATGAAAGCCTT  
L.bervis GTRATTAATGAAAGTCAAGCTTACCTGACGACCGCCGGATACCTAGTGGTGGCAGGCTTGTCCGGATTTATGGGCTAAGACGAGTGCAGGCGGTTCAATAGTCTGATGAAAGCCTT  
L.salivarius GTRATTAATGAAAGTCAAGCTTACCTGACGACCGCCGGATACCTAGTGGTGGCAGGCTTGTCCGGATTTATGGGCTAAGACGAGTGCAGGCGGTTCAATAGTCTGATGAAAGCCTT  
16S-8F  
16S-1541R  
Consensus .....

651 660 670 680 690 700 710 720 730 740 750 760 770 780  
L.gasseri CGCCTAACCGGAGAGTGCATCGAAGCTGTTGACCTGAGTGCAGAGAGGAGAGTGGAACTCCATGTTAGCCGCTGGAGTGCAGATATGGAAGACACCCAGTGGCGAAGGCGCTCTGGTC  
L.casei CGCCTAACCGGAGAGTGCATCGAAGCTGTTGACCTGAGTGCAGAGAGGAGAGTGGAACTCCATGTTAGCCGCTGGAGTGCAGATATGGAAGACACCCAGTGGCGAAGGCGCTCTGGTC  
L.plantarum CGCCTAACCGGAGAGTGCATCGAAGCTGTTGACCTGAGTGCAGAGAGGAGAGTGGAACTCCATGTTAGCCGCTGGAGTGCAGATATGGAAGACACCCAGTGGCGAAGGCGCTCTGGTC  
L.fermentum CGCCTAACCGGAGAGTGCATCGAAGCTGTTGACCTGAGTGCAGAGAGGAGAGTGGAACTCCATGTTAGCCGCTGGAGTGCAGATATGGAAGACACCCAGTGGCGAAGGCGCTCTGGTC  
L.acidophilus CGCCTAACCGGAGAGTGCATCGAAGCTGTTGACCTGAGTGCAGAGAGGAGAGTGGAACTCCATGTTAGCCGCTGGAGTGCAGATATGGAAGACACCCAGTGGCGAAGGCGCTCTGGTC  
L.bervis CGCCTAACCGGAGAGTGCATCGAAGCTGTTGACCTGAGTGCAGAGAGGAGAGTGGAACTCCATGTTAGCCGCTGGAGTGCAGATATGGAAGACACCCAGTGGCGAAGGCGCTCTGGTC  
L.salivarius CGCCTAACCGGAGAGTGCATCGAAGCTGTTGACCTGAGTGCAGAGAGGAGAGTGGAACTCCATGTTAGCCGCTGGAGTGCAGATATGGAAGACACCCAGTGGCGAAGGCGCTCTGGTC  
16S-8F  
16S-1541R  
Consensus .....

781 790 800 810 820 830 840 850 860 870 880 890 900 910  
L.gasseri TGACATGACCTGAGGCTCGAAGCATGGGTAGCAGACAGGATAGATACCTGGTATGCTACCGCTAAGCAGTGAAGTGTGG--AGGTTTCCGCCCTCAGTGTGACGATACGCAATTA  
L.casei TGACATGACCTGAGGCTCGAAGCATGGGTAGCAGACAGGATAGATACCTGGTATGCTACCGCTAAGCAGTGAAGTGTGG--AGGTTTCCGCCCTCAGTGTGACGATACGCAATTA  
L.plantarum TGACATGACCTGAGGCTCGAAGCATGGGTAGCAGACAGGATAGATACCTGGTATGCTACCGCTAAGCAGTGAAGTGTGG--AGGTTTCCGCCCTCAGTGTGACGATACGCAATTA  
L.fermentum TGACATGACCTGAGGCTCGAAGCATGGGTAGCAGACAGGATAGATACCTGGTATGCTACCGCTAAGCAGTGAAGTGTGG--AGGTTTCCGCCCTCAGTGTGACGATACGCAATTA  
L.acidophilus TGACATGACCTGAGGCTCGAAGCATGGGTAGCAGACAGGATAGATACCTGGTATGCTACCGCTAAGCAGTGAAGTGTGG--AGGTTTCCGCCCTCAGTGTGACGATACGCAATTA  
L.bervis TGACATGACCTGAGGCTCGAAGCATGGGTAGCAGACAGGATAGATACCTGGTATGCTACCGCTAAGCAGTGAAGTGTGG--AGGTTTCCGCCCTCAGTGTGACGATACGCAATTA  
L.salivarius TGACATGACCTGAGGCTCGAAGCATGGGTAGCAGACAGGATAGATACCTGGTATGCTACCGCTAAGCAGTGAAGTGTGG--AGGTTTCCGCCCTCAGTGTGACGATACGCAATTA  
16S-8F  
16S-1541R  
Consensus .....

911 920 930 940 950 960 970 980 990 1000 1010 1020 1030 1040  
L.gasseri AGCACTCCGCTGGGGAGTACGACCGCAGGTTGAACTCAAGAGGATGACGGGGGCGCAGCAGCGGTTGAGCATGTGGTTTAACTCGAGCAGCCGAGAGACTTACCGGCTTGACATCCAGT  
L.casei AGCACTCCGCTGGGGAGTACGACCGCAGGTTGAACTCAAGAGGATGACGGGGGCGCAGCAGCGGTTGAGCATGTGGTTTAACTCGAGCAGCCGAGAGACTTACCGGCTTGACATCCAGT  
L.plantarum AGCACTCCGCTGGGGAGTACGACCGCAGGTTGAACTCAAGAGGATGACGGGGGCGCAGCAGCGGTTGAGCATGTGGTTTAACTCGAGCAGCCGAGAGACTTACCGGCTTGACATCCAGT  
L.fermentum AGCACTCCGCTGGGGAGTACGACCGCAGGTTGAACTCAAGAGGATGACGGGGGCGCAGCAGCGGTTGAGCATGTGGTTTAACTCGAGCAGCCGAGAGACTTACCGGCTTGACATCCAGT  
L.acidophilus AGCACTCCGCTGGGGAGTACGACCGCAGGTTGAACTCAAGAGGATGACGGGGGCGCAGCAGCGGTTGAGCATGTGGTTTAACTCGAGCAGCCGAGAGACTTACCGGCTTGACATCCAGT  
L.bervis AGCACTCCGCTGGGGAGTACGACCGCAGGTTGAACTCAAGAGGATGACGGGGGCGCAGCAGCGGTTGAGCATGTGGTTTAACTCGAGCAGCCGAGAGACTTACCGGCTTGACATCCAGT  
L.salivarius AGCACTCCGCTGGGGAGTACGACCGCAGGTTGAACTCAAGAGGATGACGGGGGCGCAGCAGCGGTTGAGCATGTGGTTTAACTCGAGCAGCCGAGAGACTTACCGGCTTGACATCCAGT  
16S-8F  
16S-1541R  
Consensus .....



**Figure 8.** The alignment of universal primers 16S-8F and 16S-1541R with 16S rRNA gene sequence of *Lactobacillus* spp.





Figure 9. The alignment of universal primers Im 26 and Im3 with 16S rRNA gene sequence of *Bifidobacterium* spp.



**Figure 10.** The alignment of universal primers F and U926 with 16S rRNA gene sequence of *Streptococcus* spp.

**Table 6.** Genotypic identification of *Lactobacillus* spp. based on 16S rRNA gene sequencing

<b>No.</b>	<b>Subject No.</b> (day of lactation)	<b>Bacterial isolates</b>	<b>Match organism (Data bank)</b>	<b>% Identity</b>	<b>Query length (bp)</b>
1	20 (60d.)	St8	<i>Lactobacillus gasseri</i> (NCBI)	99.0	906
			<i>Lactobacillus gasseri</i> (RDP)	98.9	
2	25 (60d.)	Lac39	<i>Lactobacillus salivarius</i> (NCBI)	98.0	1513
			<i>Lactobacillus salivarius</i> (RDP)	98.5	
3	28 (60d.)	Lac31	<i>Lactobacillus fermentum</i> (NCBI)	98.0	928
			<i>Lactobacillus fermentum</i> (RDP)	97.9	
4	29 (60d.)	Lac40	<i>Lactobacillus salivarius</i> (NCBI)	99.0	1477
			<i>Lactobacillus salivarius</i> (RDP)	99.4	
5	30 (60d.)	Lac41	<i>Lactobacillus salivarius</i> (NCBI)	100.0	656
			<i>Lactobacillus salivarius</i> (RDP)	99.6	
6	35 (15d.)	Lac42	<i>Lactobacillus salivarius</i> (NCBI)	100.0	917
			<i>Lactobacillus salivarius</i> (RDP)	99.8	
7	40 (15d.)	Lac43	<i>Lactobacillus rhamnosus</i> (NCBI)	98.0	1507
			<i>Lactobacillus rhamnosus</i> (RDP)	98.4	
8	41 (15d.)	Lac44	<i>Lactobacillus casei</i> (NCBI)	99.0	786
			<i>Lactobacillus casei</i> (RDP)	98.9	
9	44 (15d.)	Lac45	<i>Lactobacillus salivarius</i> (NCBI)	94.0	624
			<i>Lactobacillus salivarius</i> (RDP)	94.6	



**Table 6.** Genotypic identification of *Lactobacillus* spp. based on 16S rRNA gene sequencing (Continued)

<b>No.</b>	<b>Subject No.</b> (day of lactation)	<b>Bacterial isolates</b>	<b>Match organism (Data bank)</b>	<b>% Identity</b>	<b>Query length (bp)</b>
10	45 (60d.)	NL1	<i>Lactobacillus salivarius</i> (NCBI)	99.0	1101
			<i>Lactobacillus salivarius</i> (RDP)	98.9	
		NL2	<i>Lactobacillus salivarius</i> (NCBI)	100.0	1157
			<i>Lactobacillus salivarius</i> (RDP)	99.6	
		NL3	<i>Lactobacillus salivarius</i> (NCBI)	99.0	1497
			<i>Lactobacillus salivarius</i> (RDP)	99.5	
11	50 (60d.)	NL5	<i>Lactobacillus salivarius</i> (NCBI)	100.0	653
			<i>Lactobacillus salivarius</i> (RDP)	99.8	
12	54 (30d.)	NL6	<i>Lactobacillus salivarius</i> (NCBI)	99.0	614
			<i>Lactobacillus salivarius</i> (RDP)	98.9	
		NL7	<i>Lactobacillus salivarius</i> (NCBI)	82.0	796
			<i>Lactobacillus salivarius</i> (RDP)	82.4	
13	55 (60d.)	NL8	<i>Lactobacillus gasseri</i> (NCBI)	100.0	1493
			<i>Lactobacillus gasseri</i> (RDP)	99.8	
14	56 (60d.)	NL9	<i>Lactobacillus salivarius</i> (NCBI)	97.0	1311
			<i>Lactobacillus salivarius</i> (RDP)	97.4	
15	59 (28d.)	NL10	<i>Lactobacillus gasseri</i> (NCBI)	99.0	901
			<i>Lactobacillus gasseri</i> (RDP)	99.5	

**Table 6.** Genotypic identification of *Lactobacillus* spp. based on 16S rRNA gene sequencing (Continued)

No.	Subject No. (day of lactation)	Bacterial isolates	Match organism (Data bank)	% Identity	Query length (bp)
16	61 (30d.)	NL12	<i>Lactobacillus salivarius</i> (NCBI)	98.0	1028
			<i>Lactobacillus salivarius</i> (RDP)	97.8	
17	62 (60d.)	NL16	<i>Lactobacillus fermentum</i> (NCBI)	99.0	903
			<i>Lactobacillus fermentum</i> (RDP)	98.9	
18	63 (60d.)	NL18	<i>Lactobacillus mucosae</i> (NCBI)	98.0	1502
			<i>Lactobacillus mucosae</i> (RDP)	98.4	
19	65 (30d.)	NL19	<i>Lactobacillus salivarius</i> (NCBI)	99.0	1389
			<i>Lactobacillus salivarius</i> (RDP)	99.5	
20	67 (60d.)	NL20	<i>Lactobacillus mucosae</i> (NCBI)	98.0	962
			<i>Lactobacillus mucosae</i> (RDP)	97.8	
21	70 (60d.)	NL25	<i>Lactobacillus mucosae</i> (NCBI)	97.0	1523
			<i>Lactobacillus mucosae</i> (RDP)	96.9	
22	71 (60d.)	NL26	<i>Lactobacillus salivarius</i> (NCBI)	98.0	661
			<i>Lactobacillus salivarius</i> (RDP)	97.8	
23	72 (60d.)	NL45	<i>Lactobacillus salivarius</i> (NCBI)	94.0	601
			<i>Lactobacillus salivarius</i> (RDP)	93.9	
24	75 (60d.)	NL46	<i>Lactobacillus mucosae</i> (NCBI)	100.0	1077
			<i>Lactobacillus mucosae</i> (RDP)	100.0	

**Table 6.** Genotypic identification of *Lactobacillus* spp. based on 16S rRNA gene sequencing (Continued)

<b>No.</b>	<b>Subject No.</b> (day of lactation)	<b>Bacterial isolates</b>	<b>Match organism (Data bank)</b>	<b>% Identity</b>	<b>Query length (bp)</b>
25	76 (60d.)	NL48	<i>Lactobacillus gasseri</i> (NCBI)	99.0	1296
			<i>Lactobacillus gasseri</i> (RDP)	99.4	
26	78 (60d.)	NL49	<i>Lactobacillus oris</i> (NCBI)	95.0	621
			<i>Lactobacillus oris</i> (RDP)	94.8	
27	81 (60d.)	NL50	<i>Lactobacillus fermentum</i> (NCBI)	97.0	747
			<i>Lactobacillus fermentum</i> (RDP)	97.4	
28	84 (60d.)	NL52	<i>Lactobacillus mucosae</i> (NCBI)	99.0	1509
			<i>Lactobacillus mucosae</i> (RDP)	98.6	
29	86 (60d.)	NL53	<i>Lactobacillus fermentum</i> (NCBI)	100.0	749
			<i>Lactobacillus fermentum</i> (RDP)	99.8	
30	87 (23d.)	NL54	<i>Lactobacillus gasseri</i> (NCBI)	97.0	809
			<i>Lactobacillus gasseri</i> (RDP)	97.4	
31	90 (60d.)	NL55	<i>Lactobacillus fermentum</i> (NCBI)	97.0	780
			<i>Lactobacillus fermentum</i> (RDP)	96.9	
32	92 (60d.)	NL56	<i>Lactobacillus rhamnosus</i> (NCBI)	99.0	948
			<i>Lactobacillus rhamnosus</i> (RDP)	98.9	

**Table 6.** Genotypic identification of *Lactobacillus* spp. based on 16S rRNA gene sequencing (Continued)

<b>No.</b>	<b>Subject No.</b> (day of lactation)	<b>Bacterial isolates</b>	<b>Match organism (Data bank)</b>	<b>% Identity</b>	<b>Query length (bp)</b>
33	95 (30d.)	NL57	<i>Lactobacillus casei</i> (NCBI)	85.0	791
			<i>Lactobacillus casei</i> (RDP)	85.4	
34	97 (60d.)	NL58	<i>Lactobacillus rhamnosus</i> (NCBI)	97.0	759
			<i>Lactobacillus rhamnosus</i> (RDP)	97.5	
35	98 (60d.)	NL60	<i>Lactobacillus casei</i> (NCBI)	98.0	658
			<i>Lactobacillus casei</i> (RDP)	98.4	
36	100 (60d.)	NL61	<i>Lactobacillus plantarum</i> (NCBI)	99.0	942
			<i>Lactobacillus plantarum</i> (RDP)	98.6	
37	102 (60d.)	NL62	<i>Lactobacillus gasseri</i> (NCBI)	98.0	986
			<i>Lactobacillus gasseri</i> (RDP)	97.9	

**Table 7.** Genotypic identification of *Bifidobacterium* spp. based on 16S rRNA gene sequencing

No.	Subject No. (day of lactation)	Bacterial isolates	Match organism (Data bank)	% Identity	Query length (bp)
1	23 (60d.)	Bif29	<i>Bifidobacterium breve</i> (NCBI)	100.0	874
			<i>Bifidobacterium breve</i> (RDP)	99.8	
2	26 (22d.)	NB1	<i>Bifidobacterium breve</i> (NCBI)	99.0	1355
			<i>Bifidobacterium breve</i> (RDP)	99.8	
3	31 (15d.)	NB2	<i>Bifidobacterium psedocatenulatum</i> (NCBI)	99.0	1360
			<i>Bifidobacterium psedocatenulatum</i> (RDP)	99.5	
4	40 (15d.)	NB3	<i>Bifidobacterium dentium</i> (NCBI)	99.0	1355
			<i>Bifidobacterium dentium</i> (RDP)	99.8	
5	41 (15d.)	NB4	<i>Bifidobacterium dentium</i> (NCBI)	99.0	1358
			<i>Bifidobacterium dentium</i> (RDP)	99.5	
6	45 (60d.)	NB5	<i>Bifidobacterium bifidum</i> (NCBI)	99.0	1056
			<i>Bifidobacterium bifidum</i> (RDP)	99.8	
		NB6	<i>Bifidobacterium dentium</i> (NCBI)	99.0	1356
			<i>Bifidobacterium dentium</i> (RDP)	99.5	
7	47 (60d.)	NB8	<i>Bifidobacterium longum</i> (NCBI)	99.0	1340
			<i>Bifidobacterium longum</i> (RDP)	99.8	

**Table 7.** Genotypic identification of *Bifidobacterium* spp. based on 16S rRNA gene sequencing (Continued)

<b>No.</b>	<b>Subject No.</b> (day of lactation)	<b>Bacterial isolates</b>	<b>Match organism (Data bank)</b>	<b>% Identity</b>	<b>Query length (bp)</b>
8	48 (60d.)	NB9	<i>Bifidobacterium psedocatenulatum</i>	98.0	1356
			(NCBI)		
			<i>Bifidobacterium psedocatenulatum</i>	98.4	
			(RDP)		
9	53 (30d.)	NB10	<i>Bifidobacterium psedocatenulatum</i>	98.0	1356
			(NCBI)		
			<i>Bifidobacterium psedocatenulatum</i>	98.6	
			(RDP)		
10	54 (30d.)	NB11	<i>Bifidobacterium dentium</i> (NCBI)	100.0	993
			<i>Bifidobacterium dentium</i> (RDP)	99.8	
11	59 (28d.)	NB12	<i>Bifidobacterium bifidum</i> (NCBI)	98.0	973
			<i>Bifidobacterium bifidum</i> (RDP)	98.4	
12	61 (30d.)	NB13	<i>Bifidobacterium bifidum</i> (NCBI)	100.0	938
			<i>Bifidobacterium bifidum</i> (RDP)	99.5	
13	64 (30d.)	NB14	<i>Bifidobacterium dentium</i> (NCBI)	100.0	1475
			<i>Bifidobacterium dentium</i> (RDP)	99.8	
14	67 (60d.)	NB15	<i>Bifidobacterium bifidum</i> (NCBI)	99.0	1365
			<i>Bifidobacterium bifidum</i> (RDP)	98.9	

**Table 7.** Genotypic identification of *Bifidobacterium* spp. based on 16S rRNA gene sequencing (Continued)

No.	Subject No. (day of lactation)	Bacterial isolates	Match organism (Data bank)	% Identity	Query length (pb)
15	70 (60d.)	NB16	<i>Bifidobacterium bifidum</i> (NCBI)	99.0	1350
			<i>Bifidobacterium bifidum</i> (RDP)	98.8	
16	71 (60d.)	NB17	<i>Bifidobacterium longum</i> (NCBI)	98.0	1347
			<i>Bifidobacterium longum</i> (RDP)	98.6	
17	72 (60d.)	NB18	<i>Bifidobacterium longum</i> (NCBI)	99.0	696
			<i>Bifidobacterium longum</i> (RDP)	99.5	
18	75 (60d.)	NB19	<i>Bifidobacterium longum</i> (NCBI)	99.0	985
			<i>Bifidobacterium longum</i> (RDP)	98.8	
19	76 (60d.)	NB20	<i>Bifidobacterium longum</i> (NCBI)	99.0	1350
			<i>Bifidobacterium longum</i> (RDP)	98.9	
20	82 (60d.)	NB25	<i>Bifidobacterium breve</i> (NCBI)	99.0	623
			<i>Bifidobacterium breve</i> (RDP)	98.8	
21	83 (60d.)	NB28	<i>Bifidobacterium longum</i> (NCBI)	99.0	1350
			<i>Bifidobacterium longum</i> (RDP)	99.5	
22	85 (60d.)	NB31	<i>Bifidobacterium breve</i> (NCBI)	98.0	701
			<i>Bifidobacterium breve</i> (RDP)	98.4	
		NB37	<i>Bifidobacterium dentium</i> (NCBI)	98.0	1355
			<i>Bifidobacterium dentium</i> (RDP)	98.6	

**Table 7.** Genotypic identification of *Bifidobacterium* spp. based on 16S rRNA gene sequencing (Continued)

<b>No.</b>	<b>Subject No.</b> (day of lactation)	<b>Bacterial isolates</b>	<b>Match organism (Data bank)</b>	<b>% Identity</b>	<b>Query length (bp)</b>
23	86 (60d.)	NB38	<i>Bifidobacterium breve</i> (NCBI)	100.0	1368
			<i>Bifidobacterium breve</i> (RDP)	99.8	
24	87 (60d.)	NB39	<i>Bifidobacterium bifidum</i> (NCBI)	98.0	1460
			<i>Bifidobacterium bifidum</i> (RDP)	98.8	
25	90 (60d.)	NB40	<i>Bifidobacterium dentium</i> (NCBI)	100.0	1365
			<i>Bifidobacterium dentium</i> (RDP)	99.5	
26	91 (60d.)	NB42	<i>Bifidobacterium bifidum</i> (NCBI)	100.0	1222
			<i>Bifidobacterium bifidum</i> (RDP)	99.8	
27	92 (60d.)	NB45	<i>Bifidobacterium psedocatenulatum</i> (NCBI)	99.0	1351
			<i>Bifidobacterium psedocatenulatum</i> (RDP)	98.9	
28	95 (60d.)	NB46	<i>Bifidobacterium breve</i> (NCBI)	98.0	1363
			<i>Bifidobacterium breve</i> (RDP)	98.5	
29	97 (60d.)	NB47	<i>Bifidobacterium longum</i> (NCBI)	99.0	1540
			<i>Bifidobacterium longum</i> (RDP)	99.4	



**Table 7.** Genotypic identification of *Bifidobacterium* spp. based on 16S rRNA gene sequencing (Continued)

<b>No.</b>	<b>Subject No.</b> (day of lactation)	<b>Bacterial isolates</b>	<b>Match organism (Data bank)</b>	<b>% Identity</b>	<b>Query length (bp)</b>
			<i>Bifidobacterium psedocatenulatum</i>	99.0	
			(NCBI)		
30	98 (60d.)	NB48	<i>Bifidobacterium psedocatenulatum</i>	98.8	1369
			(RDP)		
			<i>Bifidobacterium breve</i> (NCBI)	97.0	
31	102 (60d.)	NB49	<i>Bifidobacterium breve</i> (RDP)	97.5	1355

**Table 8.** Genotypic identification of *Streptococcus* spp. based on 16S rRNA gene sequencing

<b>No.</b>	<b>Subject No.</b> (day of lactation)	<b>Bacterial isolates</b>	<b>Match organism (Data bank)</b>	<b>% Identity</b>	<b>Query length (bp)</b>
1	2 (15d.)	St1	<i>Streptococcus salivarius</i> (NCBI)	98.0	875
			<i>Streptococcus salivarius</i> (RDP)	97.9	
2	8 (15d.)	St2	<i>Streptococcus salivarius</i> (NCBI)	98.0	765
			<i>Streptococcus salivarius</i> (RDP)	98.4	
3	10 (15d.)	St4	<i>Streptococcus</i> sp. (NCBI)	99.0	914
			<i>Streptococcus</i> sp. (RDP)	98.9	
4	17 (60d.)	St5	<i>Streptococcus salivarius</i> (NCBI)	98.0	886
			<i>Streptococcus salivarius</i> (RDP)	98.6	
5	18 (60d.)	St6	<i>Streptococcus salivarius</i> (NCBI)	98.0	888
			<i>Streptococcus salivarius</i> (RDP)	97.9	
		St7	<i>Streptococcus mitis</i> (NCBI)	98.0	893
			<i>Streptococcus mitis</i> (RDP)	98.3	
6	21 (60d.)	Lac22	<i>Streptococcus lactarius</i> (NCBI)	100.0	669
			<i>Streptococcus lactarius</i> (RDP)	99.5	
		St9	<i>Streptococcus parasanguis</i> (NCBI)	98.0	887
			<i>Streptococcus parasanguis</i> (RDP)	97.6	

**Table 8.** Genotypic identification of *Streptococcus* spp. based on 16S rRNA gene sequencing (Continued)

No.	Subject No. (day of lactation)	Bacterial isolates	Match organism (Data bank)	% Identity	Query length (pb)		
7	22 (60d.)	St10	<i>Streptococcus lactarius</i> (NCBI)	99.0	886		
			<i>Streptococcus lactarius</i> (RDP)	99.4			
		St11	<i>Streptococcus lactarius</i> (NCBI)	99.0	883		
			<i>Streptococcus lactarius</i> (RDP)	98.6			
		St12	<i>Streptococcus salivarius</i> (NCBI)	98.0	884		
			<i>Streptococcus salivarius</i> (RDP)	97.9			
		St13	<i>Streptococcus salivarius</i> (NCBI)	98.0	887		
			<i>Streptococcus salivarius</i> (RDP)	97.6			
		St14	<i>Streptococcus salivarius</i> (NCBI)	98.0	888		
			<i>Streptococcus salivarius</i> (RDP)	98.3			
		8	23 (60d.)	St15	<i>Streptococcus salivarius</i> (NCBI)	98.0	886
					<i>Streptococcus salivarius</i> (RDP)	98.5	
St16	<i>Streptococcus mitis</i> (NCBI)			99.0	884		
	<i>Streptococcus mitis</i> (RDP)			98.9			
9	50 (60d.)	NL4	<i>Streptococcus</i> sp. (NCBI)	99.0	935		
			<i>Streptococcus</i> sp. (RDP)	99.5			
10	54 (30d.)	NL9	<i>Streptococcus salivarius</i> (NCBI)	97.0	931		
			<i>Streptococcus salivarius</i> (RDP)	97.4			

**Table 8.** Genotypic identification of *Streptococcus* spp. based on 16S rRNA gene sequencing (Continued)

No.	Subject No. (day of lactation)	Bacterial isolates	Match organism (Data bank)	% Identity	Query length (bp)
11	61 (30d.)	St19	<i>Streptococcus salivarius</i> (NCBI)	95.0	864
			<i>Streptococcus salivarius</i> (RDP)	94.6	
12	67 (60days)	St20	<i>Streptococcus salivarius</i> (NCBI)	94.0	865
			<i>Streptococcus salivarius</i> (RDP)	94.5	
13	70 (60d.)	St21	<i>Streptococcus salivarius</i> (NCBI)	95.0	838
			<i>Streptococcus salivarius</i> (RDP)	94.9	
		St22	<i>Streptococcus parasanguis</i> (NCBI)	97.0	824
			<i>Streptococcus parasanguis</i> (RDP)	97.4	
14	81 (60d.)	St26	<i>Streptococcus lactarius</i> (NCBI)	99.0	849
			<i>Streptococcus lactarius</i> (RDP)	99.5	
15	87 (23d.)	St27	<i>Streptococcus</i> sp. (NCBI)	99.0	855
			<i>Streptococcus</i> sp. (RDP)	98.9	
16	95 (30d.)	St32	<i>Streptococcus</i> sp. (NCBI)	99.0	846
			<i>Streptococcus</i> sp. (RDP)	99.4	
		St33	<i>Streptococcus mitis</i> (NCBI)	97.0	641
			<i>Streptococcus mitis</i> (RDP)	96.9	
17	100 (60d.)	St34	<i>Streptococcus salivarius</i> (NCBI)	92.0	262
			<i>Streptococcus salivarius</i> (RDP)	91.8	

**Table 9.** Bacterial isolates cultivated from breast milk samples and genotypically identified

Culture	No. of isolates	No. of samples (Total=102)
MRS culture:		
Suspected <i>Lactobacillus</i>	74	71
Positive by <i>Lactobacillus</i> -specific PCR	53	49
Identified as <i>Lactobacillus</i> spp. based on 16S	40	37
rRNA sequencing		
MC culture:		
Suspected <i>Bifidobacterium</i>	62	58
Positive by <i>Bifidobacterium</i> -specific PCR	45	43
Identified as <i>Bifidobacterium</i> spp. based on 16S	33	31
rRNA sequencing		
M17 culture:		
Suspected <i>Streptococcus</i>	40	34
Positive by <i>Streptococcus</i> -specific PCR	26	23
Identified as <i>Streptococcus</i> spp. based on 16S	26	17
rRNA sequencing		

**Table 10.** *Lactobacillus*, *Bifidobacterium* and *Streptococcus* species in breast milk identified by 16S rRNA gene sequencing


<b>Bacterial species</b>	<b>Number of isolates</b>	<b>Occurrence in milk samples</b>
<b><i>Lactobacillus</i></b>		
<i>L. gasseri</i>	6	6
<i>L. salivarius</i>	16	13
<i>L. fermentum</i>	5	5
<i>L. mucosae</i>	5	5
<i>L. rhamnosus</i>	3	3
<i>L. casei</i>	3	3
<i>L. plantarum</i>	1	1
<i>L. oris</i>	1	1
<b>Total</b>	<b>40</b>	<b>37 (36.27%)</b>
<b><i>Bifidobacterium</i></b>		
<i>B. longum</i>	8	8
<i>B. breve</i>	7	6
<i>B. pseudocatenulatum</i>	5	5
<i>B. dentium</i>	8	7
<i>B. bifidum</i>	5	5
<b>Total</b>	<b>33</b>	<b>31 (30.39%)</b>
<b><i>Streptococcus</i></b>		
<i>S. salivarius</i>	13	10
<i>S. lactarius</i>	4	3
<i>Streptococcus</i> sp.	4	4
<i>S. mitis</i>	3	3
<i>S. parasangius</i>	2	2
<b>Total</b>	<b>26</b>	<b>17 (16.67%)</b>

**Table 11.** Other bacterial species found in breast milk


<b>Groups of bacteria</b>	<b>No. of isolates</b>
<i>Staphylococcus aureus</i>	5
<i>Staphylococcus epidermidis</i>	4
<i>Actinomyces radidentis</i>	1
uncultured bacteria	15
<b>Total</b>	<b>25</b>

### 3. PCR analyses of lactobacilli, bifidobacteria and streptococci from breast milk samples.

Since culture may not be able to recover all lactobacilli, bifidobacteria and streptococci, PCR was used to detect the presence of these bacteria in breast milk samples. DNA targets were extracted from samples using QIAamp DNA stool minikit (Qiagen, Hilden, Germany). DNA target were amplified by genus-specific primers L159F and L677R for *Lactobacillus* spp., Bif164F and Bif601R for *Bifidobacterium* spp. and Tuf-Strep-1 and Tuf-Strep-R for *Streptococcus* spp. The amplified product of *Lactobacillus*, *Bifidobacterium* and *Streptococcus* was 546bp, 443bp and 560bp, respectively (Figure 11). Lactobacilli, bifidobacteria and streptococci DNA was detected by PCR in 94 (92.16%), 60 (58.82%) and 56 (54.90%) out of 102 breast milk samples, respectively (Figure 12).



**Figure 11.** Genus-specific amplification by Polymerase Chain Reaction (PCR). Lane 1, 100 bp DNA ladder: lane 2, suspected *Lactobacillus* sample: lane 3, *L. salivarius* control: lane 4, suspected *Bifidobacterium* sample: lane 5, *B. bifidum* control: lane 6, suspected *Streptococcus* sample: lane 7, *S. salivarius* control: lane 8, negative control.



**Figure 12.** Percentage of bacterial DNA detected by PCR using genus-specific primers. (i) *Lactobacillus*, (ii) *Bifidobacterium* and (iii) *Streptococcus*



#### 4. Antagonistic activity of *Lactobacillus*, *Bifidobacterium* and *Streptococcus* isolates against bacterial pathogens

The inhibitory activity of 40 *Lactobacillus* isolates was demonstrated in Table 12. All 40 *Lactobacillus* isolates had no inhibitory effect against *E. coli* and *H. pylori* but these isolates had weak inhibition against ETEC, EIEC, EPEC, EHEC and *S. Typhimurium*. Out of 40 isolates, 30 (75.00%) were able to inhibit the growth of *V. cholerae* and *S. flexneri*. The strong inhibitory activity of *Lactobacillus* against *V. cholerae* and *S. flexneri* was found in 9 isolates (Lac43, Lac44, Lac45, NL1, NL6, NL7, NL8, NL18 and NL50) and 6 isolates (Lac45, NL3, NL5, NL6, NL10 and NL50), respectively. The clear zones demonstrated antagonistic activity of lactobacilli against *V. cholerae* was shown in Figure 13. Furthermore, six *Lactobacillus* isolates had weak inhibition against Methicillin-resistant *Staphylococcus aureus* (MRSA) as shown in Figure 14.

The inhibitory activity of 33 *Bifidobacterium* isolates was demonstrated in Table 13. All *Bifidobacterium* isolates had no inhibition against *E. coli* and MRSA but they had partial inhibition against ETEC, EIEC, EPEC, EHEC and *S. Typhimurium* as microcolony. Out of 33 isolates, 30 (90.91%) and 28 (84.85%) were able to inhibit the growth of *V. cholerae* and *S. flexneri*, respectively. The strong inhibitory activity of *Bifidobacterium* against *V. cholerae* and *S. flexneri* found as 10 isolates (Bif29, NB4, NB11, NB13, NB14, NB15, NB16, NB17, NB31 and NB40) and 1 isolate (NB28), respectively. The clear zones demonstrated antagonistic activity of bifidobacteria against *V. cholerae* were shown in Figure 15. In addition, 23 (69.70%) out of 33 isolates inhibited the growth of *H. pylori*. Five of these 23 *Bifidobacterium* isolates (NB6, NB8, NB14, NB28 and NB31) had strong inhibitory activities against *H. pylori*.

The inhibitory activities of *Streptococcus* were tested in 21 isolates whereas those of 5 isolates were neglected. These 5 isolates belonged to *Streptococcus mitis* and *Streptococcus parasanguis* which were considered as human pathogens. The inhibitory activities of *Streptococcus* were demonstrated in Table 14. All 21 *Streptococcus* isolates had no inhibition against all bacterial pathogens, except four isolates had partial inhibition against *S. flexneri* as microcolony. Moreover, 8

(36.36%) and 5 (22.73%) out of 21 isolates had weak inhibition against *V. cholerae* and MRSA, respectively. The summary antagonistic activity of *Lactobacillus*, *Bifidobacterium* and *Streptococcus* were shown in Tables 15-17.

**Table 12.** *Lactobacillus* antagonistic activity against bacterial pathogens

Isolates	Pathogens									
	EHEC DMST 12743	EIEC DMST 20971	EPEC DMST 20972	ETEC DMST 20970	<i>S.</i> Typhimurium ATCC 13311	<i>S.</i> <i>flexneri</i> DMST 4423	<i>V. cholerae</i> non O1 DMST 2873	<i>E. coli</i> 25922	<i>H. pylori</i> ATCC 43504	MRSA ATCC 43300
St8	-	-	-	-	-	-	-	-	-	-
Lac31	-	-	-	-	-	-	-	-	-	-
Lac39	M	M	M	-	M	weak	weak	-	-	-
Lac40	M	M	M	-	M	weak	weak	-	-	strong
Lac41	weak	weak	weak	-	M	weak	weak	-	-	strong
Lac42	-	-	-	-	-	M	M	-	-	-
Lac43	-	M	M	-	-	weak	strong	-	-	-
Lac44	-	M	M	-	weak	weak	strong	-	-	-
Lac45	weak	weak	weak	M	weak	weak	strong	-	-	-
NL1	weak	weak	M	M	weak	weak	strong	-	-	-
NL2	-	M	M	-	M	weak	weak	-	-	-
NL3	-	M	M	M	M	weak	weak	-	-	-

- : No inhibition zone; M, microcolonies : opaque zone of inhibition <1 mm; weak: a clear inhibition zone of 1-2 mm; strong: a clear inhibition zone of 3-4 mm

**Table 12.** *Lactobacillus* antagonistic activity against bacterial pathogens (Continued)

Isolates	Pathogens									
	EHEC DMST 12743	EIEC DMST 20971	EPEC DMST 20972	ETEC DMST 20970	<i>S.</i> Typhimurium ATCC 13311	<i>S. flexneri</i> DMST 4423	<i>V. cholerae</i> non O1 DMST 2873	<i>E. coli</i> 25922	<i>H. pylori</i> ATCC 43504	MRSA ATCC 43300
NL5	M	-	M	M	M	strong	weak	-	-	-
NL6	weak	weak	weak	weak	weak	strong	strong	-	-	-
NL7	weak	weak	weak	M	weak	weak	strong	-	-	-
NL8	-	-	-	-	-	weak	strong	-	-	-
NL9	weak	weak	M	-	M	weak	weak	-	-	-
NL10	-	M	-	-	-	strong	weak	-	-	-
NL12	-	M	-	-	-	weak	weak	-	-	-
NL16	-	-	-	-	-	M	weak	-	-	-
NL18	-	-	-	-	-	weak	strong	-	-	weak
NL19	M	-	M	-	-	weak	weak	-	-	-
NL20	-	-	-	-	-	-	-	-	-	-
NL25	-	M	-	M	-	weak	weak	-	-	-

- : No inhibition zone; M, microcolonies : opaque zone of inhibition <1 mm; weak: a clear inhibition zone of 1-2 mm; strong: a clear inhibition zone of 3-4 mm

**Table 12.** *Lactobacillus* antagonistic activity against bacterial pathogens (Continued)

Isolates	Pathogens									
	EHEC DMST 12743	EIEC DMST 20971	EPEC DMST 20972	ETEC DMST 20970	<i>S.</i> Typhimurium ATCC 13311	<i>S.</i> flexneri DMST 4423	<i>V. cholerae</i> non O1 DMST 2873	<i>E. coli</i> 25922	<i>H. pylori</i> ATCC 43504	MRSA ATCC 43300
NL49	-	-	-	-	-	-	-	-	-	-
NL50	-	-	-	-	-	strong	strong	-	-	weak
NL52	-	-	-	-	-	M	weak	-	-	weak
NL53	-	M	-	-	-	M	weak	-	-	weak
NL54	-	-	M	-	-	-	-	-	-	-
NL55	-	-	-	-	-	-	M	-	-	-
NL56	M	M	M	-	M	M	weak	-	-	-
NL57	M	M	M	-	M	weak	weak	-	-	-
NL58	M	M	M	M	M	weak	weak	-	-	-
NL60	-	M	M	M	-	weak	weak	-	-	-
NL61	M	M	M	M	M	weak	weak	-	-	-
NL62	-	-	-	-	-	-	-	-	-	-

- : No inhibition zone; M, microcolonies : opaque zone of inhibition <1 mm; weak: a clear inhibition zone of 1-2 mm; strong: a clear inhibition zone of 3-4 mm

**Table 13.** *Bifidobacterium* antagonistic activity against bacterial pathogens

Isolates	Pathogens									
	EHEC DMST 12743	EIEC DMST 20971	EPEC DMST 20972	ETEC DMST 20970	<i>S. Typhimurium</i> ATCC 13311	<i>S. flexneri</i> DMST 4423	<i>V. cholerae</i> non O1 DMST 2873	<i>E. coli</i> 25922	<i>H. pylori</i> ATCC 43504	MRSA ATCC 43300
Bif 29	M	M	M	M	M	weak	strong	-	weak	-
NB1	-	-	-	-	-	-	-	-	-	-
NB2	-	-	-	-	-	weak	weak	-	weak	-
NB3	-	-	-	-	-	weak	weak	-	weak	-
NB4	-	-	-	-	-	weak	strong	-	weak	-
NB5	M	M	-	-	M	weak	weak	-	weak	-
NB6	-	-	-	-	M	weak	weak	-	strong	-
NB8	-	-	-	-	-	weak	weak	-	strong	-
NB9	-	-	-	-	-	weak	weak	-	weak	-
NB10	-	-	-	-	-	weak	weak	-	-	-
NB11	-	-	-	-	-	weak	strong	-	weak	-

- : No inhibition zone; M, microcolonies : opaque zone of inhibition <1 mm; weak: a clear inhibition zone of 1-2 mm; strong: a clear inhibition zone of 3-4 mm

**Table 13.** *Bifidobacterium* antagonistic activity against bacterial pathogens (Continued)

Isolates	Pathogens									
	EHEC DMST 12743	EIEC DMST 20971	EPEC DMST 20972	ETEC DMST 20970	<i>S.</i> Typhimurium ATCC 13311	<i>S.</i> <i>flexneri</i> DMST 4423	<i>V.</i> <i>cholerae</i> non O1 DMST 2873	<i>E. coli</i> 25922	<i>H.</i> <i>pylori</i> ATCC 43504	MRSA ATCC 43300
NB12	-	M	M	-	-	weak	weak	-	-	-
NB13	-	M	-	M	M	weak	strong	-	weak	-
NB14	-	-	-	-	-	weak	strong	-	strong	-
NB15	-	M	-	M	M	weak	strong	-	weak	-
NB16	-	M	-	-	-	weak	strong	-	weak	-
NB17	-	M	-	-	M	weak	strong	-	weak	-
NB18	M	M		-	M	M	weak		weak	
NB19	M	M	-	M	M	weak	weak	-	-	-
NB20	-	M	-	-	M	-	weak	-	weak	-
NB25	-	-	-	-	-	weak	weak	-	-	-
NB28	-	-	-	-	-	strong	weak	-	strong	-

- : No inhibition zone; M, microcolonies : opaque zone of inhibition <1 mm; weak: a clear inhibition zone of 1-2 mm; strong: a clear inhibition zone of 3-4 mm

**Table 13.** *Bifidobacterium* antagonistic activity against bacterial pathogens (Continued)

Isolates	Pathogens									
	EHEC DMST 12743	EIEC DMST 20971	EPEC DMST 20972	ETEC DMST 20970	<i>S.</i> Typhimurium ATCC 13311	<i>S.</i> <i>flexneri</i> DMST 4423	<i>V.</i> <i>cholerae</i> non O1 DMST 2873	<i>E. coli</i> 25922	<i>H.</i> <i>pylori</i> ATCC 43504	MRSA ATCC 43300
NB31	-	M	M	-	M	M	strong	-	strong	-
NB37	-	-	-	-	-	M	weak	-	-	-
NB38	-	-	-	-	-	weak	weak	-	-	-
NB39	M	M	M	M	M	weak	weak	-	weak	-
NB40	-	-	-	-	M	weak	strong	-	weak	-
NB42	-	-	-	-	-	M	weak	-	weak	-
NB45	-	-	-	-	M	M	weak	-	weak	-
NB46	-	-	-	-	-	-	-	-	-	-
NB47	-	-	-	-	-	-	-	-	-	-
NB48	-	-	-	-	-	M	weak	-	weak	-
NB49	-	-	-	-	-	-	M	-	-	-

- : No inhibition zone; M, microcolonies : opaque zone of inhibition <1 mm; weak: a clear inhibition zone of 1-2 mm; strong: a clear inhibition zone of 3-4 mm



**Table 14.** *Streptococcus* antagonistic activity against bacterial pathogens


Isolates	Pathogens									
	EHEC DMST 12743	EIEC DMST 20971	EPEC DMST 20972	ETEC DMST 20970	<i>S.</i> Typhimurium ATCC 13311	<i>S.</i> <i>flexneri</i> DMST 4423	<i>V.</i> <i>cholerae</i> non O1 DMST 2873	<i>E. coli</i> 25922	<i>H.</i> <i>pylori</i> ATCC 43504	MRSA ATCC 43300
St1	-	-	-	-	-	-	-	-	-	-
St2	-	-	-	-	-	-	-	-	-	-
St4	-	-	-	-	-	-	-	-	-	-
St5	-	-	-	-	-	-	M	-	-	-
St6	-	-	-	-	-	-	weak	-	-	-
Lac22	-	-	-	-	-	-	-	-	-	-
St10	-	-	-	-	-	-	-	-	-	weak
St11	-	-	-	-	-	-	-	-	-	weak
St12	-	-	-	-	-	M	weak	-	-	M
St13	-	-	-	-	-	M	weak	-	-	M
St14	-	-	-	-	-	M	weak	-	-	-

- : No inhibition zone; M, microcolonies : opaque zone of inhibition <1 mm; weak: a clear inhibition zone of 1-2 mm; strong: a clear inhibition zone of 3-4 mm


**Table 14.** *Streptococcus* antagonistic activity against bacterial pathogens. (Continued)

Isolates	Pathogens									
	EHEC DMST 12743	EIEC DMST 20971	EPEC DMST 20972	ETEC DMST 20970	<i>S.</i> Typhimurium ATCC 13311	<i>S.</i> <i>flexneri</i> DMST 4423	<i>V.</i> <i>cholerae</i> non O1 DMST 2873	<i>E. coli</i> 25922	<i>H.</i> <i>pylori</i> ATCC 43504	MRSA ATCC 43300
St15	-	-	-	-	-	-	weak	-	-	-
NL4	-	-	-	-	-	-	-	-	-	weak
NL9	-	-	-	-	-	-	-	-	-	weak
St19	-	-	-	-	-	-	-	-	-	M
St20	-	-	-	-	-	-	-	-	-	-
St21	-	-	-	-	-	-	-	-	-	M
St26	-	-	-	-	-	-	-	-	-	-
St27	-	-	-	-	-	-	weak	-	-	weak
St32	-	-	-	-	-	-	weak	-	-	M
St34	-	-	-	-	-	M	weak	-	-	M


- : No inhibition zone; M, microcolonies : opaque zone of inhibition <1 mm; weak: a clear inhibition zone of 1-2 mm; strong: a clear inhibition zone of 3-4 mm



**Figure 13.** Antagonistic activity of *Lactobacillus* against *Vibrio cholerae* with clear zone, microcolonies and no inhibition zone in 140 mm plate



**Figure 14.** Antagonistic activity of *Lactobacillus* against methicillin-resistant *Staphylococcus aureus* (MRSA) with clear zone and no inhibition zone in 140 mm plate



**Figure 15.** Antagonistic activity of *Bifidobacterium* against *Vibrio cholerae* with clear zone and microcolonies in 140 mm plate

**Table 15.** The summary antagonistic activity of *Lactobacillus* spp. against bacterial pathogens

<b>Pathogens</b>	<b>Inhibition results (number of isolates)</b>
ETEC	Inhibition (10): weak (1), microcolony (9)
EIEC	Inhibition (21): weak (6), microcolony (15)
EPEC	Inhibition (20): weak (4), microcolony (16)
EHEC	Inhibition (14): weak (6), microcolony (8)
S.Typhimurium	Inhibition (16): weak (5), microcolony (11)
<i>E. coli</i>	No inhibition
<i>V. cholerae</i>	Inhibition (30): strong (9), weak (19), microcolony (2)
<i>S. flexneri</i>	Inhibition (30): strong (6), weak (20), microcolony (4)
MRSA	Weak inhibition (6)
<i>H. pylori</i>	No inhibition

**Table 16.** The summary antagonistic activity of *Bifidobacterium* spp. against bacterial pathogens

<b>Pathogens</b>	<b>Inhibition results (number of isolates)</b>
ETEC	Inhibition as microcolony (5)
EIEC	Inhibition as microcolony (12)
EPEC	Inhibition as microcolony (4)
EHEC	Inhibition as microcolony (5)
S.Typhimurium	Inhibition as microcolony (13)
<i>E. coli</i>	No inhibition
<i>V. cholerae</i>	Inhibition (30): strong (10), weak (19), microcolony (1)
<i>S. flexneri</i>	Inhibition (28): strong (1), weak (21), microcolony (6)
MRSA	No inhibition
<i>H. pylori</i>	Inhibition (23): strong(5), weak (18)

**Table 17.** The summary antagonistic activity of *Streptococcus* spp. against bacterial pathogens

Pathogens	Inhibition results (number of isolates)
ETEC	} No inhibition
EIEC	
EPEC	
EHEC	
S.Typhimurium	
<i>E. coli</i>	
<i>V. cholerae</i>	Inhibition (9): weak (8), microcolony (1)
<i>S. flexneri</i>	Partial in inhibition as microcolony (4)
MRSA	Weak inhibition of (5)
<i>H. pylori</i>	No inhibition

## CHAPTER V

### DISCUSSION

Breast milk is the best food for growing infant and has been shown to be a source of commensal and/or probiotic bacteria [2]. The commensal bacteria presented in breast milk were such as staphylococci, streptococci, lactobacilli, enterococci and bifidobacteria [3, 4]. These bacterial groups were shown to be associated with neonates gut microbiota and may also play role in the reduction of the incidence of infections in the breast-fed infant [2, 5]. Our results showed the diversity of lactobacilli, bifidobacteria and streptococci in breast milk detected by the use of culture-dependent techniques and genotypic identification. MRS medium was a culture medium for the cultivation of *Lactobacillus* and *Bifidobacterium* [140]. However, our study demonstrated that only *Lactobacillus* was recovered on MRS agar. *Bifidobacterium* was detected only on MC agar which is Columbia medium modified by the addition of glucose, cysteine hydrochloride, agar and bromocresol purple for the differentiation of acid-producing as described by Beerens [68]. There are many type of media for detection of *Bifidobacterium* such as TPY medium (trypticase-phytone-yeast) described by Scardovi (1986) [141] and Columbia agar containing horse blood (5%, V/V) [140]. In fact, *Streptococcus* may grow on MRS medium but this work could not isolate these bacteria from this medium. *Streptococcus* isolates were detected on M 17 medium which is a selective media for lactic acid streptococci and recommended for the isolation of *S. thermophilus* from yogurt [142].

The skin swabs were cultured for *Lactobacillus*, *Bifidobacterium* and *Streptococcus* in the same condition as breast milk samples and none of them were recovered. This suggested that *Lactobacillus*, *Bifidobacterium* and *Streptococcus* found in breast milk were not from the contamination of these bacteria from nipple and the surrounding skin of volunteers. The origin of the live *Lactobacillus*, *Bifidobacterium* and *Streptococcus* in breast milk is still controversial. They may be

from exogenous source such as the infant mouth and fecal of the mother [143] or the maternal gut involving maternal dendritic cells and macrophages [5, 144].

All isolates of *Lactobacillus*, *Bifidobacterium* and *Streptococcus* were genotypically identified by 16S rRNA gene sequencing. Forty *Lactobacillus* isolates were identified to 8 species such as *L. gasseri*, *L. salivarius*, *L. fermentum*, *L. mucosae*, *L. rhamnosus*, *L. casei*, *L. plantarum* and *L. oris*. These *Lactobacillus* isolates were recovered from 37 (36.27%) milk samples. The result demonstrated that the diversity of species was more than that found in previous studies but the number of positive samples was varied. Heikkila *et al.* isolated 7 *Lactobacillus* from 4 (10%) of 40 healthy lactating mothers in Finland. The majority of samples were taken within 90 days of delivery. These *Lactobacillus* species were *L. rhamnosus* and *L. crispatus* [3]. Martin *et al.* reported the isolation of three *Lactobacillus* species such as *L. gasseri* and *L. fermentum* from 8 (100%) lactating mothers [2, 145]. However, this study did not mention about the age of lactation.

Thirty-three *Bifidobacterium* isolates were identified to 5 species such as *B. longum*, *B. breve*, *B. pseudocatenulatum*, *B. dentium* and *B. bifidum*. These *Bifidobacterium* isolates were recovered from 31 (30.39%) milk samples. The diversity of species was more but the number of positive samples was less than those of the previous study. Martin *et al.* was the first to report the isolation of bifidobacteria from 8 (34.78%) of 23 healthy lactating mothers in Spain. These *Bifidobacterium* species were *B. breve*, *B. adolescentis* and *B. bifidum* [4].

Twenty-six *Streptococcus* isolates were identified to 5 species such as *S. salivarius*, *S. lactarius*, *Streptococcus* sp., *S. mitis* and *S. parasanguis*. These *Streptococcus* isolates were recovered from in 17 (16.67%) milk samples. The diversity of species and the number of positive samples was less than those found in previous studies. Heikkila *et al.* isolated *Streptococcus* from 40 healthy lactating mothers in Finland. The result was shown 151 *Streptococcus* isolates and recovered from 29 (72.5%) milk samples. The *Streptococcus* species such as *S. salivarius*, *S. mitis*, *S. parasanguis*, *S. peroris*, *S. agalactiae* and *Streptococcus* sp. (oral) [3]. In fact, genus *Streptococcus* was the second most abundant in breast milk and associated with oral species. In this work *S. lactarius* which was reported as a novel species in breast milk [146] was also recovered from milk samples. *Staphylococcus* isolates



which were picked up by technical errors from catalase test and positive with *Lactobacillus*-specific amplification revealed that genus-specific primers had homology with *Staphylococcus* DNA. Alignment of these primers with *S. aureus* and *S. epidermidis* 16S rRNA genes showed that they had 59.09% and 86.36%, respectively. It is therefore possible that the genus-specific primers could amplify *S. epidermidis* which is skin flora.

Polymerase chain reaction (PCR) method was used for detect of lactobacilli, bifidobacteria and streptococci DNAs in breast milk. Targets DNA were extracted by Qiagen stool mini kit and add a bead-beading to the chemical lyses for increase cells lysis step. PCR amplicons were generated with genus-specific primers for *Lactobacillus*, *Bifidobacterium* and *Streptococcus*. The results demonstrated the presence of lactobacilli, bifidobacteria and streptococci DNAs in 94 (92.16%), 60 (58.82%) and 56 (54.90%) of 102 breast milk samples, respectively. Based on the false-positive result of genus-specific amplification of bacterial isolates in Table 9 , the positive result of DNA presence in breast milk samples was estimated to be 76.94% of *Lactobacillus*, 84% of *Bifidobacterium* and 100% of *Streptococcus*. Collado *et al.* reported the presence of *Lactobacillus*, *Bifidobacterium* and *Streptococcus* in 50 (100%) lactating mothers by quantitative real-time PCR [136]. In addition, Martin *et al.* reported the detection of *Bifidobacterium* in 22 (95.65%) of 23 milk samples by quantitative real-time PCR. They also showed that the percentage of *Bifidobacterium* DNA was  $\leq 16\%$  of total bacterial DNA [4]. Our result demonstrated that the number of bacterial isolates cultivated from breast milk samples was lower than that detected by PCR. This resulted from the fact that culture method is not perfect to recover all bacterial species in samples.

Since *Lactobacillus* and *Bifidobacterium* are anaerobic bacteria, they are sensitive to oxygen. Samples should be transported in anaerobic condition which was not feasible for liquid samples like breast milk and skin swab in peptone water. To acquire anaerobic condition, the lid of sample tube must be loosen resulting in sample leak. In addition, sample transportation was carried in cold which was not appropriate temperature for cold-sensitive *Streptococcus*. The result of *Streptococcus* prevalence in breast milk was then less than that of previous study [3].

Antagonistic activity assay was performed in all isolates of *Lactobacillus*, *Bifidobacterium* and *Streptococcus* against bacterial pathogens such as enterotoxigenic *E. coli* (ETEC), enteroinvasive *E. coli* (EIEC), enteropathogenic *E. coli* (EPEC), enterohemorrhagic *E. coli* (EHEC), *Salmonella* Typhimurium, *Shigella flexneri*, *Vibrio cholerae*, *Helicobacter pylori* and methicillin-resistant *Staphylococcus aureus* (MRSA). Thirteen *Lactobacillus* isolates such as Lac43 (*L. rhamnosus*), Lac44 (*L. casei*), Lac45 (*L. salivarius*), NL1 (*L. salivarius*), NL3 (*L. salivarius*), NL5 (*L. salivarius*), NL6 (*L. salivarius*), NL7 (*L. salivarius*), NL8 (*L. gasseri*), NL10 (*L. gasseri*), NL18 (*L. mucosae*), NL26 (*L. salivarius*) and NL50 (*L. fermentum*) had strong antagonistic activity against *V. cholerae* and *S. flexneri* and weak antagonistic activity against ETEC, EIEC, EPEC, EHEC and *S. Typhimurium*. Furthermore, six isolates of *Lactobacillus* such as Lac 40 (*L. salivarius*), Lac41 (*L. salivarius*), NL26 (*L. salivarius*), NL50 (*L. fermentum*), NL52 (*L. mucosae*) and NL53 (*L. fermentum*) could inhibit the growth of methicillin-resistant *Staphylococcus aureus* (MRSA). Since 2006, only Olivares *et al.* has reported breast - milk originated *Lactobacillus* such as *L. salivarius* CECT5713 and *L. gasseri* CECT5714 could inhibit the growth of *Salmonella cholerasuis*, *Escherichia coli*, *Staphylococcus aureus*, *Listeria monocytogenes* and *Clostridium tyrobutyricum*, [32]. Antagonistic activity was reported in *Lactobacillus* isolated from other sources such as four *Lactobacillus reuteri* strains could inhibit the growth of enteric pathogens (EHEC, ETEC, *Salmonella enterica*, *Shigella sonnei* and *Vibrio cholerae*) [11]. Parvathi *et al.* demonstrated that *Lactobacillus fermentum* isolated from the intestinal biopsy samples could inhibit the growth of enteric pathogens such as *E. coli*, *S. paratyphi*, and *S. sonnei* [147]. Raffaella *et al.* reported *Lactobacillus acidophilus* ATCC 4356 could inhibit growth of *Campylobacter jejuni* strains [148].

Eleven *Bifidobacterium* isolates such as Bif29 (*B. breve*), NB4 (*B. dentium*), NB11 (*B. dentium*), NB13 (*B. bifidum*), NB14 (*B. dentium*), NB15 (*B. bifidum*), NB16 (*B. bifidum*), NB17 (*B. longum*), NB28 (*B. longum*), NB31 (*B. breve*) and NB40 (*B. dentium*) had strong antagonistic activity against *V. cholerae* and *S. flexneri* and had partial antagonistic activity against ETEC, EIEC, EPEC, EHEC and *S. Typhimurium* as microcolony. In addition, five *Bifidobacterium* isolates including NB6 (*B. dentium*), NB8 (*B. longum*), NB14 (*B. dentium*), NB28 (*B. longum*) and NB31 (*B.*

*breve*) had strong antagonistic activity against *H. pylori*. Breast-milk originated *Bifidobacterium* spp. have not been reported for their antagonistic activity. Only *Bifidobacterium* isolated from feces were studied previously. Gibson *et al.* has shown that *B. infantis* isolated from infant feces could inhibit the growth of *E. coli* and *Clostridium perfringens* [149]. Bevilacqua *et al.* has shown bifidobacteria isolated from human feces could inhibit the growth of *Clostridium sporogenes* [150]. Collado *et al.* had demonstrated that *Bifidobacterium* isolated from feces could inhibit the growth of *Helicobacter pylori* [151].

Eight *Streptococcus* isolates such as St6 (*S. salivarius*), St12 (*S. salivarius*), St13 (*S. salivarius*), St14 (*S. salivarius*), St15 (*S. salivarius*), St 32 (*Streptococcus* sp.) and St34 (*S. salivarius*) had weak antagonistic activity against *V. cholerae*. Five isolates including St10 (*S. lactarius*), St11 (*S. lactarius*), NL4 (*Streptococcus* sp.), NL9 (*S. salivarius*) and St27 (*Streptococcus* sp.) weakly inhibited the growth of MRSA. There was only one report of Heikkila *et al.* demonstrating that *Streptococcus salivarius* isolated from breast milk had antagonistic activity against *Staphylococcus aureus* [3].

Beneficial bacteria such as *Lactobacillus*, *Bifidobacterium* and *Streptococcus* isolated from breast milk had the ability to inhibit the growth of pathogenic bacteria. It has been documented that bacterial antagonistic activity may be from the production of acid, hydrogen peroxide or bacteriocin and small organic molecules [9, 145, 149-152]. Sigrid *et al.* reported the antibacterial activity of *Lactobacillus rhamnosus* GG against *Salmonella typhimurium* by the production of antimicrobial compound which was a low molecular weight, heat-stable, non-proteinaceous substance, thought to be lactic acid [153]. Collado *et al.* demonstrated that six *Bifidobacterium* isolated from feces could inhibit the growth of *H. pylori*. These antagonistic effects were found to relate to heat-stable, proteinaceous bactericidal substance, suspected to be antimicrobial peptides [151]. Cheikhoussef *et al.* purified bacteriocin called bifidin I from *Bifidobacterium infantis* BCRC 14602 and demonstrated its ability to inhibit the growth of many Gram-positive and Gram-negative bacteria which cause food spoilage and food-borne diseases [76]. Mathot *et al.* reported that *S. thermophilus* could produce bacteriocin called thermophilins with the ability to inhibit the growth of *Clostridium tyrobutyricum* [13].

The mechanisms which breast milk-derived lactobacilli, bifidobacteria and streptococci employed to suppress the growth of pathogens in this study were not determined. They were of interest to investigate in further study.

## CHAPTER VI

### CONCLUSION

Culture and identification of beneficial bacteria from breast milk and swabs of nipple and surrounding skin of Thai healthy mothers were performed. It was found that 40 *Lactobacillus*, 33 *Bifidobacterium* and 26 *Streptococcus* isolates were recovered from 37 (36.27%), 31 (30.39%) and 17 (16.67%) samples, respectively. None of these bacteria was recovered from skin swabs. Isolated *Lactobacillus* spp. included *L. gasseri*, *L. salivarius*, *L. fermentum*, *L. mucosae*, *L. rhamnosus*, *L. casei*, *L. plantarum* and *L. oris* whereas isolated *Bifidobacterium* spp. were *B. longum*, *B. breve*, *B. pseudocatenulatum*, *B. dentium* and *B. bifidum*. Isolated *Streptococcus* was found to be *S. salivarius*, *S. lactarius*, *Streptococcus* sp., *S. mitis* and *S. parasangius*

Test for antagonistic activity against ETEC, EIEC, EPEC, EHEC and *S. Typhimurium* revealed that all isolates of *Lactobacillus*, *Bifidobacterium* and *Streptococcus* had weak, partial and no activity, respectively. Thirteen *Lactobacillus* isolates (Lac43, Lac44, Lac45, NL1, NL3, NL5, NL6, NL7, NL8, NL10, NL18, NL26 and NL50) and 11 *Bifidobacterium* isolates (Bif29, NB4, NB11, NB13, NB14, NB15, NB16, NB17, NB28, NB31 and NB40) demonstrated strong antagonistic activity against *V. cholerae* and *S. flexneri*. Furthermore, six *Lactobacillus* isolates (Lac 40, Lac41, NL26, NL50, NL52 and NL53) and 5 *Streptococcus* isolates (St10, St11, NL4, NL9 and St27) weakly inhibited the growth of MRSA. In addition, five *Bifidobacterium* isolates (NB6, NB8, NB14, NB28 and NB31) had strong antagonistic activity against *H. pylori*.

The majority of lactobacilli, bifidobacteria and streptococci that had strong inhibitory activities against bacterial pathogens belonged to *L. salivarius*, *L. gasseri*, *L. mucosae*, *L. fermentum*, *B. dentium*, *B. bifidum*. Since specific strains of *Lactobacillus*, *Bifidobacterium* and *Streptococcus* had probiotic properties, these breast milk-derived bacteria were probiotic candidates for further study to elucidate their antagonistic mechanism against gastrointestinal bacterial pathogens.

## REFERENCES

- [1] Martin R, Heilig GHJ, Zoetendal EG, Smidt H, Rodriguez JM. Diversity of the *Lactobacillus* group in breast milk and vagina of healthy women and potential role in the colonization of the infant gut. Journal of Applied Microbiology. 103,6 (2007):2638-44.
- [2] Martin R, Langa S, Reviriego C, Jimenez E, Marin ML, Xaus J, et al. Human milk is a source of lactic acid bacteria for the infant gut. Journal of Pediatrics. 143,6 (2003):754-8.
- [3] Heikkila MP, Saris PEJ. Inhibition of *Staphylococcus aureus* by the commensal bacteria of human milk. Journal of Applied Microbiology. 95,3 (2003):471-8.
- [4] Martin R, Jimenez E, Heilig H, Fernandez L, Marin ML, Zoetendal EG, et al. Isolation of bifidobacteria from breast milk and assessment of the bifidobacterial population by PCR-denaturing gradient gel electrophoresis and quantitative real-time PCR. Applied and Environmental Microbiology. 75,4 (2009):965-9.
- [5] Martin R, Langa S, Reviriego C, Jimenez E, Marin ML, Olivares M, et al. The commensal microflora of human milk: New perspectives for food bacteriotherapy and probiotics. Trends in Food Science and Technology. 15,3-4 (2004):121-7.
- [6] Felis GE, Dellaglio F. Taxonomy of lactobacilli and bifidobacteria. Current Issues in Intestinal Microbiology. 8,2 (2007):44-61.
- [7] Lara-Villoslada F, Olivares M, Sierra S, Miguel Rodriguez J, Boza J, Xaus J. Beneficial effects of probiotic bacteria isolated from breast milk. British Journal of Nutrition. 98(2007):96-100.
- [8] Preidis GA, Versalovic J. Targeting the Human Microbiome With Antibiotics, Probiotics, and Prebiotics: Gastroenterology Enters the Metagenomics Era. Gastroenterology. 136,6 (2009):2015-31.
- [9] Huovinen P. Bacteriotherapy: The time has come. British Medical Journal. 323,7309 (2001):353-4.
- [10] Hutt P, Shchepetova J, Loivukene K, Kullisaar T, Mikelsaar M. Antagonistic activity of probiotic lactobacilli and bifidobacteria against entero- and uropathogens. Journal of Applied Microbiology. 100,6 (2006):1324-32.

- [11] Spinler JK, Taweechoatipatr M, Rognerud CL, Ou CN, Tumwasorn S, Versalovic J. Human-derived probiotic *Lactobacillus reuteri* demonstrate antimicrobial activities targeting diverse enteric bacterial pathogens. Anaerobe. 14,3 (2008):166-71.
- [12] Cheikhyoussef A, Pogori N, Chen W, Zhang H. Antimicrobial proteinaceous compounds obtained from bifidobacteria: From production to their application. International Journal of Food Microbiology. 125,3 (2008):215-22.
- [13] Mathot AG, Beliard E, Thuault D. *Streptococcus thermophilus* 580 produces a bacteriocin potentially suitable for inhibition of *Clostridium tyrobutyricum* in hard cheese. Journal of Dairy Science. 86,10 (2003):3068-74.
- [14] William B. P. Breast Milk Immunology. Am J Dis Child. 133(1979):83-7.
- [15] Walker A. Breast Milk as the Gold Standard for Protective Nutrients. Journal of Pediatrics. 156,2 (2010):3-7.
- [16] Rescigno M, Urbano M, Valzasina B, Francolini M, Rotta G, Bonasio R, et al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nature Immunology. 2,4 (2001):361-7.
- [17] Roitt I. Essential immunology: Oxford Blackwell Scientific, 1994.
- [18] Kandler OaNW. Genus *Lactobacillus*. . In: P.H.A. Sneath NSM, M.E. Sharpe and J.G. Holt ed., Bergey's manual of systemict bacteriology, p. 1209-32. Baltimore London Williams and Wilkins, 1986.
- [19] Tannock GW. Identification of lactobacilli and bifidobacteria. Current issues in molecular biology. 1,1-2 (1999):53-64.
- [20] Giovanna E., Dellaglio FaF. Taxonomy of Lactobacilli and Bifidobacteria. Intestinal Microbiology.8 (2007):44-61.
- [21] Hammes WPaV, R.F. The genus *Lactobacillus* In: Holzapfel BJBWaWH ed., The Genera of Lactic Acid Bacteria, p. 19-54. UK: Blackoe Academic and Professional, 1995.
- [22] Berthier F, Ehrlich SD. Rapid species identification within two groups of closely related lactobacilli using PCR primers that target the 16S/23S rRNA spacer region. Microbiology Letters. 161,1 (1998):97-106.
- [23] Tilsala-Timisjärvi A, Alatossava T. Development of oligonucleotide primers from the 16S-23S rRNA intergenic sequences for identifying different

- dairy and probiotic lactic acid bacteria by PCR. International Journal of Food Microbiology. 35,1 (1997):49-56.
- [24] Szajewska H, Kotowska M, Mrukowicz JZ, Armńska M, Mikołajczyk W. Efficacy of *Lactobacillus* GG in prevention of nosocomial diarrhea in infants. Journal of Pediatrics. 138,3 (2001):361-5.
- [25] Cremonini F, Di Caro S, Covino M, Armuzzi A, Gabrielli M, Santarelli L, et al. Effect of different probiotic preparations on anti-*Helicobacter pylori* therapy-related side effects: A parallel group, triple blind, placebo-controlled study. American Journal of Gastroenterology. 97,11 (2002):2744-9.
- [26] Rosenfeldt V, Michaelsen KF, Jakobsen M, Larsen CN, Møller PL, Pedersen P, et al. Effect of probiotic *Lactobacillus* strains in young children hospitalized with acute diarrhea. Pediatric Infectious Disease Journal. 21,5 (2002):411-6.
- [27] Bendali F, Madi N, Sadoun D. Beneficial effects of a strain of *Lactobacillus paracasei* subsp. *paracasei* in *Staphylococcus aureus*-induced intestinal and colonic injury. International Journal of Infectious Diseases. 15,11 (2011):787-94.
- [28] Aso Y, Akazan H. Prophylactic effect of a *Lactobacillus casei* preparation on the recurrence of superficial bladder cancer. Urologia Internationalis. 49,3 (1992):125-9.
- [29] Lin SY, Ayres JW, Winkler Jr W, Sandine WE. *Lactobacillus* effects on cholesterol: in vitro and in vivo results. Journal of Dairy Science. 72,11 (1989):2885-99.
- [30] Khedkar CD GR, Mantri JM, Kulkarni SA, Khedkar GD. Effect of feeding *acidophilus* milk on serum cholesterol in human volunteers. . Dairy Foods Home Science. 8(1993):12-33.
- [31] Corr SC, Li Y, Riedel CU, O'Toole PW, Hill C, Gahan CGM. Bacteriocin production as a mechanism for the antiinfective activity of *Lactobacillus salivarius* UCC118. Proceedings of the National Academy of Sciences of the United States of America. 104,18 (2007):7617-21.
- [32] Olivares M, Díaz-Roperó MP, Martín R, Rodríguez JM, Xaus J. Antimicrobial potential of four *Lactobacillus* strains isolated from breast milk. Journal of Applied Microbiology. 101,1 (2006):72-9.
- [33] Tissier H. Le bacterium coli et la reaction chromophil d'Escherich. Biology. 51(1899):943-5.



- [34] Orla-Jensen S. La classification des bactéries lactiques, 1924.
- [35] Poupard JA, I. Husain, and R. F. Norris. Biology of the bifidobacteria. Bacteriology.37 (1973):136-65.
- [36] Bergey DH, R. E. Buchanan, and N. E. Gibbone. Bergey's manual of determinative bacteriology, 1974.
- [37] Lee JH, O'Sullivan DJ. Genomic insights into bifidobacteria. Microbiology and Molecular Biology Reviews. 74,3 (2010):378-416.
- [38] Reuter G. Vergleichenden Untersuchung über die Bifidus-Flora im Sauglings und Erwachsenenstuhl. (1963):486–507.
- [39] Cardovi V, Crociani F. *Bifidobacterium catenulatum*, *Bifidobacterium dentium*, and *Bifidobacterium angulatum*: three new species and their deoxyribonucleic acid homology relationships. International Journal of Systematic Bacteriology. 24,1 (1974):6-20.
- [40] Mitsuoka T. Comparative studies on bifidobacteria isolated from the alimentary tract of man and animals (including descriptions of *Bifidobacterium thermophilum* nov. spec. and *Bifidobacterium pseudolongum* nov.spec.). Zentralbl Bakteriolog Orig. 210(1969):52-64.
- [41] Meile L, Ludwig W, Rueger U, Gut C, Kaufmann P, Dasen G, et al. *Bifidobacterium lactis* sp. nov., a moderately oxygen tolerant species isolated from fermented milk. Systematic and Applied Microbiology. 20,1 (1997):57-64.
- [42] Scardovi V, Trovatelli LD. New species of bifid bacteria from *Apis mellifica* L. and *Apis indica* F. A contribution to the taxonomy and biochemistry of the genus *Bifidobacterium*. Allgemeine, landwirtschaftliche und technische Mikrobiologie. 123,1 (1969):64-88.
- [43] Tissier H. Recherches sur la flore intestinale des nourrissons (etatnormal et pathologique). 1900.
- [44] Killer J, Kopečný J, Mrázek J, Rada V, Benada O, Koppová I, et al. *Bifidobacterium bombi* sp. nov., from the bumblebee digestive tract. International Journal of Systematic and Evolutionary Microbiology. 59,8 (2009):2020-4.
- [45] Scardovi V, L. D. Trovatelli, B. Biavati, and G. Zani. *Bifidobacterium cuniculi*, *Bifidobacterium choerinum*, *Bifidobacterium boum*, and *Bifidobacterium pseudocatenulatum*—4 new species and their

- deoxyribonucleic-acid homology relationships. Bacteriology.29 (1979):291–311.
- [46] Reuter G. Vergleichenden Untersuchung über die Bifidus-Flora im Säuglings und Erwachsenenstuhl. Zentralbl.191 (1963):486–507.
- [47] Biavati B, V. Scardovi, and W. E. C. Moore. *Bifidobacterium cuniculi*, *Bifidobacterium choerinum*, *Bifidobacterium boum*, and *Bifidobacterium pseudocatenulatum* –4 new species and their deoxyribonucleic-acid homology relationships. Bacteriology.32 (1982):358-73.
- [48] Delcenserie V, Gavini F, Beerens H, Tresse O, Franssen C, Daube G. Description of a new species, *Bifidobacterium crudilactis* sp. nov., isolated from raw milk and raw milk cheeses. Systematic and Applied Microbiology. 30,5 (2007):381-9.
- [49] Lauer E. *Bifidobacterium gallicum* sp. nov. isolated from human feces. International Journal of Systematic Bacteriology. 40,1 (1990):100-2.
- [50] Watabe J, Benno Y, Mitsuoka T. *Bifidobacterium gallinarum* sp. nov.: A new species isolated from the ceca of chickens. International Journal of Systematic Bacteriology. 33,2 (1983):127-32.
- [51] Matteuzzi D, Crociani F, Zani G, Trovatelli LD. *Bifidobacterium suis* n. sp.: a new species of the genus *Bifidobacterium* isolated from pig feces. Zeitschrift für Allgemeine Mikrobiologie. 11,5 (1971):387-95.
- [52] Scardovi V, Zani G. *Bifidobacterium magnum* sp. nov., a large, acidophilic bifidobacterium isolated from rabbit feces. International Journal of Systematic Bacteriology. 24,1 (1974):29-34.
- [53] Biavati B, Mattarelli P. *Bifidobacterium ruminantium* sp. nov. and *Bifidobacterium merycicum* sp. nov. from the rumens of cattle. International Journal of Systematic Bacteriology. 41,1 (1991):163-8.
- [54] Yaeshima T, Fujisawa T, Mitsuoka T. *Bifidobacterium globosum*, subjective synonym of *Bifidobacterium pseudolongum*, and description of *Bifidobacterium pseudolongum* subsp. *pseudolongum* comb. nov. and *Bifidobacterium pseudolongum* subsp. *globosum* comb. nov. Systematic and Applied Microbiology. 15,3 (1992):380-5.
- [55] Simpson PJ, Ross RP, Fitzgerald GF, Stanton C. *Bifidobacterium psychraerophilum* sp. nov. and *Aeriscardovia aeriphila* gen. nov., sp. nov., isolated from a porcine caecum. International Journal of Systematic and Evolutionary Microbiology. 54,2 (2004):401-6.

- [56] Trovatelli LD, Crociani F, Pedinotti M, Scardovi V. *Bifidobacterium pullorum* sp. nov.: a new species isolated from chicken feces and a related group of bifidobacteria isolated from rabbit feces. Archives of Microbiology. 98,3 (1974):187-98.
- [57] Biavati B, Mattarelli P, Crociani F. *Bifidobacterium saeculare*: A new species isolated from feces of rabbit. Systematic and Applied Microbiology. 14,4 (1991):389-92.
- [58] Hoyles L, Inganäs E, Falsen E, Drancourt M, Weiss N, McCartney AL, et al. *Bifidobacterium scardovii* sp. nov., from human sources. International Journal of Systematic and Evolutionary Microbiology. 52,3 (2002):995-9.
- [59] Biavati B, V. Scardovi, and W. E. C. Moore. Electrophoretic patterns of proteins in the genus *Bifidobacterium* and proposal of 4 new species. Bacteriology.32 (1982):358–73.
- [60] Dong X, Xin Y, Jian W, Liu X, Ling D. *Bifidobacterium thermacidophilum* sp. nov., isolated from an anaerobic digester. International Journal of Systematic and Evolutionary Microbiology. 50,1 (2000):119-25.
- [61] Ballongue J. Bifidobacteria and Probiotic action ed., Lactic acid bacteria, p. 357-432. New York: Marcel Dekker, 1993.
- [62] Scardovi V. Genus *Bifidobacterium* In: Sneath P.H.A. MNS, Sharp M.E. and Holt J.G. ed., Bergey's Manual of Syatematic Bacteriology, p. 1418-34. Baltimore, U.S.A: William and Wilkins, 1986.
- [63] Klijn A, Mercenier A, Arigoni F. Lessons from the genomes of bifidobacteria. Microbiology Reviews. 29,3 (2005):491-509.
- [64] Ventura M, van Sinderen D, Fitzgerald GF, Zink R. Insights into the taxonomy, genetics and physiology of bifidobacteria. International Journal of General and Molecular Microbiology. 86,3 (2004):205-23.
- [65] Gomes AMP, Malcata FX. *Bifidobacterium* spp. and *Lactobacillus acidophilus*: Biological, biochemical, technological and therapeutical properties relevant for use as probiotics. Trends in Food Science and Technology. 10,4-5 (1999):139-57.
- [66] Mara DD, Oragui JI. Sorbitol-fermenting bifidobacteria as specific indicators of human faecal pollution. Journal of Applied Bacteriology. 55,2 (1983):349-57.

- [67] Munoa FJ, Pares R. Selective medium for isolation and enumeration of *Bifidobacterium* spp. Applied and Environmental Microbiology 54,7 (1988):1715-8.
- [68] Beerens H. An elective and selective isolation medium for *Bifidobacterium* spp. Letters in Applied Microbiology. 11,3 (1990):155-7.
- [69] Zhuravlev YN, Kozyrenko MM, Artyukova EV, Reunova GD, Ilyushko MV. Fingerprinting genomes of the far eastern species of the genus *Iris* L. by RAPD-PCR. Genetika. 34,3 (1998):368-72.
- [70] Roy D, Sirois S. Molecular differentiation of *Bifidobacterium* species with amplified ribosomal DNA restriction analysis and alignment of short regions of the *ldh* gene. Microbiology Letters. 191,1 (2000):17-24.
- [71] Ventura M, Elli M, Reniero R, Zink R. Molecular microbial analysis of *Bifidobacterium* isolates from different environments by the species-specific amplified ribosomal DNA restriction analysis (ARDRA). Microbiology Ecology. 36,2-3 (2001):113-21.
- [72] Simpson PJ, Stanton C, Fitzgerald GF, Ross RP. Genomic diversity and relatedness of bifidobacteria isolated from a porcine cecum. Journal of Bacteriology. 185,8 (2003):2571-81.
- [73] Ventura M, Zink R. Rapid identification, differentiation, and proposed new taxonomic classification of *Bifidobacterium lactis*. Applied and Environmental Microbiology. 68,12 (2002):6429-34.
- [74] Sakata S, Chun SR, Kitahara M, Sakamoto M, Hayashi H, Fukuyama M, et al. Characterization of the genus *Bifidobacterium* by automated ribotyping and 16S rRNA gene sequences. Microbiology and Immunology. 50,1 (2006):1-10.
- [75] O'Sullivan DJ. Genomics can advance the potential for probiotic cultures to improve liver and overall health. Current Pharmaceutical Design. 14,14 (2008):1376-81.
- [76] Cheikhyoussef A, Cheikhyoussef N, Chen H, Zhao J, Tang J, Zhang H, et al. Bifidin I - A new bacteriocin produced by *Bifidobacterium infantis* BCRC 14602: Purification and partial amino acid sequence. Food Control. 21,5 (2010):746-53.
- [77] Lee JH, Karamychev VN, Kozyavkin SA, Mills D, Pavlov AR, Pavlova NV, et al. Comparative genomic analysis of the gut bacterium *Bifidobacterium longum* reveals loci susceptible to deletion during pure culture growth. BMC Genomics. 9(2008).

- [78] Arunachalam K, Gill H, Chandra RK. Enhancement of natural immune function by dietary consumption of *Bifidobacterium lactis* (HN019). European Journal of Clinical Nutrition. 54,3 (2000):263-7.
- [79] Hoarau C, Martin L, Faugaret D, Baron C, Dauba A, Aubert-Jacquín C, et al. Supernatant from *Bifidobacterium* differentially modulates transduction signaling pathways for biological functions of human dendritic cells. PLoS ONE. 3,7 (2008).
- [80] Qiao H, Duffy LC, Griffiths E, Dryja D, Leavens A, Rossman J, et al. Immune responses in rhesus rotavirus-challenged Balb/c mice treated with bifidobacteria and prebiotic supplements. Pediatric Research. 51,6 (2002):750-5.
- [81] Yasui H, Kiyoshima J, Ushijima H. Passive protection against rotavirus-induced diarrhea of mouse pups born to and nursed by dams fed *Bifidobacterium breve* YIT4064. Journal of Infectious Diseases. 172,2 (1995):403-9.
- [82] Duffy LC, Zielezny MA, Riepenhoff-Talty M, Dryja D, Sayahtheri-Altaié S, Griffiths E, et al. Effectiveness of *Bifidobacterium bifidum* in mediating the clinical course of murine rotavirus diarrhea. Pediatric Research. 35,6 (1994):690-5.
- [83] Shu Q, Qu F, Gill HS. Probiotic treatment using *Bifidobacterium lactis* HN019 reduces weanling diarrhea associated with rotavirus and *Escherichia coli* infection in a piglet model. Journal of Pediatric Gastroenterology and Nutrition. 33,2 (2001):171-7.
- [84] Saavedra JM, Bauman NA, Oung I, Perman JA, Yolken RH. Feeding of *Bifidobacterium bifidum* and *Streptococcus thermophilus* to infants in hospital for prevention of diarrhoea and shedding of rotavirus. Lancet. 344,8929 (1994):1046-9.
- [85] Chouraqui JP, Van Egroo LD, Fichot MC. Acidified milk formula supplemented with *Bifidobacterium lactis*: impact on infant diarrhea in residential care settings. Journal of Pediatric Gastroenterology and Nutrition. 38,3 (2004):288-92.
- [86] Thibault H, Aubert-Jacquín C, Goulet O. Effects of long-term consumption of a fermented infant formula (with *Bifidobacterium breve* c50 and *Streptococcus thermophilus* 065) on acute diarrhea in healthy infants. Journal of Pediatric Gastroenterology and Nutrition. 39,2 (2004):147-52.
- [87] Siggers RH, Siggers J, Boye M, Thymann T, Mølbak L, Leser T, et al. Early administration of probiotics alters bacterial colonization and limits

- diet-induced gut dysfunction and severity of necrotizing enterocolitis in preterm pigs. Journal of Nutrition. 138,8 (2008):1437-44.
- [88] Li Y, Shimizu T, Hosaka A, Kaneko N, Ohtsuka Y, Yamashiro Y. Effects of *Bifidobacterium breve* supplementation on intestinal flora of low birth weight infants. Pediatrics International. 46,5 (2004):509-15.
- [89] Wang C, Shoji H, Sato H, Nagata S, Ohtsuka Y, Shimizu T, et al. Effects of oral administration of *Bifidobacterium breve* on fecal lactic acid and short-chain fatty acids in low birth weight infants. Journal of Pediatric Gastroenterology and Nutrition. 44,2 (2007):252-7.
- [90] Agrawal A, Houghton LA, Morris J, Reilly B, Guyonnet D, Goupil Feuillerat N, et al. Clinical trial: The effects of a fermented milk product containing *Bifidobacterium lactis* DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Alimentary Pharmacology and Therapeutics. 29,1 (2009):104-14.
- [91] Guyonnet D, Chassany O, Ducrotte P, Picard C, Mouret M, Mercier CH, et al. Effect of a fermented milk containing *Bifidobacterium animalis* DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: A multicentre, randomized, double-blind, controlled trial. Alimentary Pharmacology and Therapeutics. 26,3 (2007):475-86.
- [92] Marteau P, Cuillerier E, Meance S, Gerhardt MF, Myara A, Bouvier M, et al. *Bifidobacterium animalis* strain DN-173 010 shortens the colonic transit time in healthy women: A double-blind, randomized, controlled study. Alimentary Pharmacology and Therapeutics. 16,3 (2002):587-93.
- [93] Meance S, Cayuela C, Turchet P, Raimondi A, Lucas C, Antoine JM. A fermented milk with a *Bifidobacterium* probiotic strain DN-173 010 shortened oro-fecal gut transit time in elderly. Microbial Ecology in Health and Disease. 13,4 (2001):217-22.
- [94] Jiang T, Mustapha A, Savaiano DA. Improvement of Lactose Digestion in Humans by Ingestion of Unfermented Milk Containing *Bifidobacterium longum*. Journal of Dairy Science. 79,5 (1996):750-7.
- [95] He T, Priebe MG, Zhong Y, Huang C, Harmsen HJM, Raangs GC, et al. Effects of yogurt and bifidobacteria supplementation on the colonic microbiota in lactose-intolerant subjects. Journal of Applied Microbiology. 104,2 (2008):595-604.

- [96] Ataie-Jafari A, Larijani B, Alavi Majd H, Tahbaz F. Cholesterol-lowering effect of probiotic yogurt in comparison with ordinary yogurt in mildly to moderately hypercholesterolemic subjects. Annals of Nutrition and Metabolism. 54,1 (2009):22-7.
- [97] Kießling G, Schneider J, Jahreis G. Long-term consumption of fermented dairy products over 6 months increases HDL cholesterol. European Journal of Clinical Nutrition. 56,9 (2002):843-9.
- [98] Greany KA, Nettleton JA, Wangen KE, Thomas W, Kurzer MS. Probiotic consumption does not enhance the cholesterol-lowering effect of soy in postmenopausal women. Journal of Nutrition. 134,12 (2004):3277-83.
- [99] Kim N, Kunisawa J, Kweon MN, Eog Ji G, Kiyono H. Oral feeding of *Bifidobacterium bifidum* (BGN4) prevents CD4+ CD45RBhigh T cell-mediated inflammatory bowel disease by inhibition of disordered T cell activation. Clinical Immunology. 123,1 (2007):30-9.
- [100] McCarthy J, O'Mahony L, O'Callaghan L, Sheil B, Vaughan EE, Fitzsimons N, et al. Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut. 52,7 (2003):975-80.
- [101] Takahashi T, Nakagawa E, Nara T, Yajima T, Kuwata T. Effects of Orally Ingested *Bifidobacterium longum* on the Mucosal IgA Response of Mice to Dietary Antigens. Bioscience, Biotechnology and Biochemistry. 62,1 (1998):10-5.
- [102] Christensen HR, Larsen CN, Kæstel P, Rosholm LB, Sternberg C, Michaelsen KF, et al. Immunomodulating potential of supplementation with probiotics: A dose-response study in healthy young adults. Immunology and Medical Microbiology. 47,3 (2006):380-90.
- [103] Furrie E, Macfarlane S, Kennedy A, Cummings JH, Walsh SV, O'Neil DA, et al. Synbiotic therapy (*Bifidobacterium longum*/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: A randomised controlled pilot trial. Gut. 54,2 (2005):242-9.
- [104] O'Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, et al. *Lactobacillus* and *Bifidobacterium* in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles. Gastroenterology. 128,3 (2005):541-51.
- [105] Sekine K, Toida T, Saito M. A new morphologically characterized cell wall preparation (whole peptidoglycan) from *Bifidobacterium infantis* with a higher efficacy on the regression of an established tumor in mice. Cancer Research. 45,3 (1985):1300-7.

- [106] Rowland IR, Rumney CJ, Coutts JT, Lievens LC. Effect of *Bifidobacterium longum* and inulin on gut bacterial metabolism and carcinogen-induced aberrant crypt foci in rats. Carcinogenesis. 19,2 (1998):281-5.
- [107] Le Leu RK, Hu Y, Brown IL, Woodman RJ, Young GP. Synbiotic intervention of *Bifidobacterium lactis* and resistant starch protects against colorectal cancer development in rats. Carcinogenesis. 31,2 (2010):246-51.
- [108] Rafter J, M. Bennett, G. Caderni, Y. Clune, R. Hughes, P. C. Karlsson, A. Klinder, M. O’Riordan, G. C. O’Sullivan, B. Pool-Zobel, G. Rechkemmer, M. Roller, I. Rowland, M. Salvadori, H. Thijs, J. Van Loo, B. Watzl, and J. K. Collins. Dietary synbiotics reduce cancer risk factors in polypectomized and colon cancer patients: Am. J., 2007.
- [109] Hardie JM, Bowden GH. Physiological classification of oral viridans streptococci. Journal of Dental Research. 55,A (1976):166-76.
- [110] Kawamura Y, Hou XG, Sultana F, Liu S, Yamamoto H, Ezaki T. Transfer of *Streptococcus adjacens* and *Streptococcus defectivus* to *Abiotrophia* gen. nov. as *Abiotrophia adjacens* comb. nov. and *Abiotrophia defectiva* comb. nov., respectively. International Journal of Systematic Bacteriology. 45,4 (1995):798-803.
- [111] Skinner FA, Quesnel, L.B. Streptococci. London, New York, San Francisco: Academic Press, 1978.
- [112] Parente E, and Cogan, T.M. Starter culture : general aspects. In: P.F. Fox PLHM, T.M. Cogan, and T.P. Guinea ed., Cheese : Chemistry, physics and microbiology, p. 122-47. San Diego, CA, USA: Elsevier Academic press, 2004.
- [113] Hols P, Hancy F, Fontaine L, Grossiord B, Prozzi D, Leblond-Bourget N, et al. New insights in the molecular biology and physiology of *Streptococcus thermophilus* revealed by comparative genomics. Microbiology Reviews. 29,3 (2005):435-63.
- [114] Lick S, Keller M, Bockelmann W, Heller KJ. Rapid identification of *Streptococcus thermophilus* by primer-specific PCR amplification based on its lacZ gene. Systematic and Applied Microbiology. 19,1 (1996):74-7.
- [115] Brigidi P, Swennen E, Vitali B, Rossi M, Matteuzzi D. PCR detection of *Bifidobacterium* strains and *Streptococcus thermophilus* in feces of human subjects after oral bacteriotherapy and yogurt consumption. International Journal of Food Microbiology. 81,3 (2003):203-9.



- [116] Delorme C. Safety assessment of diary microorganism: *Streptococcus thermophilus*. International Journal of Food Microbiology. 126(2008):274-7.
- [117] Bruno-Bárcena JM, Andrus JM, Libby SL, Klaenhammer TR, Hassan HM. Expression of a heterologous manganese superoxide dismutase gene in intestinal lactobacilli provides protection against hydrogen peroxide toxicity. Applied and Environmental Microbiology 70,8 (2004):4702-10.
- [118] Rizkalla SJ, Lou, W., Chevalier, A., Pacher, N., and Slama, G. Chronic consumption of fresh but not heated yoghurt improves breath-hydrogen status and short-chain fatty acid profiles: a controlled in healthy men with or without lactose maldigestion. American Journal of Clinical Nutrition. 72(2000):1474-9.
- [119] Ouwehand AC. Antimicrobial components from lactic acid bacteria. In: Salminen SavW, A. 2 nd ed., Lactic Acid Bacteria: Microbiology and Functional Aspects, p. 139-59. New York: Marcel Dekker Inc, 1998.
- [120] Woolford MK. Microbiological screening of food preservatives cold sterilant and specific antimicrobial agents as potential silage additives. Journal of Science Food Agricultural. 26(1975.): 229-37.
- [121] Earnshaw RG. The antimicrobial action of lactic acid bacteria: natural food preservation systems. In: Wood BJB ed., The Lactic Acid Bacteria in Health and Disease, p. 211-32. London , New York: Elsevier Applied Science, 1992.
- [122] Ahmad N, and Marth, E.H. . Behaviour of *Listeria monocytogenes* at 7, 13, 21 and 35 degree in tryptose broth acidified with acetic, citric or lactic acid. Journal of Food Protection. 52(1989.):688-95.
- [123] Wong HC, Chen YL. Effects of lactic acid bacteria and organic acids on growth and germination of *Bacillus cereus*. Applied and Environmental Microbiology. 54,9 (1988):2179-84.
- [124] Cords BR, and Dychdala, G.R. . Sanitizers: halogens, surface-active agents, and peroxides. 2nd ed., Antimicrobials in Foods, p. 469-537. New York: Davidson, P.M. and Branen, A.L., Marcel Dekker Inc, 1993.
- [125] Hotchkiss JH, Chen JH, Lawless HT. Combined effects of carbon dioxide addition and barrier films on microbial and sensory changes in pasteurized milk. Journal of Dairy Science. 82,4 (1999):690-5.
- [126] Jay JM. Antimicrobial properties of diacetyl. Applied and Environmental Microbiology 44,3 (1982):525-32.

- [127] Talarico TL, Casas IA, Chung TC, Dobrogosz WJ. Production and isolation of reuterin, a growth inhibitor produced by *Lactobacillus reuteri*. Antimicrobial Agents and Chemotherapy. 32,12 (1988):1854-8.
- [128] Ouwehand ACaV, S. Antimicrobial components from lactic acid bacteria. In: S. Salminen Av, and A.Ouwehand 3<sup>rd</sup> ed., Lactic Acid Bacteria : Microbiology and Function Aspects, p. 375-95. New York: Marcel Dekker., 2004.
- [129] Parish ME, and Davidson, P.M. . Methods for evaluation. In: Davidson PMAb, A.L 2<sup>nd</sup> ed., Antimicrobials in Foods, p. 597-615 New York: Marcel Dekker Inc., 1993.
- [130] Piddock LJV. Techniques used for the determination of antimicrobial resistance and sensitivity in bacteria. Journal of Applied Bacteriology. 68,4 (1990):307-18.
- [131] Barefoot SF, Klaenhammer TR. Detection and activity of lactacin B, a bacteriocin produced by *Lactobacillus acidophilus*. Applied and Environmental Microbiology. 45,6 (1983):1808-15.
- [132] Hastings JW, Stiles ME. Antibiosis of *Leuconostoc gelidum* isolated from meat. Journal of Applied Bacteriology. 70,2 (1991):127-34.
- [133] Davidson PM, and Parish, M.E. . Methods for testing the efficacy of food antimicrobials. Journal of Food Technology. 1(1989):148-55.
- [134] Heilig HGHJ, Zoetendal EG, Vaughan EE, Marteau P, Akkermans ADL, De Vos WM. Molecular diversity of *Lactobacillus* spp. and other lactic acid bacteria in the human intestine as determined by specific amplification of 16S ribosomal DNA. Applied and Environmental Microbiology. 68,1 (2002):114-23.
- [135] Bernhard AE, Field KG. Identification of nonpoint sources of fecal pollution in coastal waters by using host-specific 16S ribosomal DNA genetic markers from fecal anaerobes. Applied and Environmental Microbiology. 66,4 (2000):1587-94.
- [136] Collado MC, Delgado S, Maldonado A, Rodríguez JM. Assessment of the bacterial diversity of breast milk of healthy women by quantitative real-time PCR. Letters in Applied Microbiology. 48,5 (2009):523-8.
- [137] Pena JA, Li SY, Wilson PH, Thibodeau SA, Szary AJ, Versalovic J. Genotypic and Phenotypic Studies of Murine Intestinal *Lactobacilli*: Species Differences in Mice with and without Colitis. Applied and Environmental Microbiology. 70,1 (2004):558-68.

- [138] Satokari RM, Vaughan EE, Akkermans ADL, Saarela M, De Vos WM. Bifidobacterial diversity in human feces detected by genus-specific PCR and denaturing gradient gel electrophoresis. (2001):55-6.
- [139] Cebeci A, Gurakan GC. Molecular methods for identification of *Lactobacillus delbrueckii* subsp. *bulgaricus* and *Streptococcus thermophilus* using methionine biosynthesis and 16S rRNA genes. Journal of Dairy Research. 75,4 (2008):392-8.
- [140] A. Léké MBR, and C. Mullié. Insights in the Human Bifidobacterial Flora Through Culture-Dependent and Independent Techniques. Applied Microbiology. (2007):758-65.
- [141] Hadadji M, Benama R, Saidi N, Henni DE, Kihal M. Identification of cultivable *Bifidobacterium* species isolated from breast-fed infants feces in West-Algeria. African Journal of Biotechnology. 4,5 (2005):422-30.
- [142] Rybka S, Kailasapathy K. Media for the enumeration of yoghurt bacteria. International Dairy Journal. 6,8-9 (1996):839-50.
- [143] Mackie RI, Sghir A, Gaskins HR. Developmental microbial ecology of the neonatal gastrointestinal tract. American Journal of Clinical Nutrition. 69,5 (1999):1035S-45S.
- [144] Perez PF, Doré J, Leclerc M, Levenez F, Benyacoub J, Serrant P, et al. Bacterial imprinting of the neonatal immune system: Lessons from maternal cells? Pediatrics. 119,3 (2007):724-32.
- [145] Martin R, Olivares M, Marin ML, Fernandez L, Xaus J, Rodriguez JM. Probiotic potential of 3 lactobacilli strains isolated from breast milk. Journal of Human Lactation. 21,1 (2005):8-17.
- [146] Virginia Martín RM-L, Juan Miguel Rodríguez, and Antonio Maldonado-Barragán. *Streptococcus lactarius* sp. nov., isolated from breast milk of healthy women International Journal of Systematic and Evolutionary Microbiology. 61(2010):1048-52.
- [147] Varma P, Dinesh KR, Menon KK, Biswas R. *Lactobacillus Fermentum* Isolated from Human Colonic Mucosal Biopsy Inhibits the Growth and Adhesion of Enteric and Foodborne Pathogens. Journal of Food Science. 75,9 (2010):M546-M51.
- [148] Raffaella Campana SF, Eleonora Ciandrini, Wally Baffone. Antagonistic Activity of *Lactobacillus acidophilus* ATCC 4356 on the Growth and Adhesion/Invasion Characteristics of Human *Campylobacter jejuni*. Current Microbiology. 64(2012):371-8.

- [149] Gibson GR, Wang X. Regulatory effects of bifidobacteria on the growth of other colonic bacteria. Journal of Applied Bacteriology. 77,4 (1994):412-20.
- [150] Bevilacqua L, Ovidi M, Di Mattia E, Trovatelli LD, Canganella F. Screening of *Bifidobacterium* strains isolated from human faeces for antagonistic activities against potentially bacterial pathogens. Microbiological Research. 158,2 (2003):179-85.
- [151] Collado MC, González A, González R, Hernández M, Ferrús MA, Sanz Y. Antimicrobial peptides are among the antagonistic metabolites produced by *Bifidobacterium* against *Helicobacter pylori*. International Journal of Antimicrobial Agents. 25,5 (2005):385-91.
- [152] Fernández L, Delgado S, Herrero H, Maldonado A, Rodríguez JM. The bacteriocin nisin, an effective agent for the treatment of *staphylococcal mastitis* during lactation. Journal of Human Lactation. 24,3 (2008):311-6.
- [153] Sigrud C.J. De Keersmaecker TLAV, Jos Desair, Kathleen Marchal, Jos Vanderleyden & Nagy Ia. Strong antimicrobial activity of *Lactobacillus rhamnose* against *Salmonella typhimurium* is due to accumulation of lactic acid. FEMS Microbiology Letters. 256(2006):89-96.

## **APPENDICES**

## **APPENDIX A**

### **MATERIALS AND EQUIPMENTS**

#### **Materials and reagents**

- Agarose (Research organism, USA)
- Anaerobic indicator (Oxoid, Basingstroke, Hamps, UK)
- Boric acid (Sigma, USA)
- Brain heart infusion agar (Difco, USA)
- Brain heart infusion broth (Difco, USA)
- Columbia blood agar base (Oxoid, Basingstroke, Hamps, UK)
- Cysteine hydrochloride (Sigma, USA)
- Dextrose bacteriological (Oxoid, Basingstroke, Hamps, UK)
- Ethylene diamine tetraacetic acid (EDTA) (Sigma, USA)
- Ethidium bromide (Bio Rad, USA)
- Gaspak (AnaeroPack-Anaero, Mitsubishi, Japan)
- GeneRuler™ 100bp DNA Ladder Plus (Fermentas, USA)
- Glycerol (Merck, Germany)
- MRS agar (Oxoid, Basingstroke, Hamps, UK)
- MRS broth (Oxoid, Basingstroke, Hamps, UK)
- M17 agar (Oxoid, Basingstroke, Hamps, UK)
- M17 broth (Oxoid, Basingstroke, Hamps, UK)
- Peptone bacteriological (Oxoid, Basingstroke, Hamps, UK)
- Proteinase K (Sigma, USA)

- QIAamp<sup>®</sup> DNA Stool Mini Kit (Qiagen, Hilden, Germany)
- QIAquick PCR Purification Kit (Qiagen, Hilden, Germany)
- Sodium chloride (NaCl) (Sigma, USA)
- Tris base (Sigma, USA)
- Tween 20 (Merck, Germany)
- Tween 80 (Sigma, USA)
- Yeast extract (Difco, USA)

## **2. Equipments**

- Anaerobic Chamber (Concept Plus, Ruskinn Technology, UK)
- Anaerobic Jar (BBL, USA)
- Autoclave (Hirayama, Japan)
- Autopipettes (Gilson, France)
- Centrifuge (Kubota, Japan)
- Deep Freezer (-20<sup>0</sup>C) (Sanyo, Japan)
- Deep Freezer (-80<sup>0</sup>C) (Sanyo, Japan)
- Electrophoresis chamber (BioRad, USA)
- Frogger (DAN-KAR CCRP, USA)
- Gel doc (BioRad, USA)
- Heat block (Scientific, USA)
- Hot air oven (Haraeus, Germany)
- Incubator (Forma Scientific, USA)
- Light Microscope (Nikon, Japan)
- Microcentrifuge (Eppendorf, USA)

- pH meter (Orion, USA)
- Thermal cyclers (Eppendorf, Hamburg, Germany)
- Vortex mixer (Scientific, USA)
- Water bath (Memmert, USA)

### **3. Software and program**

- GenBank DNA database search (<http://www.ncbi.nlm.gov/BLAST>).
- Multalin program (<http://bioinfo.genotoul.fr/multalin>)
- Sequence match program of the Ribosomal Database Project II (RDP-II; <http://rdp.cme.msu.edu>)



## APPENDIX B

### PREPARATION OF MEDIA AND REAGENT

#### Media for lactobacilli

##### 1. MRS agar

MRS agar (oxoid)	62	g
Distilled water	1,000	ml

##### 2. MRS broth

MRS broth (oxoid)	52	g
Distilled water	1,000	ml

##### 3. 20% glycerol MRS broth

Glycerol	20	ml
Distilled water	40	ml
MRS broth	40	ml

(MRS 2.08 g + DW 40 ml)

20% glycerol MRS broth using for kept lactobacilli cell in deep freeze.

#### Media for bifidobacteria

##### 4. Modified Columbia (MC) medium

Columbia agar base (oxoid)	39	g
Glucose	5	g
Cysteine hydrochloride	0.5	g
Agar	5	g
Distilled water	1,000	ml

The pH was adjusted to 7.3 before autoclaving at 121<sup>0</sup>C for 15 minutes.

When use the media as differential medium add 0.03 g/l of bromocresol purple indicator for observed glucose fermentation.

#### 5. Brain Heart Infusion Broth (BHB)

Brain Heart Infusion (BBL)	37	g
Yeast extract	5	g
Cysteine hydrochloride	0.5	g
Distilled water	1,000	ml

The pH was adjusted to 7.2 before autoclaving at 121<sup>0</sup>C for 15 minutes.

Brain heart infusion broth using as enrichment medium.

#### 6. Brain Heart Infusion Agar (BHA)

Brain Heart Infusion Agar (BBL)	52	g
Yeast extract	5	g
Cysteine hydrochloride	0.5	g
Distilled water	1,000	ml

Brain heart infusion agar using for antagonistic activity assay.

#### 7. 20% glycerol Brain Heart Infusion Broth

Brain Heart Infusion (BBL)	3.7	g
Yeast extract	0.5	g
Cysteine hydrochloride	0.05	g
Glycerol	20	ml
Distilled water	80	ml

20% glycerol BHB using for kept bifidobacteria cell in deep freeze.

### Media for streptococci

#### 8. M17 agar

M17 agar (oxoid)	48.25	g
Distilled water	950	ml
10% lactose solution	50	ml

**9. 20% glycerol M17 broth**

Glycerol	20	ml
Distilled water	40	ml
M17 broth (oxid)	40	ml
(M 17 1.37 g+ Lactose solution 5 ml + DW 35 ml)		

**Reagent for molecular analysis****10. 0.5M EDTA, pH 8.0**

Ethylene diamine tetraacetic acid (EDTA)	93.05	g
Distilled water	500	ml

Dissolve 93.05 g of EDTA in 400 ml of distilled water, then the pH was adjusted to 8.0 with NaOH (pellets) and final volume was brought up to 500 ml. The stock reagent sterile by autoclaving at 121<sup>0</sup>C at 15 pounds/inch<sup>2</sup> pressure for 15 minutes. The solution was stored at room temperature.

**11. 5X TBE**

Tris base	54	g
Boric acid	27.5	g
0.5M EDTA pH 8.0	20	ml
Distilled water	1,000	ml

Dissolve all of ingredients in 1,000 ml of distilled water. The stock reagent sterile by autoclaving at 121<sup>0</sup>C at 15 pounds/inch<sup>2</sup> pressure for 15 minutes. The solution was stored at room temperature.

**12. 1M Tris-HCl, pH 8.0**

Tris base	121.1 g
Distilled water	1,000 ml

Dissolve 121.1 g of Tris base in 800 ml of distilled water. Adjust the pH to the desired value by adding concentrated HCl 42 ml and allow the solution to cool to room temperature before making final adjustments to the pH 8.0. Adjust the volume of the solution to 1 liter with distilled water. Dispense in to aliquots and sterilize by autoclaving.

**13. 10X Digestion buffer**

The stock reagent 10X digestion buffer contained 5% tween 20 and 10 mg/ml proteinase K in 0.2 M Tris pH 8.3. For example prepare 4 ml of the stock reagent.


Tween 20	0.2 ml
Proteinase K	40 mg
1M Tris pH 8.3	0.8 ml
Distilled water	3.0 ml

Dissolve 40 mg of Proteinase K in 3 ml of distilled water adding Tween 20 and 1M Tris pH 8.3 making final volume to 4 ml. Mix well and store at 4<sup>0</sup>C.


## APPENDIX C

### FLOW CHART OF PROTOCOL


#### 1. Collection of breast milk




## 2. Isolation of *Lactobacillus*, *Bifidobacterium* and *Streptococcus* from breast milk



### 3. Antagonistic activity assay of lactobacilli and bifidobacteria using agar spot method



#### 4. Antagonistic activity assay of streptococci using agar spot method





## APPENDIX D

### NECLEOTIDE ALINGMENT

1. The similarly alignment 16S rRNA gene sequence of *Lactobacillus* spp. isolated from breast milk with the 16S rRNA gene sequence of *Lactobacillus* spp. published in NCBI data bank.

```
>gb|DQ901733.1| Lactobacillus salivarius strain DSM 20555 16S ribosomal RNA gene
partial sequence
Length=1063
```

```
Score = 867 bits (469), Expect = 0.0
Identities = 488/497 (98%), Gaps = 1/497 (0%)
Strand=Plus/Plus
```

```
Query 398 AGGTC TTGACATCCTTTGACCACCTAAGAGATTAGGCTTTCCCTTCGGGGACAAAGTGAC 457
          |||
Sbjct 554 AGGTC TTGACATCCTTTGACCACCTAAGAGATTAGGCTTTCCCTTCGGGGACAAAGTGAC 613

Query 458 AGGTGGTGCATGGCTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTAAAGTCCC GCAACGA 517
          |||
Sbjct 614 AGGTGGTGCATGGCTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTAAAGTCCC GCAACGA 673

Query 518 GCGCAACCC TTGTAGTCAGTTGCCAGCATTAAGTTGGGCAC TCTGGCGAGACTGCCGGTG 577
          |||
Sbjct 674 GCGCAACCC TTGTTGTCAGTTGCCAGCATTAAGTTGGGCAC TCTGGCGAGACTGCCGGTG 733

Query 578 ACAAAACCGGAGGAAGGTGGGGACGACGTCAAGTCATCATGCCCTTATGACCTGGGCTAC 637
          |||
Sbjct 734 ACAAAACCGGAGGAAGGTGGGGACGACGTCAAGTCATCATGCCCTTATGACCTGGGCTAC 793

Query 638 ACACGTGCTACAATGGACGGTACAACGAGTCGCGAGACCGCGAGGTTTAGCTAATCTCTT 697
          |||
Sbjct 794 ACACGTGCTACAATGGACGGTACAACGAGTCGCGAGACCGCGAGGTTTAGCTAATCTCTT 853

Query 698 AAAGCCGTTCTCAGTTCGGATTGTAGGCTGCAACTCGCCTACATGAAGTCGGAATCGCTA 757
          |||
Sbjct 854 AAAGCCGTTCTCAGTTCGGATTGTAGGCTGCAACTCGCCTACATGAAGTCGGAATCGCTA 913

Query 758 GTAATCGCGAATCAGCATGTCGCGGTGAATACGTTCCCGGGCCTTTTACGGACCGCCCGT 817
          |||
Sbjct 914 GTAATCGCGAATCAGCATGTCGCGGTGAATACGTTCCCGGGCCTTTTACGGACCGCCCGT 973

Query 818 CACACCATGAGAGTTTGTTCCTTCCGAAAGCCGGTGGGGTAACCGCAAGGAGCCAGCCGT 877
          |||
Sbjct 974 CACACCATGAGAGTTTGTAAACCC-AAAGCCGGTGGGGTAACCGCAAGGAGCCAGCCGT 1032

Query 878 CTAAGGTGGGACAGATG 894
```

>gb|FJ55/004.1| *Lactobacillus gasseri* strain NCC2856 16S ribosomal RNA gene, partial sequence  
Length=151

Score = 1605 bits (869), Expect = 0.0  
Identities = 880/885 (99%), Gaps = 2/885 (0%)  
Strand=Plus/Plus

```

Query   397   TTCGGCTCAACCGGAGAATTGCATCAGAAACTGTTGAACTTGAGTGCAGAAGAGGAGAGT   456
          |||
Sbjct   619   TTCGGCTCAACCGGAGAATTGCATCAGAAACTGTTGAACTTGAGTGCAGAAGAGGAGAGT   678

Query   457   GGAACTCCATGTGTAGCGGTGGAATGCGTAGATATATGGAAGAACACCAAGTGGCGAAGGC   516
          |||
Sbjct   679   GGAACTCCATGTGTAGCGGTGGAATGCGTAGATATATGGAAGAACACCAAGTGGCGAAGGC   738

Query   517   GGCTCTCTGGTCTGCAACTGACGCTGAGGCTCGAAAGCATGGGTAGCGAACAGGATTAGA   576
          |||
Sbjct   739   GGCTCTCTGGTCTGCAACTGACGCTGAGGCTCGAAAGCATGGGTAGCGAACAGGATTAGA   798

Query   577   TACCCTGGTAGTCCATGCCGTA AACGATGAGTGC TAAGTGTTGGGAGGTTTCCGCCTCTC   636
          |||
Sbjct   799   TACCCTGGTAGTCCATGCCGTA AACGATGAGTGC TAAGTGTTGGGAGGTTTCCGCCTCTC   858

Query   637   AGTGCTGCAGCTAACGCATTAAGCAC TCCGCCTGGGGAGTACGACCCGCAAGGTTGAAACT   696
          |||
Sbjct   859   AGTGCTGCAGCTAACGCATTAAGCAC TCCGCCTGGGGAGTACGACCCGCAAGGTTGAAACT   918

Query   697   CAAAGGAATTGACGGGGGCCCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCAACG   756
          |||
Sbjct   919   CAAAGGAATTGACGGGGGCCCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCAACG   978

Query   757   CGAAGAACCTTACCAGGTC TTGACATCCAGTGCAAACCTAAGAGATTAGGAGTTCCCTTC   816
          |||
Sbjct   979   CGAAGAACCTTACCAGGTC TTGACATCCAGTGCAAACCTAAGAGATTAGGAGTTCCCTTC   1038

Query   817   GGGGACGCTGAGACAGGTGGTGCATGGCTGTCGTCAGCTCGTGCTGAGATGTTGGGTT   876
          |||
Sbjct  1039   GGGGACGCTGAGACAGGTGGTGCATGGCTGTCGTCAGCTCGTGCTGAGATGTTGGGTT   1098

Query   877   AAGTCCC GCAACGAGCGCAACCC TTGTCATTAGTTGCCATCATT AAGTTGGGCACTCTAA   936
          |||
Sbjct  1099   AAGTCCC GCAACGAGCGCAACCC TTGTCATTAGTTGCCATCATT AAGTTGGGCACTCTAA   1158

Query   937   TGAGACTGCCGGTGACAAACCGGAGGAAGGTGGGGATGACGTC AAGTCATCATGCCCCTT   996
          |||
Sbjct  1159   TGAGACTGCCGGTGACAAACCGGAGGAAGGTGGGGATGACGTC AAGTCATCATGCCCCTT   1218

Query   997   ATGACCTGGGCTACACACGTGCTACAATGGACGGTACAACGAGAAGCGAACCTGCGAAGG   1056
          |||
Sbjct  1219   ATGACCTGGGCTACACACGTGCTACAATGGACGGTACAACGAGAAGCGAACCTGCGAAGG   1278

Query  1057   CAAGCGGATCTCTGAAAGCCGTTCTCAGTTCGGACTGTAGGCTGCAACTCGCCTACACGA   1116
          |||
Sbjct  1279   CAAGCGGATCTCTGAAAGCCGTTCTCAGTTCGGACTGTAGGCTGCAACTCGCCTACACGA   1338

Query  1117   AGCTGGAATCGCTAGTAATCGCGGATCAGCACGCCGCGGTTGAATACGTTCCC GGGCCTTG   1176
          |||
Sbjct  1339   AGCTGGAATCGCTAGTAATCGCGGATCAGCACGCCGCGGTTGAATACGTTCCC GGGCCTTG   1398

Query  1177   TACACACCGCCC GTCACACCATGAGAGTCTGTAACACCCAAAGCCGGTGGGATAACCTTT   1236
          |||
Sbjct  1399   TACACACCGCCC GTCACACCATGAGAGTCTGTAACACCCAAAGCCGGTGGGATAACCTTT   1458

Query  1237   ATAGGAGTCAGCCGCTAATGTAGGACAGA-GATTAGTGGTTAAG   1280
          |||
Sbjct  1459   ATAGGAGTCAGCCGCTAAGGTAGGACAGATGATTAG-GGTGAAG   1502

```

gb|AF126738.1|AF126738 Lactobacillus mucosae 16S ribosomal RNA gene, complete sequence  
Length=1568

Score = 2651 bits (1435), Expect = 0.0  
Identities = 1477/1495 (99%), Gaps = 14/1495 (1%)  
Strand=Plus/Plus

```

Query 8 ATACATGCAAGTCGAACGCGTTGGCCCAACTGATTGAACGTGCTTGCACGGACTTGACGT 67
      |||
Sbjct 44 ATACATGCAAGTCGAACGCGTTGGCCCAACTGATTGAACGTGCTTGCACGGACTTGACGT 103

Query 68 TGGTTTACCAGCGAGTGGCGGACGGGTGAGTAACACGTAGGTAACCTGCCCAAAGCGGG 127
      |||
Sbjct 104 TGGTTTACCAGCGAGTGGCGGACGGGTGAGTAACACGTAGGTAACCTGCCCAAAGCGGG 163

Query 128 GGATAACATTTGAAACAGATGCTAATACCGCATAACAATTTGAATCGCATGATTCAAAT 187
      |||
Sbjct 164 GGATAACATTTGAAACAGATGCTAATACCGCATAACAATTTGAATCGCATGATTCAAAT 223

Query 188 TTAAAAGATGGCTTCGGCTATCACTTTGGGATGGACCTGCGGCGCATTAGCTTGTGGTA 247
      |||
Sbjct 224 TTAAAAGATGGCTTCGGCTATCACTTTGGGATGGACCTGCGGCGCATTAGCTTGTGGTA 283

Query 248 GGGTAACGGCCTACCAAGGCTGTGATGCGTAGCCGAGTTGAGAGACTGATCGGCCACAAT 307
      |||
Sbjct 284 GGGTAACGGCCTACCAAGGCTGTGATGCGTAGCCGAGTTGAGAGACTGATCGGCCACAAT 343

Query 308 GGAAGTACGACACGGTCCATACTCCTACGGGAGGCAGCAGTAGGGAATCTTCCACAATGG 367
      |||
Sbjct 344 GGAAGTACGACACGGTCCATACTCCTACGGGAGGCAGCAGTAGGGAATCTTCCACAATGG 403

Query 368 GCGCAAGCCTGATGGAGCAACACCGCGTGAGTGAAGAAGGGTTTCGGCTCGTAAAGCTCT 427
      |||
Sbjct 404 GCGCAAGCCTGATGGAGCAACACCGCGTGAGTGAAGAAGGGTTTCGGCTCGTAAAGCTCT 463

Query 428 GTTGTTAGAGAAGAAGCTGCGTGAGAGCAACTGTTACGCAAGTACGGTATCTAACCAAGA 487
      |||
Sbjct 464 GTTGTTAGAGAAGAAGCTGCGTGAGAGCAACTGTTACGCAAGTACGGTATCTAACCAAGA 523

Query 488 AAGTCACGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGTGGCAAGCGTTATCCG 547
      |||
Sbjct 524 AAGTCACGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGTGGCAAGCGTTATCCG 583

Query 548 GATTTATTGGGCATAAAGCGAGCGCAGGCGGTTTGATAAGTCTGATGTGAAAGCCTTTGG 607
      |||
Sbjct 584 GATTTATTGGGCATAAAGCGAGCGCAGGCGGTTTGATAAGTCTGATGTGAAAGCCTTTGG 643

Query 608 CTTAACCAAAGAAGTGCATCGAAACTGTCAGACTTGAGTGCAGAAGAGGACAGTGGAAAC 667
      |||
Sbjct 644 CTTAACCAAAGAAGTGCATCGAAACTGTCAGACTTGAGTGCAGAAGAGGACAGTGGAAAC 703

Query 668 TCCATGTGTAGCGGTGGAATGCGTAGATATATGGAAGAACACCAAGTGGCGAAGGCGGCTG 727
      |||
Sbjct 704 TCCATGTGTAGCGGTGGAATGCGTAGATATATGGAAGAACACCAAGTGGCGAAGGCGGCTG 763

Query 728 TCTGGTCTGCAACTGACGCTGAGGCTCGAAAAGCATGGGTAGCGAAAACACGATTAGATA 787
      |||
Sbjct 764 TCTGGTCTGCAACTGACGCTGAGGCTCG--AAAGCATGGGTAGCG--AACAGGATTAGATA 820

Query 788 CCCCTGGTAGTTCCATGCCCGTAAAACGATGAAGTGTAGGTGTTGGAAGGGGTTTCCGC 847
      |||
Sbjct 821 -CCCTGGTAG-TCCATG-CCGT-AAACGATG-AGTGCTAGGTGTTGG-A-GGGTTTCCG- 872

Query 848 CCCTTCAGTGCCGCAGCTAACGCATTAAGCACTCCGCCTGGGGGAGTNCGACCGCAAGGT 907
      |||
Sbjct 873 CCCTTCAGTGCCGCAGCTAACGCATTAAGCACTCCGCCT-GGGGAGTACGACCGCAAGGT 931

Query 908 TGAAACTCAAAGGAATTGACGGGGGCCCCGCACAAGCGGTGGAGCATGTGGTTTAATTTCG 967
      |||
Sbjct 932 TGAAACTC-AAAGGAATTGACGGGGGCCCCGCACAAGCGGTGGAGCATGTGGTTTAATTTCG 990

Query 968 AAGATACGCGAAGAACCCTACCAGGTCTTGACATCTTGCGCCAACCCCTAGAGATAGGGCG 1027
      |||
Sbjct 991 AAGCTACGCGAAGAACCCTACCAGGTCTTGACATCTTGCGCCAACCCCTAGAGATAGGGCG 1050

Query 1028 TTTCTTCGGGAACGCAATGACAGGTGGTGCATGGTCTGCTCAGCTCGTGTCTGAGAT 1087

```

>gb|EU825658.1| *Lactobacillus fermentum* strain 1 16S ribosomal RNA gene, partial sequence  
Length=1554

Score = 1007 bits (545), Expect = 0.0  
Identities = 586/607 (97%), Gaps = 7/607 (1%)  
Strand=Plus/Plus

```

Query 124  GGGGAGGTACGACCCGCAAGGGTTGGAGACTCAAAGGAAATTGAACGGGGGGCCCGCNCA 183
          |||
Sbjct  899  GGGGA-GTACGA-CCGCAA-GGTT-GAAACTCAAAGG-AATTG-ACGGGGGGCCCGCACA 952

Query 184  AGCGGTGGAGCATGTGGTTTAATTGGAAGCTACGCGAAGAACC TTA-CAGGTGTTGAGAT 242
          |||
Sbjct  953  AGCGGTGGAGCATGTGGTTTAATTCGAAGCTACGCGAAGAACC TTACCAGGTCCTTGACAT 1012

Query 243  CTTGGGCCAACCC TAGAGATAGGGCGTTTCCTTNGGGAACGCAATGACAGGTGGTGATG 302
          |||
Sbjct 1013  CTTGCGCCAACCC TAGAGATAGGGCGTTTCCTTCGGGAACGCAATGACAGGTGGTGATG 1072

Query 303  GTGGTCGTCAGCTCGTGTCGTGAGATGTTNGGTTAAGTCCC GCAACGAGCGCAACCC TTG 362
          |||
Sbjct 1073  GTCGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCC GCAACGAGCGCAACCC TTG 1132

Query 363  TTAATAGTTGCCAGCATTAAAGTTGGGCAC TCTAGTGAGACTGCCNGTGACANACCGGAGG 422
          |||
Sbjct 1133  TTACTAGTTGCCAGCATTAAAGTTGGGCAC TCTAGTGAGACTGCCGGTGACAAACCGGAGG 1192

Query 423  AAGGTGGGGACGACGTCAGATCATCATGCC CCTTATGACCTGGGCTACACACGTGCTACA 482
          |||
Sbjct 1193  AAGGTGGGGACGACGTCAGATCATCATGCC CCTTATGACCTGGGCTACACACGTGCTACA 1252

Query 483  ATGGACGGTACAACGGGTCGCGAACTCGCGAGGGCAAGCAAATCTCTTAAACCCGTTCTC 542
          |||
Sbjct 1253  ATGGACGGTACAACGAGTCGCGAACTCGCGAGGGCAAGCAAATCTCTTAAACCCGTTCTC 1312

Query 543  AGTTCGGACTGCAGGCTGCAACTCGCCTGCACGAAGTCGGAATCGCTAGTAATCGCGGAT 602
          |||
Sbjct 1313  AGTTCGGACTGCAGGCTGCAACTCGCCTGCACGAAGTCGGAATCGCTAGTAATCGCGGAT 1372

Query 603  CAGCATGCCGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCC GTCACACCATGAGA 662
          |||
Sbjct 1373  CAGCATGCCGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCC GTCACACCATGAGA 1432

Query 663  GTTTGTAAACACCCAAAGTCGGTGGGGTAACCTTTTAGGAGCCAGCCGCCTAAGGTGGGAC 722
          |||
Sbjct 1433  GTTTGTAAACACCCAAAGTCGGTGGGGTAACCTTTTAGGAGCCAGCCGCCTAAGGTGGGAC 1492

Query 723  AGATGAT 729
          |||
Sbjct 1493  AGATGAT 1499

```

>dbj|AB120029.1| Lactobacillus plantarum gene for 16S rRNA, partial sequence,  
strain:A6bLP03  
Length=625

Score = 1016 bits (550), Expect = 0.0  
Identities = 555/557 (99%), Gaps = 2/557 (0%)  
Strand=Plus/Plus

```

Query 9   CATGCAAGGTCTGAACGAACTCTTGGTATTGATTGGTGCTTGCATCATGATTTACATTTGA 68
          |||
Sbjct 18   CATGCAA-GTCGAACGAACTC-TGGTATTGATTGGTGCTTGCATCATGATTTACATTTGA 75

Query 69   GTGAGTGGCGAACTGGTGAGTAACACGTGGGAAACCTGCCAGAAAGCGGGGATAACACC 128
          |||
Sbjct 76   GTGAGTGGCGAACTGGTGAGTAACACGTGGGAAACCTGCCAGAAAGCGGGGATAACACC 135

Query 129  TGGAAACAGATGCTAATACCGCATAACAAC TTGGACCGCATGGTCCGAGTTTGAAAGATG 188
          |||
Sbjct 136  TGGAAACAGATGCTAATACCGCATAACAAC TTGGACCGCATGGTCCGAGTTTGAAAGATG 195

Query 189  GCTTCGGCTATCAC TTTTGGATGGTCCC GCGGCGTATTAGC TAGATGGTGGGGTAACGGC 248
          |||
Sbjct 196  GCTTCGGCTATCAC TTTTGGATGGTCCC GCGGCGTATTAGC TAGATGGTGGGGTAACGGC 255

Query 249  TCACCATGGCAATGATACGTAGCCGACCTGAGAGGGTAATCGGCCACATTGGGACTGAGA 308
          |||
Sbjct 256  TCACCATGGCAATGATACGTAGCCGACCTGAGAGGGTAATCGGCCACATTGGGACTGAGA 315

Query 309  CACGGCCCAAAC TCTACGGGAGGCAGCAGTAGGGAAATCTTCCACAATGGACGAAAGTCT 368
          |||
Sbjct 316  CACGGCCCAAAC TCTACGGGAGGCAGCAGTAGGGAAATCTTCCACAATGGACGAAAGTCT 375

Query 369  GATGGAGCAACGCCGCGTGAGTGAAGAAGGGTTTCGGCTCGTAAAAC TCTGTTGTTAAAG 428
          |||
Sbjct 376  GATGGAGCAACGCCGCGTGAGTGAAGAAGGGTTTCGGCTCGTAAAAC TCTGTTGTTAAAG 435

Query 429  AAGAACATATCTGAGAGTAACTGTTCAGGTATTGACGGTATTTAACCAGAAAGCCACGGC 488
          |||
Sbjct 436  AAGAACATATCTGAGAGTAACTGTTCAGGTATTGACGGTATTTAACCAGAAAGCCACGGC 495

Query 489  TAACTACGTGCCAGCAGCCGCGGTAATACGTAGGTGGCAAGCGTTGTCCGGATTTATTGG 548
          |||
Sbjct 496  TAACTACGTGCCAGCAGCCGCGGTAATACGTAGGTGGCAAGCGTTGTCCGGATTTATTGG 555

Query 549  GCGTAAAGCGAGCGCAA 565
          |||
Sbjct 556  GCGTAAAGCGAGCGCAA 572

```

>gb|JQ412726.1| *Lactobacillus casei* strain L8 16S ribosomal RNA gene, partial sequence  
Length=1518

Score = 673 bits (364), Expect = 0.0  
Identities = 369/371 (99%), Gaps = 2/371 (1%)  
Strand=Plus/Plus

```

Query 7   CTATACATGCCAAGTCGGAACGAGTTCTCGTTGATGATCGGTGCTTGCACCGAGATTCAA 66
          |||
Sbjct 15  CTATACATG-CAAGTC-GAACGAGTTCTCGTTGATGATCGGTGCTTGCACCGAGATTCAA 72

Query 67  CATGGAACGAGTGGCGGACGGGTGAGTAACACGTGGGTAACCTGCCCTTAAGTGGGGGAT 126
          |||
Sbjct 73  CATGGAACGAGTGGCGGACGGGTGAGTAACACGTGGGTAACCTGCCCTTAAGTGGGGGAT 132

Query 127 AACATTTGAAACAGATGCTAATACCGCATAGATCCAAGAACCGCATGGTTCTTGGCTGA 186
          |||
Sbjct 133 AACATTTGAAACAGATGCTAATACCGCATAGATCCAAGAACCGCATGGTTCTTGGCTGA 192

Query 187 AAGATGGCGTAAGCTATCGCTTTTGGATGGACCCGCGGC GTATTAGCTAGTTGGTGAGGT 246
          |||
Sbjct 193 AAGATGGCGTAAGCTATCGCTTTTGGATGGACCCGCGGC GTATTAGCTAGTTGGTGAGGT 252

Query 247 AATGGCTCACCAAGGCGATGATACGTAGCCGAAC TGAGAGGTTGATCGGCCACATTGGGA 306
          |||
Sbjct 253 AATGGCTCACCAAGGCGATGATACGTAGCCGAAC TGAGAGGTTGATCGGCCACATTGGGA 312

Query 307 CTGAGACACGGCCCAAAC TCTACGGGAGGCAGCAGTAGGGAATCTTCCACAATGGACGC 366
          |||
Sbjct 313 CTGAGACACGGCCCAAAC TCTACGGGAGGCAGCAGTAGGGAATCTTCCACAATGGACGC 372

Query 367 AAGTCTGATGG 377
          |||
Sbjct 373 AAGTCTGATGG 383

```

>gb|HQ697661.1| *Lactobacillus oris* strain 47-219 16S ribosomal RNA gene, partial sequence  
Length=567

Score = 248 bits (134), Expect = 1e-62  
Identities = 152/163 (93%), Gaps = 0/163 (0%)  
Strand=Plus/Plus

```

Query 21  AGCGCACTGNCCAACAGAAATGACGTGCTTGCACTGATTTGACGTTGNATTTCCAGTGA 80
          |||
Sbjct 63  AGCGCACTGGCCCAACAGAAATGACGTGCTTGCACTGATTTGACGTTGGATTCCAGTGA 122

Query 81  GCGGCGGACGGGTGAGTANACGTGGCCACCTGCCCAAAGCGGGGGATAACATTTGGA 140
          |||
Sbjct 123  GCGGCGGACGGGTGAGTAACACGTGGGCAACCTGCCCAAAGCGGGGGATAACATTTGGA 182

Query 141 AACAGGTGCTAATACCGCATAATTTGGAATACTATATGttttt 183
          |||
Sbjct 183 AACAGGTGCTAATACCGCATAACTTGAAAACCATGGTTTT 225

```

>gb|HM218396.1| *Lactobacillus rhamnosus* strain NM94-5 16S ribosomal RNA gene, partial sequence  
Length=1504

Score = 2623 bits (1420), Expect = 0.0  
Identities = 1469/1491 (99%), Gaps = 16/1491 (1%)  
Strand=Plus/Plus

```

Query 10  ATACATGCAAGTCGAACGAGTTCTGATTATTGAAAGGTGCTTGCATCTTGATTTAATTTT 69
          |||
Sbjct 28  ATACATGCAAGTCGAACGAGTTCTGATTATTGAAAGGTGCTTGCATCTTGATTTAATTTT 87

Query 70  GAACGAGTGGCGGACGGGTGAGTAACACGTGGGTAACCTGCCCTTAAGTGGGGGATAACA 129
          |||
Sbjct 88  GAACGAGTGGCGGACGGGTGAGTAACACGTGGGTAACCTGCCCTTAAGTGGGGGATAACA 147

Query 130  TTTGGAAACAGATGCTAATACCGCATAAATCCAAGAACCGCATGGTCTTGCTGAAAGA 189
          |||
Sbjct 148  TTTGGAAACAGATGCTAATACCGCATAAATCCAAGAACCGCATGGTCTTGCTGAAAGA 207

Query 190  TGGCGTAAGCTATCGCTTTTGGATGGACCCGCGGCGTATTAGCTAGTTGGTGAGGTAACG 249
          |||
Sbjct 208  TGGCGTAAGCTATCGCTTTTGGATGGACCCGCGGCGTATTAGCTAGTTGGTGAGGTAACG 267

Query 250  GCTCACCAAGGCAATGATACGTAGCCGAACGTAGAGGTTGATCGGCCACATTGGGACTGA 309
          |||
Sbjct 268  GCTCACCAAGGCAATGATACGTAGCCGAACGTAGAGGTTGATCGGCCACATTGGGACTGA 327

Query 310  GACACGGCCCAAACCTCTACGGGAGGCAGCAGTAGGGAATCTTCCACAAATGGACGCAAGT 369
          |||
Sbjct 328  GACACGGCCCAAACCTCTACGGGAGGCAGCAGTAGGGAATCTTCCACAAATGGACGCAAGT 387

Query 370  CTGATGGAGCAACGCCGCGTGAGTGAAGAAGGCTTTCGGGTCGTAAAACCTCTGTTGTTGG 429
          |||
Sbjct 388  CTGATGGAGCAACGCCGCGTGAGTGAAGAAGGCTTTCGGGTCGTAAAACCTCTGTTGTTGG 447

Query 430  AGAAGAATGGTCGGCAGAGTAACTGTTGTGCGGTGACGGTATCCAACAGAAAGCCACG 489
          |||
Sbjct 448  AGAAGAATGGTCGGCAGAGTAACTGTTGTGCGGTGACGGTATCCAACAGAAAGCCACG 507

Query 490  GCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGTGGCAAGCGTTATCCGGATTTATT 549
          |||
Sbjct 508  GCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGTGGCAAGCGTTATCCGGATTTATT 567

Query 550  GGGCGTAAAGCGAGCGCAGCCGGTTTTTNTTAAGTCTGANGTGAAAANCCNTCGGGCT 609
          |||
Sbjct 568  GGGCGTAAAGCGAGCGCAGCCGGTTTTT-T-AAGTC-TGATGTGAAAGC-CC-TCGG-CT 621

Query 610  TTNCCCCGAGGGAAAGTGCATCCGGAAACTGGGAAAACCTTGGAGTGCAGAAGNAGGACAG 669
          |||
Sbjct 622  TAA-CC-GAGG-AA-GTGCATC-GGAAACTGGGAAA-CTT-GAGTGCAGAAG-AGGACAG 673

Query 670  TGGAAACTCCATGTGTAGCGGTGAAATGCGTAGATATATGGAAGAACCAGTGGCGAAG 729
          |||
Sbjct 674  TGGAA-CTCCATGTGTAGCGGTGAAATGCGTAGATATATGGAAGAACCAGTGGCGAAG 732

Query 730  GCGGCTGTCTGGTCTGTAACGTACGCTGAGGCTCGAAAGCATGGGTAGCGAACAGGATTA 789
          |||
Sbjct 733  GCGGCTGTCTGGTCTGTAACGTACGCTGAGGCTCGAAAGCATGGGTAGCGAACAGGATTA 792

Query 790  GATACCCCTGGTAGTCCATGCCGTAACGATGAATGCTAGGTGTTGGAGGGTTTCCGCC 849
          |||
Sbjct 793  GATACCC-TGGTAGTCCATGCCGTAACGATGAATGCTAGGTGTTGGAGGGTTTCCGCC 851

Query 850  TTCAGTGCCGCAGCTAACGCATTAAGCATTCCGCCGGGGAGTACGACC GCAAGGTTGAA 909
          |||
Sbjct 852  TTCAGTGCCGCAGCTAACGCATTAAGCATTCCGCCGGGGAGTACGACC GCAAGGTTGAA 911

Query 910  ACTCAAAGGAATTGACGGGGGCCCGCAC AAGCGGTGGAGCATGTGGTTTAATTGGAAGCA 969
          |||
Sbjct 912  ACTCAAAGGAATTGACGGGGGCCCGCAC AAGCGGTGGAGCATGTGGTTTAATTGGAAGCA 971

```

Query	970	ACGCGAAGAACCTTACCAGGCTTGACATCTTTTGATCACCTGAGAGATCAGGTTTCCCC	1029
Sbjct	972	ACGCGAAGAACCTTACCAGGCTTGACATCTTTTGATCACCTGAGAGATCAGGTTTCCCC	1031
Query	1030	TTCGGGGGCAAATGACAGGTGGTGCATGGTTGTCGTCAGCTCGTGTCTGTGAGATGTTGG	1089
Sbjct	1032	TTCGGGGGCAAATGACAGGTGGTGCATGGTTGTCGTCAGCTCGTGTCTGTGAGATGTTGG	1091
Query	1090	GTTAAGTCCC GCAACGAGCGCAACCCCTTATGACTAGTTGCCAGCATTAGTTGGGCACTC	1149
Sbjct	1092	GTTAAGTCCC GCAACGAGCGCAACCCCTTATGACTAGTTGCCAGCATTAGTTGGGCACTC	1151
Query	1150	TAGTAAGACTGCCGGTGACAAACCGAGGAAGGTGGGGATGACGTCAAATCATCATGCC	1209
Sbjct	1152	TAGTAAGACTGCCGGTGACAAACCGAGGAAGGTGGGGATGACGTCAAATCATCATGCC	1211
Query	1210	CTTATGACCTGGGC TACACACGTGCTACAATGGATGGTACAACGAGTTGCGAGACCGCGA	1269
Sbjct	1212	CTTATGACCTGGGC TACACACGTGCTACAATGGATGGTACAACGAGTTGCGAGACCGCGA	1271
Query	1270	GGTCAAGCTAATCTCTTAAAGCCATTCTCAGTTCGGACTGTAGGCTGCAACTCGCCTACA	1329
Sbjct	1272	GGTCAAGCTAATCTCTTAAAGCCATTCTCAGTTCGGACTGTAGGCTGCAACTCGCCTACA	1331
Query	1330	CGAAGTCGGAATCGCTAGTAATCGCGGATCAGCACGCCGCGGTGAATACGTTCCC GGGCC	1389
Sbjct	1332	CGAAGTCGGAATCGCTAGTAATCGCGGATCAGCACGCCGCGGTGAATACGTTCCC GGGCC	1391
Query	1390	TTGTACACACCGCCCGTACACCATGAGAGTTTGTAAACACCCGAAGCCGGTGGCGTAACC	1449
Sbjct	1392	TTGTACACACCGCCCGTACACCATGAGAGTTTGTAAACACCCGAAGCCGGTGGCGTAACC	1451
Query	1450	CTTTTAGGGAGCGAGCCGTCTAAGGTGGGACAAATGATTAGTGTGAAGTCG	1500
Sbjct	1452	CTTTTAGGGAGCGAGCCGTCTAAGGTGGGACAAATGATTAGGGTGAAGTCG	1502



2. The similarly alignment 16S rRNA gene sequence of *Bifidobacterium* spp. isolated from breast milk with the 16S rRNA gene sequence of *Bifidobacterium* spp. published in NCBI data bank.

```
>dbj|AB690245.1| Bifidobacterium longum gene for 16S rRNA, partial sequence, strain:
JCM 1250
Length=1464

Score = 2220 bits (1202), Expect = 0.0
Identities = 1271/1303 (98%), Gaps = 10/1303 (1%)
Strand=Plus/Plus

Query  27   AAC-GGAT-CATCAAGGCTTTG-TTggggggggAGAG-AGAGTAACGGGTGATTAATGCC  82
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Sbjct  47   AACGGGATCCATC-GGGCTTTGCTT-GGTGGTGAGAGTGCCG-AACGGGTGAGTAATGCG  103

Query  83   TGCCCGACCTGCCCCATACACCGGAATAGCTCCTGGAAACGGGTGGTAATGCCGGATGTT  142
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Sbjct 104   TGACCGACCTGCCCCATACACCGGAATAGCTCCTGGAAACGGGTGGTAATGCCGGATGTT  163

Query 143   CCAGTTGATCGCATGGTCTTCTGGGAAAGCTTTCGCGGTATGGGATGGGGTCGCGTCC TA  202
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Sbjct 164   CCAGTTGATCGCATGGTCTTCTGGGAAAGCTTTCGCGGTATGGGATGGGGTCGCGTCC TA  223

Query 203   TCAGCTTGACGGCGGGGTAACGGCCCACC GTGGCTTCAACGGGAGCCGGCCTGAGAGGG  262
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Sbjct 224   TCAGCTTGACGGCGGGGTAACGGCCCACC GTGGCTTCAACGGGAGCCGGCCTGAGAGGG  283

Query 263   CGACCGGCCACATTGGGACTGAAATACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGA  322
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Sbjct 284   CGACCGGCCACATTGGGACTGAGATACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGA  343

Query 323   ATATTGCACAATGGGCGCAAGCCTGATGCAGCGACCCCGCGTGAGGCATGGAGGCC TT CG  382
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Sbjct 344   ATATTGCACAATGGGCGCAAGCCTGATGCAGCGACCCCGCGTGAGGCATGGAGGCC TT CG  403

Query 383   GGTGTAAACCTCTTTTATCGGGGAGCAAGCGTGAGTGAGTTTACCTTTGAATAAGCAC  442
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Sbjct 404   GGTGTAAACCTCTTTTATCGGGGAGCAAGCGTGAGTGAGTTTACCTTTGAATAAGCAC  463

Query 443   CGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTACGGTGCAAGCGTTATCCGGAATTA  502
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Sbjct 464   CGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGTGCAAGCGTTATCCGGAATTA  523

Query 503   TTGGGCATAAAGGGCTCC TAGGC GGGTCTGCTC GACC GGTGTGAAAGTCCATCGCTTAAC  562
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Sbjct 524   TTGGGCATAAAGGGCTCGTAGGC GGTTCGTCGCGTCCGGTGTGAAAGTCCATCGCTTAAC  583

Query 563   GGTGGATCCGCGCCGGGTACGGGCGGGCTTGAGTGC GGTAGGGGAGACTGGAATTCCCGG  622
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Sbjct 584   GGTGGATCCGCGCCGGGTACGGGCGGGCTTGAGTGC GGTAGGGGAGACTGGAATTCCCGG  643

Query 623   TGTAACGGTGGAATGTGTAGATATCGGGAAGAACACCAATGGCGAAGGCAGGTCTCTGGG  682
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Sbjct 644   TGTAACGGTGGAATGTGTAGATATCGGGAAGAACACCAATGGCGAAGGCAGGTCTCTGGG  703

Query 683   CCGTTACTGACGCTGAGGAGCGAAAGCGTGGGAGCGAACAGGATTAGATACCCTGGTAG  742
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Sbjct 704   CCGTTACTGACGCTGAGGAGCGAAAGCGTGGGAGCGAACAGGATTAGATACCCTGGTAG  763

Query 743   TCCACGCCGTA AACGGTGGATGCTGGATGTGGGGCCCGTTCCACGGGTTCCTGTCGGAG  802
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Sbjct 764   TCCACGCCGTA AACGGTGGATGCTGGATGTGGGGCCCGTTCCACGGGTTCCTGTCGGAG  823

Query 803   CTAACGCGTTAAGCATCCCGCCTGGGAGTAGCGGCCGCAAGGCTAAAAC TCAAAGAAATT  862
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Sbjct 824   CTAACGCGTTAAGCATCCCGCCTGGGAGTAGCGGCCGCAAGGCTAAAAC TCAAAGAAATT  883

Query 863   GACGGGGGCCCGCACAAGCGGGGAGCATGCGGATTAATTCGATGCAACGCAAGAACCT  922
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Sbjct 884   GACGGGGGCCCGCACAAGCGGGGAGCATGCGGATTAATTCGATGCAACGCAAGAACCT  943

Query 923   TACCTGGGCTTGACATGTTCCCGACGATCCAGAGATGGGGTTTCCC TTCGGGGCGGGTT  982
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Sbjct 944   TACCTGGGCTTGACATGTTCCCGACGATCCAGAGATGGGGTTTCCC TTCGGGGCGGGTT  1003

Query 983   CACAGGTGGTGCATGGTCTGTCAGCTCTGTCGTGAGATGTTGGGTTAAGTCCCGCAA  1042
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Sbjct 1004   CACAGGTGGTGCATGGTCTGTCAGCTCTGTCGTGAGATGTTGGGTTAAGTCCCGCAA  1063

Query 1043   CGAGCGCAACCC TCGCCCCGTGTTGCCAGCGGATTGTGCCGGGAATCACGGGGGACCGC  1102
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Sbjct 1064   CGAGCGCAACCC TCGCCCCGTGTTGCCAGCGGATTGTGCCGGGAATCACGGGGGACCGC  1123
```

```

Query 1103 CGGGGTAACTCGGAGGAAGGTGGGGATGACGTCAGATCATCATGCCCCCTTACGTCCAGG 1162
          |||
Sbjct 1124 CGGGGTAACTCGGAGGAAGGTGGGGATGACGTCAGATCATCATGCCCCCTTACGTCCAGG 1183
          |||
Query 1163 GCTTCACGCATGCTACAATGGCCGGTACAACGGGATGCGACGCGGCACGC GGAGCGGAT 1222
          |||
Sbjct 1184 GCTTCACGCATGCTACAATGGCCGGTACAACGGGATGCGACGCGGCACGC GGAGCGGAT 1243
          |||
Query 1223 CCCTGAAAACCGGTCTCAGTTCGGATCGCAGTCTGCAACTCGACTGCGTGAAGGCGGAGT 1282
          |||
Sbjct 1244 CCCTGAAAACCGGTCTCAGTTCGGATCGCAGTCTGCAACTCGACTGCGTGAAGGCGGAGT 1303
          |||
Query 1283 CGGTAGTAATC-CGGAATCAGCAACGTCCCGG-GAATGTGTTC 1323
          |||
Sbjct 1304 CGCTAGTAATCGCG-AATCAGCAACGTCCCGGGAATGCGTTC 1345
          |||

```

>gb|GU936674.1| Bifidobacterium bifidum strain R0071 16S ribosomal RNA gene, partial sequence  
Length=1368

Score = 2224 bits (1204), Expect = 0.0  
Identities = 1274/1305 (98%), Gaps = 15/1305 (1%)  
Strand=Plus/Plus

Query	29	GGACTCGATCGCGGCTTTGCCTGGTGGT	GAGAGTGGCGAACGGGTGAGTAATGCGTGACC	88
Sbjct	4	GGA-TCCATCG-GGCTTTGC	TTGGTGGT	61
Query	89	GACCTGCCCCATGCTCCGGAATAGCTCCTGGAACGGGTGTAATGCCGGATGTTCCACA	148	
Sbjct	62	GACCTGCCCCATGCTCCGGAATAGCTCCTGGAACGGGTGTAATGCCGGATGTTCCACA	121	
Query	149	TGATCGCATGTGATTGTGGGAAAGATTCTATCGGCGTGGGATGGGGTCGCGTCCTATCAG	208	
Sbjct	122	TGATCGCATGTGATTGTGGGAAAGATTCTATCGGCGTGGGATGGGGTCGCGTCCTATCAG	181	
Query	209	CTTGTTGGT	GAGGTAACGGCTC	268
Sbjct	182	CTTGTTGGT	GAGGTAACGGCTC	241
Query	269	CGGCCACATTGGGACTGAGATACGGCCAGACTCCTACGGGAGGCAGCAGTGGGGAATAT	328	
Sbjct	242	CGGCCACATTGGGACTGAGATACGGCCAGACTCCTACGGGAGGCAGCAGTGGGGAATAT	301	
Query	329	TGCACAATGGGCGCAAGCCTGATGCAGCGACGCCGCGTGAGGGATGGAGGCC TTCGGGTT	388	
Sbjct	302	TGCACAATGGGCGCAAGCCTGATGCAGCGACGCCGCGTGAGGGATGGAGGCC TTCGGGTT	361	
Query	389	GTAAACCTCTTTTGTGGAGCAAGCCTTCGGGTGAGTGTACCTTTTCAATAAGCGCCG	448	
Sbjct	362	GTAAACCTCTTTTGTGGAGCAAGCCTTCGGGTGAGTGTACCTTTTCAATAAGCGCCG	421	
Query	449	GCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGCGCAAGCGTTATCCGGATTTATT	508	
Sbjct	422	GCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGCGCAAGCGTTATCCGGATTTATT	481	
Query	509	GGGCGTAAAGGGCTCGTAGGCGGCTCGTCGCGTCCGGTGTGAAAGTCCATCGTTAACGG	568	
Sbjct	482	GGGCGTAAAGGGCTCGTAGGCGGCTCGTCGCGTCCGGTGTGAAAGTCCATCGTTAACGG	541	
Query	569	TGGATCTGCGCCGGGTACGGGCGGGCTGGAGTGCGGTAGGGGAGACTGGAATTTCCGGTG	628	
Sbjct	542	TGGATCTGCGCCGGGTACGGGCGGGCTGGAGTGCGGTAGGGGAGACTGGAATTTCCGGTG	601	
Query	629	TAACGGTGAATGTGTAGATATCGGGAAGAACACCGATGGCGAAGGCAGGTCTCTGGGCC	688	
Sbjct	602	TAACGGTGAATGTGTAGATATCGGGAAGAACACCGATGGCGAAGGCAGGTCTCTGGGCC	661	
Query	689	GTCACTGACGCTGAGGAGCGAAAGCGTGGGGAGCGAACAGGATTAGATACCTGGTAGTC	748	
Sbjct	662	GTCACTGACGCTGAGGAGCGAAAGCGTGGGGAGCGAACAGGATTAGATACCTGGTAGTC	721	
Query	749	CACGCCGTAACGGTGGACGCTGGATGTGGGGCACGTTCCACGTGTTCCGTGTCTGAACT	808	
Sbjct	722	CACGCCGTAACGGTGGACGCTGGATGTGGGGCACGTTCCACGTGTTCCGTGTCTGAACT	781	
Query	809	AACGCGTTAAGCGTCCC	868	
Sbjct	782	AACGCGTTAAGCGTCCC	840	
Query	869	ACCGGGGGCCCTACACAAAGCGGGGGGAGCATGCAGAATTAACCTTCGATTTCAACCCGAA	928	
Sbjct	841	AC-GGGGGCCCCG-CACAA-GCGGCGG-AGCATGCGGA-TTAA-TTCGATG-CAACGCGAA	893	
Query	929	AAGACCTTACCTGGGCTTGACATGTTCCCGACGACGCCAGAGATGGCGTTTCCCTTCGG	988	
Sbjct	894	GA-ACC-TTACCTGGGCTTGACATGTTCCCGACGACGCCAGAGATGGCGTTTCCCTTCGG	951	
Query	989	GGCGGGTTACAGGTGGTTCATGGTCGTCGTCAGCTCGTGTGTGAGATGTTGGGTAAAG	1048	
Sbjct	952	GGCGGGTTACAGGTGGTTCATGGTCGTCGTCAGCTCGTGTGTGAGATGTTGGGTAAAG	1011	

```

Query 1049 TCCCGCAACGAGCGCAACCCTCGCCCCGTGTTGCCAGCACGTTATGGTGGGAAC TCACGG 1108
           |||
Sbjct 1012 TCCCGCAACGAGCGCAACCCTCGCCCCGTGTTGCCAGCACGTTATGGTGGGAAC TCACGG 1071

Query 1109 GGGACCGCCGGGGTTAACTCGGAGGAAGGTGGGGATGACGTCAGATCATCATGCCCTTA 1168
           |||
Sbjct 1072 GGGACCGCCGGGGTTAACTCGGAGGAAGGTGGGGATGACGTCAGATCATCATGCCCTTA 1131

Query 1169 CGTCCAGGGCTTCACGCATGGTACAATGGCCGGTACAACGGGATGCGACATGGCGACATG 1228
           |||
Sbjct 1132 CGTCCAGGGCTTCACGCATGCTACAATGGCCGGTACAGCGGGATGCGACATGGCGACATG 1191

Query 1229 GAGCGGATCCCTGAAAACCGGTCACAGTTCGGATCGGAGCCTGCAACCCGGCTCCG-GAA 1287
           |||
Sbjct 1192 GAGCGGATCCCTGAAAACCGGTCACAGTTCGGATCGGAGCCTGCAACCCGGCTCCGTGAA 1251

Query 1288 GGCGGAGTCGCTAGTAATACGCGGATCAGCAACGTCGCGG-GAAT 1331
           |||
Sbjct 1252 GGCGGAGTCGCTAGTAAT-CGCGGATCAGCAACGCCGCGGTGAAT 1295

```

>gb|HQ259740.1| Bifidobacterium breve strain LCR5 16S ribosomal RNA gene, partial  
sequence  
Length=1393

Score = 2314 bits (1253), Expect = 0.0  
Identities = 1282/1296 (99%), Gaps = 1/1296 (0%)  
Strand=Plus/Plus

```

Query 32  CCATCGAGCTTTGCTTGGTGGTGAGAGTGGCGAACGGGTGAGTAATGCGTGACCGACCTG 91
      |||
Sbjct 46  CCATCGGGCTTTGCCTGGTGGTGAGAGTGGCGAACGGGTGAGTAATGCGTGACCGACCTG 105

Query 92  CCCCATGCACCGGAATAGCTCCTGGAACCGGTGGTAATGCCGGATGCTCCATCACACCG 151
      |||
Sbjct 106  CCCCATGCACCGGAATAGCTCCTGGAACCGGTGGTAATGCCGGATGCTCCATCACACCG 165

Query 152  CATGGTGTGTTGGGAAAGCCTTTGCGGCATGGGATGGGGTCCGCTCCTATCAGCTTGATG 211
      |||
Sbjct 166  CATGGTGTGTTGGGAAAGCCTTTGCGGCATGGGATGGGGTCCGCTCCTATCAGCTTGATG 225

Query 212  GCGGGGTAACGGCCACCATGGCTTCGACGGGTAGCCGGCTGAGAGGGCGACCGGCCAC 271
      |||
Sbjct 226  GCGGGGTAACGGCCACCATGGCTTCGACGGGTAGCCGGCTGAGAGGGCGACCGGCCAC 285

Query 272  ATTGGGACTGAGATACGGCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATTGCACAA 331
      |||
Sbjct 286  ATTGGGACTGAGATACGGCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATTGCACAA 345

Query 332  TGGGCGCAAGCCTGATGCAGCGACGCCGCGTGAGGGATGGAGGCC TTCGGGTTGTAAACC 391
      |||
Sbjct 346  TGGGCGCAAGCCTGATGCAGCGACGCCGCGTGAGGGATGGAGGCC TTCGGGTTGTAAACC 405

Query 392  TCTTTTGTAGGGAGCAAGGCATTTTGTGTTGAGTGTACCTTTCGAATAAGCACCGGCTA 451
      |||
Sbjct 406  TCTTTTGTAGGGAGCAAGGCATTTTGTGTTGAGTGTACCTTTCGAATAAGCACCGGCTA 465

Query 452  ACTACGTGCCAGCAGCCGCGGTAATACGTAGGGTGCAAGCGTTATCCGGAATTATTGGGC 511
      |||
Sbjct 466  ACTACGTGCCAGCAGCCGCGGTAATACGTAGGGTGCAAGCGTTATCCGGAATTATTGGGC 525

Query 512  GTAAAGGGCTCGTAAGCGGTTCTGTCCTCCGTCGGTGTGAAAGTCCATCGCTTAACGGTGG 571
      |||
Sbjct 526  GTAAAGGGCTCGTAGGCGGTTCTGTCCTCCGTCGGTGTGAAAGTCCATCGCTTAACGGTGG 585

Query 572  TCCGCGCCGGGTACGGGCGGGCTTGAGTGCGGTAGGGGAGACTGGAATTCCC GGTGTAAC 631
      |||
Sbjct 586  TCCGCGCCGGGTACGGGCGGGCTTGAGTGCGGTAGGGGAGACTGGAATTCCC GGTGTAAC 645

Query 632  GGTGGAATGTGTAGATATCGGGAAGAACAACCAATGGCGAAGGCAGGTCTCTGGGCCGTTA 691
      |||
Sbjct 646  GGTGGAATGTGTAGATATCGGGAAGAACAACCAATGGCGAAGGCAGGTCTCTGGGCCGTTA 705

Query 692  CTGACGCTGAAGAACGAAAGCCTGGGGAGCCAACAGGATTAGATACCCTGGTAGTCCACG 751
      |||
Sbjct 706  CTGACGCTGAGGAGCGAAAGCCTGGGGAGCGAACAGGATTAGATACCCTGGTAGTCCACG 765

Query 752  CCGTAAACGGTGGATGCTGGATGTGGGGCCCGTTCCACGGGTTCCGTGTCCGAACTAACG 811
      |||
Sbjct 766  CCGTAAACGGTGGATGCTGGATGTGGGGCCCGTTCCACGGGTTCCGTGTCCGAACTAACG 825

Query 812  CGTTAAGCATCCCGCCTGGGGAGTACGGCCGCAAGGCTAAAAC TCAAAGAAATTGACGGG 871
      |||
Sbjct 826  CGTTAAGCATCCCGCCTGGGGAGTACGGCCGCAAGGCTAAAAC TCAAAGAAATTGACGGG 885

Query 872  GGCCCCGCACAAGCGGC GGAACATGCGGATTAATTCGATGCAACGCGAAGAACCTTACCTG 931
      |||
Sbjct 886  GGCCCCGCACAAGCGGC GGAACATGCGGATTAATTCGATGCAACGCGAAGAACCTTACCTG 945

Query 932  GGCTTGACATGTTCCCGACGATCCCAGAGATGGGGTTTCCCTTCGGGGCGGGTTCACAGG 991
      |||
Sbjct 946  GGCTTGACATGTTCCCGACGATCCCAGAGATGGGGTTTCCCTTCGGGGCGGGTTCACAGG 1005

Query 992  TGGTGCATGGTCGTCGTCAGCTCGTGTCTGTGAGATGTTGGGTTAAGTCCC GCAACGAGCG 1051
      |||
Sbjct 1006  TGGTGCATGGTCGTCGTCAGCTCGTGTCTGTGAGATGTTGGGTTAAGTCCC GCAACGAGCG 1065

Query 1052  CAACCCCTGCCCCGTGTTGCCAGCGGATTGTGCCGGGAAC TACGGGGGACCGCCGGGGT 1111
      |||
Sbjct 1066  CAACCCCTGCCCCGTGTTGCCAGCGGATTGTGCCGGGAAC TACGGGGGACCGCCGGGGT 1125

```

```

Query 1112 TAACTCGGAGGAAGGTGGGGATGACGTCAGATCATCATGCCCCTTACGTCCAGGGCTTCA 1171
          |||
Sbjct 1126 TAACTCGGAGGAAGGTGGGGATGACGTCAGATCATCATGCCCCTTACGTCCAGGGCTTCA 1185

Query 1172 CGCATGCTACAATGGCCGGTACAACGGGATGCGACAGTGCGAGCTGGAGCGGATCCCTGA 1231
          |||
Sbjct 1186 CGCATGCTACAATGGCCGGTACAACGGGATGCGACAGTGCGAGCTGGAGCGGATCCCTGA 1245

Query 1232 AAACCGGTCTCAGTTCGGATCGCAGTCTGCAACTCGACTGCGTGAAGGCGGAGTCGCTAG 1291
          |||
Sbjct 1246 AAACCGGTCTCAGTTCGGATCGCAGTCTGCAACTCGACTGCGTGAAGGCGGAGTCGCTAG 1305

Query 1292 TAATCGCGAATCAGCAACGTCGTCGGTGAATGTGtt 1327
          |||
Sbjct 1306 TAATCGCGAATCAGCAACGTCG-CGGTGAATGCGTT 1340

```

>ref|NR\_037117.1| Bifidobacterium pseudocatenuatum strain B1279 16S ribosomal RNA, partial sequence  
Length=1513

Score = 2361 bits (1278), Expect = 0.0  
Identities = 1294/1302 (99%), Gaps = 0/1302 (0%)  
Strand=Plus/Plus

```

Query  24  AACGGAATCCATCAGGC TTTGCTTGGTGGT GAGGGTGGCGAACGGGTGAGTAATGCGTGA  83
      |||
Sbjct  56  AACGGGATCCATCAGGC TTTGCTTGGTGGT GAGAGTGGCGAACGGGTGAGTAATGCGTGA  115

Query  84  CCGACCTGCCCCATACACC GGAATAGCTCCTGGAAACGGGTGTAATGCCGGATGCTCCG  143
      |||
Sbjct 116  CCGACCTGCCCCATACACC GGAATAGCTCCTGGAAACGGGTGTAATGCCGGATGCTCCG  175

Query 144  ACTCCTCGCATGGGGTGTGCGGAAAGATTTTCATCGGTATGGGATGGGGTTCGCGTCCTATC  203
      |||
Sbjct 176  ACTCCTCGCATGGGGTGTGCGGAAAGATTTTCATCGGTATGGGATGGGGTTCGCGTCCTATC  235

Query 204  AGGTAGTCGGCGGGGTAACGGCCACCAGCCTACGACGGGTAGCCGGCTGAGAGGGCG  263
      |||
Sbjct 236  AGGTAGTCGGCGGGGTAACGGCCACCAGCCTACGACGGGTAGCCGGCTGAGAGGGCG  295

Query 264  ACCGGCCACATTGGGACTGAGATACGGCCAGACTCCTACGGGAGGCAGCAGTGGGGAAT  323
      |||
Sbjct 296  ACCGGCCACATTGGGACTGAGATACGGCCAGACTCCTACGGGAGGCAGCAGTGGGGAAT  355

Query 324  ATTGACAATGGGCGCAAGCCTGATGACGACGACGCCGCGTGC GGGATGACGGCCTTCGGG  383
      |||
Sbjct 356  ATTGACAATGGGCGCAAGCCTGATGACGACGACGCCGCGTGC GGGATGACGGCCTTCGGG  415

Query 384  TTGTAAACCCTTTTGATCGGGAGCAAGCCTTCGGGTGAGTGTACCTTTTGAATAAGCAC  443
      |||
Sbjct 416  TTGTAAACCCTTTTGATCGGGAGCAAGCCTTCGGGTGAGTGTACCTTTTGAATAAGCAC  475

Query 444  CGGCTAAC TACGTGCCAGCAGCCGCGGTAATACGTAGGGTGC AAGCGTTATCCGGAATTA  503
      |||
Sbjct 476  CGGCTAAC TACGTGCCAGCAGCCGCGGTAATACGTAGGGTGC AAGCGTTATCCGGAATTA  535

Query 504  TTGGGCGTAAAGGGCTCGTAGGCGGTTCTGTCGCGTCCGGTGTGAAAGTCCATCGCTTAAC  563
      |||
Sbjct 536  TTGGGCGTAAAGGGCTCGTAGGCGGTTCTGTCGCGTCCGGTGTGAAAGTCCATCGCTTAAC  595

Query 564  GGTGGATCTGCGCCGGGTACGGGCGGGCTGGAGTGCGGTAGGGGAGACTGGAATTCCCGG  623
      |||
Sbjct 596  GGTGGATCTGCGCCGGGTACGGGCGGGCTGGAGTGCGGTAGGGGAGACTGGAATTCCCGG  655

Query 624  TGTAACGGTGAATGTGTAGATATCGGGAAGAACAACCAATGGC GAAGGCAGGTCTCTGGG  683
      |||
Sbjct 656  TGTAACGGTGAATGTGTAGATATCGGGAAGAACAACCAATGGC GAAGGCAGGTCTCTGGG  715

Query 684  CCGTTACTGACGCTGAGGAGCGAAAGCGTGGGGAGCGAACAGGATTAGATACCCTGGTAG  743
      |||
Sbjct 716  CCGTTACTGACGCTGAGGAGCGAAAGCGTGGGGAGCGAACAGGATTAGATACCCTGGTAG  775

Query 744  TCCACGCCGTAACGGTGGATGCTGGATGTGGGGCCCGTTCCACGGGTTCCGTGTCGGAG  803
      |||
Sbjct 776  TCCACGCCGTAACGGTGGATGCTGGATGTGGGGCCCGTTCCACGGGTTCCGTGTCGGAG  835

Query 804  CTAACGCGTTAAGCATCCCGCCTGGGGAGTACGGCCGCAAGGCTAAAAC TCAAGAAATT  863
      |||
Sbjct 836  CTAACGCGTTAAGCATCCCGCCTGGGGAGTACGGCCGCAAGGCTAAAAC TCAAGAAATT  895

Query 864  GACGGGGGCCCGACAAGCGGCGGAGCATGCGGATTAATTTCGATGCAACGCGAAGAACCT  923
      |||
Sbjct 896  GACGGGGGCCCGACAAGCGGCGGAGCATGCGGATTAATTTCGATGCAACGCGAAGAACCT  955

Query 924  TACCTGGGC TTGACATGTTCCCGACAGCGGCAGAGATGTCGCTTCCCTTCGGGGCGGGTT  983
      |||
Sbjct 956  TACCTGGGC TTGACATGTTCCCGACAGCCGTAGAGATATGGCTTCCCTTCGGGGCGGGTT  1015

Query 984  CACAGGTGGTGCATGGTCGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAA  1043
      |||
Sbjct 1016  CACAGGTGGTGCATGGTCGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAA  1075

Query 1044  CGAGCGCAACCCTCGCCCTGTGTTGCCAGCACGTCGTGGTGGGAAC TACGGGGGACCGC  1103
      |||
Sbjct 1076  CGAGCGCAACCCTCGCCCTGTGTTGCCAGCACGTCGTGGTGGGAAC TACGGGGGACCGC  1135

```

```
Query 1104 CGGGGTCAACTCGGAGGAAGGTGGGGATGACGTCAGATCATCATGCCCCTTACGTCCAGG 1163
          |||
Sbjct 1136 CGGGGTCAACTCGGAGGAAGGTGGGGATGACGTCAGATCATCATGCCCCTTACGTCCAGG 1195
          |||
Query 1164 GCTTCACGCATGCTACAATGGCCGGTACAACGGGATGCGACACGGCGACGTGGAGCGGAT 1223
          |||
Sbjct 1196 GCTTCACGCATGCTACAATGGCCGGTACAACGGGATGCGACACGGCGACGTGGAGCGGAT 1255
          |||
Query 1224 CCCTGAAAACCGGTCTCAGTTCGGATTGGAGTCTGCAACCCGACTCCATGAAGGCGGAGT 1283
          |||
Sbjct 1256 CCCTGAAAACCGGTCTCAGTTCGGATTGGAGTCTGCAACCCGACTCCATGAAGGCGGAGT 1315
          |||
Query 1284 CGCTAGTAATCGCGGATCAGCAACGCCGCGGTGAATGCGTTC 1325
          |||
Sbjct 1316 CGCTAGTAATCGCGGATCAGCAACGCCGCGGTGAATGCGTTC 1357
          |||
```



>gb|GU361819.1| Bifidobacterium dentium strain KCTC 3222 16S ribosomal RNA gene, partial sequence  
Length=1483

Score = 2314 bits (1253), Expect = 0.0  
Identities = 1274/1284 (99%), Gaps = 1/1284 (0%)  
Strand=Plus/Plus

```

Query 33      GGGGGTTCGCTTCCGGGTGAGAGTGGCGAACGGGTGAGTAATGCGTGACCGACCTGCCCC 92
                |||
Sbjct 49      GGGGGTTCGCC TCCGGGTGAGAGTGGCGAACGGGTGAGTAATGCGTGACCGACCTGCCCC 108
                |||
Query 93      ATACACCGGAATAGCTCCTGGAAACGGGTGGTAATGCCGGATGCTCCGGTTGGATGCATG 152
                |||
Sbjct 109     ATACACCGGAATAGCTCCTGGAAACGGGTGGTAATGCCGGATGCTCCGGTTGGATGCATG 168
                |||
Query 153     TCCTTCCGGGAAA-GATCCGTCGGTATGGGATGGGGTCGCGTCC TATCAGCTTGATGGCG 211
                |||
Sbjct 169     TCCTTCCGGGAAAAGTTCCATCGGTATGGGATGGGGTCGCGTCC TATCAGCTTGATGGCG 228
                |||
Query 212     GGGTAACGGCCCACCATGGCTTCGACGGGTAGCCGGCCTGAGAGGGCGACCGGCCACATT 271
                |||
Sbjct 229     GGGTAACGGCCCACCATGGCTTCGACGGGTAGCCGGCCTGAGAGGGCGACCGGCCACATT 288
                |||
Query 272     GGGACTGAGATACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATTGCACAATGG 331
                |||
Sbjct 289     GGGACTGAGATACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATTGCACAATGG 348
                |||
Query 332     GCGCAAGCCTGATGCAGCGACGCCGCGTGC GGGATGGAGGCC TTCGGGTTGTAAACCGCT 391
                |||
Sbjct 349     GCGCAAGCCTGATGCAGCGACGCCGCGTGC GGGATGGAGGCC TTCGGGTTGTAAACCGCT 408
                |||
Query 392     TTTGATCGGGAGCAAGCCC TTCGGGGT GAGTGTACCTTTCGAATAAGCACCGGCTAACTA 451
                |||
Sbjct 409     TTTGATCGGGAGCAAGCCC TTCGGGGT GAGTGTACCTTTCGAATAAGCACCGGCTAACTA 468
                |||
Query 452     CGTGCCAGCAGCCGCGGTAATACGTAGGGTGCAAGCGTTATCCGGAATTATTGGGCGTAA 511
                |||
Sbjct 469     CGTGCCAGCAGCCGCGGTAATACGTAGGGTGCAAGCGTTATCCGGAATTATTGGGCGTAA 528
                |||
Query 512     AGGGCTCGTAGGCGGTTCTGTCGCGTCCGGTGTGAAAGCCCCATCGCTTAACGGTGGGTCTG 571
                |||
Sbjct 529     AGGGCTCGTAGGCGGTTCTGTCGCGTCCGGTGTGAAAGCCCCATCGCTTAACGGTGGGTCTG 588
                |||
Query 572     CGCCGGGTACGGGC GGGCTGGAGTGC GGTAGGGGAGACTGGAATTCCC GGTGTAAACGGTG 631
                |||
Sbjct 589     CGCCGGGTACGGGC GGGCTGGAGTGC GGTAGGGGAGACTGGAATTCCC GGTGTAAACGGTG 648
                |||
Query 632     GAATGTGTAGATATCGGGAAGAACAACCAATGGCGAAGGCAGGTCTCTGGGCCGTCCTGA 691
                |||
Sbjct 649     GAATGTGTAGATATCGGGAAGAACAACCAATGGCGAAGGCAGGTCTCTGGGCCGTCCTGA 708
                |||
Query 692     CGCTGAGGAGCGAAAGCGTGGGGAGCGAACAGGATTAGATACCCTGGTAGTCCACGCCGT 751
                |||
Sbjct 709     CGCTGAGGAGCGAAAGCGTGGGGAGCGAACAGGATTAGATACCCTGGTAGTCCACGCCGT 768
                |||
Query 752     AAACGGTGGATGCTGGATGTGGGGCCC GTTCCACGGGTTCCGTGTCGGAGCTAACGCGTT 811
                |||
Sbjct 769     AAACGGTGGATGCTGGATGTGGGGCCC GTTCCACGGGTTCCGTGTCGGAGCTAACGCGTT 828
                |||
Query 812     AAGCATCCCGCCTGGAGAGTACGGCCGCAAGGC TAACACTCAAAGAAATTGACGGGGGCC 871
                |||
Sbjct 829     AAGCATCCCGCCTGGGGAGTACGGCCGCAAGGC TAAAAC TCAAAGAAATTGACGGGGGCC 888
                |||
Query 872     CGCACAAAGCGGCGGAGCATGCGGATTAATTCGATGCAACGC GAAAAACCTTACCTGGGCT 931
                |||
Sbjct 889     CGCACAAAGCGGCGGAGCATGCGGATTAATTCGATGCAACGC GAAAGAACCTTACCTGGGCT 948
                |||
Query 932     TGACATGTTCCCGACAGCCGTAGAGATATGGCC TCCCTTCGGGGCGGGTTACAGGTGGT 991
                |||
Sbjct 949     TGACATGTTCCCGACAGCCGTAGAGATACGGCC TCCCTTCGGGGCGGGTTACAGGTGGT 1008
                |||
Query 992     GCATGGTCTGTCGTACGCTCGTGTGTCGTGAGATGTTGGGTTAAGTCCC GCAACGAGCGCAAC 1051
                |||
Sbjct 1009    GCATGGTCTGTCGTACGCTCGTGTGTCGTGAGATGTTGGGTTAAGTCCC GCAACGAGCGCAAC 1068
                |||

```

```

Query 992 GCATGGTCGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCAGCAACGAGCGCAAC 1051
          |||
Sbjct 1009 GCATGGTCGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCAGCAACGAGCGCAAC 1068
          |||

Query 1052 CCTCGCCCTGTGTTGCCAGCACGTCATGGTGGGAACTCACGGGGGACC GCCGGGGTCAAC 1111
          |||
Sbjct 1069 CCTCGCCCTGTGTTGCCAGCACGTCATGGTGGGAACTCACGGGGGACC GCCGGGGTCAAC 1128
          |||

Query 1112 TCGGAGGAAGGTGGGGATGACGTCAGATCATCATGCCCCCTTACGTCCAGGGCTTCACGCA 1171
          |||
Sbjct 1129 TCGGAGGAAGGTGGGGATGACGTCAGATCATCATGCCCCCTTACGTCCAGGGCTTCACGCA 1188
          |||

Query 1172 TGCTACAATGGCCGGTACAGCGGGATGCGACATGGCGACATGGAGCGGATCCCTGAAAAC 1231
          |||
Sbjct 1189 TGCTACAATGGCCGGTACAGCGGGATGCGACATGGCGACATGGAGCGGATCCCTGAAAAC 1248
          |||

Query 1232 CGGTCTCAGTTCGGATTGGAGTCTGCAACCCGACTCCATGAAGGCGGAGTCGCTAGTAAT 1291
          |||
Sbjct 1249 CGGTCTCAGTTCGGATTGGAGTCTGCAACCCGACTCCATGAAGGCGGAGTCGCTAGTAAT 1308
          |||

Query 1292 CGCGGATCAGCAACGCCGCGGTGA 1315
          |||
Sbjct 1309 CGCGGATCAGCAACGCCGCGGTGA 1332
          |||

```

3. The similarly alignment 16S rRNA gene sequence of *Streptococcus* spp. isolated from breast milk with the 16S rRNA gene sequence of *Streptococcus* spp. published in NCBI data bank.

```
>gb|GU045364.1| Streptococcus lactarius strain MV1 16S ribosomal RNA gene, partial
sequence
Length=1452
```

```
Score = 907 bits (491), Expect = 0.0
Identities = 500/504 (99%), Gaps = 2/504 (0%)
Strand=Plus/Plus
```

```
Query 20 GTGCCTAATACATGCAAGTAGAACGCTGAAGGAAGGAGCTTGCTCTTTCTGGATGAGTTG 79
      |||
Sbjct 20 GTGCCTAATACATGCAAGTAGAACGCTGAAGGAAGGAGCTTGCTCTTTCTGGATGAGTTG 79

Query 80 CGAACGGGTGAGTAACGCGTAGGTAACCTGCCTCTTAGCGGGGGATAACTATTGGAAACG 139
      |||
Sbjct 80 CGAACGGGTGAGTAACGCGTAGGTAACCTGCCTCTTAGCGGGGGATAACTATTGGAAACG 139

Query 140 ATAGCTAATACCGCATAAAAAGTCGACATTGCATGAAGTTGACTTGAAAGGTGCAATTGCA 199
      |||
Sbjct 140 ATAGCTAATACCGCATAAACAGTCGACATTGCATGAAGTTGACTTGAAAGGTGCAATTGCA 199

Query 200 TCACTAAGAGATGGACCTGCGTTGTATTAGCTAGTTGGTGAGGTAACGGCTCACCAAGGC 259
      |||
Sbjct 200 TCACTAAGAGATGGACCTGCGTTGTATTAGCTAGTTGGTGAGGTAACGGCTCACCAAGGC 259

Query 260 GACGATACATAGCCGACCTGAGAGGGTGATCGGCCACACTGGGACTGAGACACGGCCAG 319
      |||
Sbjct 260 AACGATACATAGCCGACCTGAGAGGGTGATCGGCCACACTGGGACTGAGACACGGCCAG 319

Query 320 ACTCCTACGGGAGGCAGCAGTAGGGAATCTTCGGCAATGGGGGAACCCTGACCGAGCAA 379
      |||
Sbjct 320 ACTCCTACGGGAGGCAGCAGTAGGGAATCTTCGGCAATGGGGGAACCCTGACCGAGCAA 379

Query 380 CGCCGCGTGAGTGAAGAAGGTTTTTCGGATCGTAAAGCTCTGTTGTAAGAGAAGAACGAGT 439
      |||
Sbjct 380 CGCCGCGTGAGTGAAGAAGGTTTTTCGGATCGTAAAGCTCTGTTGTAAGAGAAGAACGAGT 439

Query 440 GTGAGAGTGGAAGTTCACACTGTGACGGTATCTTACCAGAAAGGGACGGCTAACTACGT 499
      |||
Sbjct 440 GTGAGAGTGGAAGTTCACACTGTGACGGTATCTTACCAGAAAGGGACGGCTAACTACGT 499

Query 500 GCCAGCACGCCGCGGTGAATACGT 523
      |||
Sbjct 500 GCCAGCA-GCCGCGGT-AATACGT 521
```

gb|AY188352.1| Streptococcus salivarius strain ATCC 7073 16S ribosomal RNA gene, complete sequence  
Length=1546

Score = 1480 bits (801), Expect = 0.0  
Identities = 813/818 (99%), Gaps = 4/818 (0%)  
Strand=Plus/Plus

```

Query 16  CGGC-TG-CT-ATACATGCAAGTAGAACGCTGAAGAGAGGAGCTTGCCTTCTTGGATGA 72
          ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Sbjct 38  CGGCGTGCCTAATACATGCAAGTAGAACGCTGAAGAGAGGAGCTTGCCTTCTTGGATGA 97

Query 73  GTTGCGAACGGGTGAGTAACGCGTAGGTAACCTGCCTTGTAGCGGGGATAACTATTGGA 132
          ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Sbjct 98  GTTGCGAACGGGTGAGTAACGCGTAGGTAACCTGCCTTGTAGCGGGGATAACTATTGGA 157

Query 133 AACGATAGCTAATACCGCATAACAATGGATGACACATGTCATTTATTTGAAAGGGGCAAT 192
          ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Sbjct 158 AACGATAGCTAATACCGCATAACAATGGATGACACATGTCATTTATTTGAAAGGGGCAAT 217

Query 193 TGCTCCACTACAAGATGGACCTGCGTTGTATTAGCTAGTAGGTGAGGTAACGGCTCACCT 252
          ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Sbjct 218 TGCTCCACTACAAGATGGACCTGCGTTGTATTAGCTAGTAGGTGAGGTAACGGCTCACCT 277

Query 253 AGGCGACGATACATAGCCGACCTGAGAGGGTGATCGGCCACACTGGGACTGAGACACGGC 312
          ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Sbjct 278 AGGCGACGATACATAGCCGACCTGAGAGGGTGATCGGCCACACTGGGACTGAGACACGGC 337

Query 313 CCAGACTCCTACGGGAGGCAGCAGTAGGGAATCTTCGGCAATGGGGGCAACCTTGACCGA 372
          ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Sbjct 338 CCAGACTCCTACGGGAGGCAGCAGTAGGGAATCTTCGGCAATGGGGGCAACCTTGACCGA 397

Query 373 GCAACGCCGCGTGAGTGAAGAAGGTTTTTCGGATCGTAAAGCTCTGTTGTAAGTCAAGAAC 432
          ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Sbjct 398 GCAACGCCGCGTGAGTGAAGAAGGTTTTTCGGATCGTAAAGCTCTGTTGTAAGTCAAGAAC 457

Query 433 GAGTGTGAGAGTGGAAAATTCACACTGTGACGGTAGCTTACCAGAAAGGGACGGCTAACT 492
          ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Sbjct 458 GAGTGTGAGAGTGGAAAATTCACACTGTGACGGTAGCTTACCAGAAAGGGACGGCTAACT 517

Query 493 ACGTGCCAGCAGCCGCGGTAATACGTAGGTCCCAGCGTTGTCCGGATTTATTGGGC GTA 552
          ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Sbjct 518 ACGTGCCAGCAGCCGCGGTAATACGTAGGTCCCAGCGTTGTCCGGATTTATTGGGC GTA 577

Query 553 AAGCGAGCGCAGGCGGTTTGATAAGTCTGAAGTTAAAGGCTGTGGCTCAACCATAGTTTCG 612
          ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Sbjct 578 AAGCGAGCGCAGGCGGTTTGATAAGTCTGAAGTTAAAGGCTGTGGCTCAACCATAGTTTCG 637

Query 613 CTTTGAAAACGTGCAAACTTGAGTGCAGAAGGGGAGAGTGGAATTCATGTGTAGCGGTG 672
          ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Sbjct 638 CTTTGAAAACGTGCAAACTTGAGTGCAGAAGGGGAGAGTGGAATTCATGTGTAGCGGTG 697

Query 673 AAATGCGTAGATATATGGAGGAACACCGGTGGCGAAAGCGGCTCTCTGGTCTGTAAC TGA 732
          ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Sbjct 698 AAATGCGTAGATATATGGAGGAACACCGGTGGCGAAAGCGGCTCTCTGGTCTGTAAC TGA 757

Query 733 CGCTGAGGCTCGAAAGCGTGGGAGCGAACAGGATTAGATACCTGGTAGTCCACGCCGT 792
          ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Sbjct 758 CGCTGAGGCTCGAAAGCGTGGGAGCGAACAGGATTAGATACCTGGTAGTCCACGCCGT 817

Query 793 AAACGATGAGTGCTAGGTGTTGGATCCTTTCCGG-ATT 829
          ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Sbjct 818 AAACGATGAGTGCTAGGTGTTGGATCCTTTCCGGGATT 855

```

## **BIOGRAPHY**

Miss Yupawadee Chaodong was born on November 13, 1985 in Buriram, Thailand. She graduated with Bachelor degree of Science in Biotechnology from the Faculty of Agricultural Technology at Walailak University in 2008.